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Abstract 
The aim of this project was to investigate the role of the Flightless I (FliI) protein in tumour 
growth and metastasis in vitro and in vivo using cultured colon cancer cells and a mouse 
colon cancer model. FliI is a member of the actin-remodelling protein family, which consists 
of gelsolin, adseverin, capG, villin and supervillin family members, which play important 
roles in cellular motility, contraction and adhesion. Several studies have investigated the 
function of FliI and its mechanism of action in both in vitro and in vivo models of wound 
healing in mouse skin. These studies showed that knockdown of FliI improved wound 
healing via increased cell proliferation, epithelial cell migration and enhanced wound 
closure, while also resulting in reduced scarring and inflammation. In contrast, 
overexpression of FliI caused impaired wound healing with larger, fewer closed wounds, 
reduced cellular proliferation and delayed epithelial migration, as well as excessive scarring.  
Since there are parallels between the wound healing/scarring process and cancer 
progression, the aim of this study was to investigate the role of Flil in cancer growth and 
spread. Recently it has been shown that FliI expression also correlated with increased 
tumour growth in a mouse model of squamous cell carcinoma, while FliI inhibition using a 
neutralising antibody reduced tumour growth and invasion in this model. The FliI protein 
itself has been shown to be both localised intracellularly and also secreted; therefore, we 
have studied tumour growth both in mice with reduced FliI expression (FliI heterozygous 
knockout +/− mice) and also in wild type (WT) mice injected with cancer cells that have FliI 
knockdown using siRNA. In vitro, FliI expression levels were found to have significant effects 
on cell migration, cell proliferation, cell adhesion and invasiveness. Knockdown of FliI 
increased cell motility and proliferation, and was found to increase cell adhesion via 
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upregulation of focal adhesion (FA) proteins, while reducing FliI expression greatly inhibited 
cellular invasion associated with reduced expression of an invadopodia marker. In vivo, 
colon cancer cells showed decreased spread to form fewer lung metastases in mice with 
reduced FliI expression (FliI heterozygous mice).  
This suggests that host FliI expression levels can regulate tumour growth, possibly through 
an effect on tumour stromal cell behaviour. Interestingly, knockdown of FliI using siRNA also 
resulted in smaller primary tumours in mice, suggesting FliI expression in cancer cells could 
influence tumour growth in this model as well. In vitro, FliI expression correlated with 
decreased adhesion and increased invasion, suggesting FliI may play a role in tumour 
progression via effects on cell adhesion and invasion, potentially via effects on invadopodia 
formation. These findings suggest that FliI inhibition in both stromal and cancer cells may be 
a promising target for limiting tumour growth and spread. In addition, administration of a 
FliI-neutralising antibody (FnAB) showed potential for reducing tumour progression in 
metastatic models and reducing tumour spheroid invasion in vitro. Overall, the results 
suggest FliI may be a promising target for inhibiting tumour growth and metastasis.  
The significance of this study is that FliI has been shown to play a role in mediating cellular 
functions which are important in tumour progression. FliI expression increased cellular 
invasion, possibly via an invadopodia mechanism correlated with increased cortactin 
expression. FliI expression has also been shown to influence tumour growth and spread in 
murine colon cancer models, while FliI inhibition either in the host or in cancer cells reduced 
tumour progression and metastasis. Importantly, this study demonstrates that the inhibition 
of FliI expression intracellularly and within hosts could modify the tumour 
microenvironment, thus reducing tumour growth. This present study also serves as a 
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preliminary finding on the administration of FnAB to potentially reduce tumour growth and 
spread in animal models, which indicates that FliI could be a potential target for cancer 
therapy. 
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Chapter 1 Literature Review 
1.1 Introduction 
Current therapeutics targeting cancer cells are well established but are often insufficient to 
control tumour growth and cancer spread. Tumours consist, in many cases, of the tumour 
cells themselves and a connective tissue stroma that surrounds the cancer cells and includes 
several other cell types, including fibroblasts and inflammatory cells. This has led to the 
acceptance of co-targeting both the cancer cells and their microenvironment including cells 
such as stromal fibroblasts and inflammatory cells, but also the extracellular matrix (ECM) 
and matricellular proteins (Pollard, 2009; G. Wong & Rustgi, 2013) as another approach to 
cancer therapy.  
Growing evidence suggests that interaction between cancer cells and their 
microenvironment contributes to cancer growth and progression. The plasticity of cancer-
associated stroma is one of the main contributors involved in morphological and functional 
transitions that support the pathogenesis of cancer cells (S.-Y. Sung et al., 2008). The 
modification of the cytoskeleton may also be important in modifying cancer cell motility, 
resulting in cancer spread or metastasis. The balance between cell adhesion and cell motility 
is likely to be a major determinant of cancer cell movement (Detchokul, Williams, Parker, & 
Frauman, 2013). 
It is known that wound healing in the skin and tumour stroma shares several similar cellular 
and molecular characteristics. Because of this it has been postulated that tumours represent 
a ‘wound that never heals’ or possibly a wound that over-heals (Dvorak, 1986). The 
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development and functional characterisation of the microenvironment, such as recruitment 
of inflammatory cells, fibroblasts, and the presence of extracellular matrix and matrix 
remodelling proteins, have been highlighted and show the similarity between wound repair 
mechanisms and cancer. However, there are crucial differences in terms of the ability to 
differentiate and the invasive growth of malignant tumours and, in addition, the failure of 
cancer growth to resolve to scar tissue as occurs in wound repair (Schäfer & Werner, 2008). 
The parallels between the scarring process and cancer progression and their 
microenvironments led us to hypothesise that those factors known to regulate wound 
healing and scarring may potentially play a role in tumour growth and spread. The focus of 
this project was to determine the role of Flightless I (FliI), which is a negative regulator of 
wound repair, in cancer growth and metastasis. FliI belongs to the gelsolin family of actin 
severing and remodelling proteins, which are involved in cell motility, contraction and 
adhesion, but it may also mediate other protein interactions.  
A number of studies have been done to determine the role of FliI as a negative regulator of 
wound healing using in vivo and in vitro models of healing (Cowin et al., 2007; Jackson, 
Kopecki, Adams, & Cowin, 2012; Z. Kopecki & Cowin, 2008). These studies found that under- 
expressing FliI by generating heterozygous knockout mice improved wound healing, with 
wounds showing increased cell proliferation and keratinocyte migration. In contrast, FliI-
overexpressing mice that had one or two extra FliI transgenes showed significantly impaired 
wound healing, resulting in larger wounds associated with reduced cellular proliferation and 
migration and increased scarring. 
A better understanding of how the tumour microenvironment affects cancer progression 
could lead to new targets for the destruction of cancer cells via interruption of the complex 
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networks that exist between cancer cells, host cells and the surrounding extracellular matrix 
or the tumour microenvironment. Therefore, FliI might represent one such target where 
intracellular inhibition or its secreted form via molecular inhibitors or monoclonal antibodies 
might enable a reduction in tumour growth and spread. 
1.2 Colon Cancer 
Colorectal cancer (CRC) is a common lethal cancer in Western countries. Approximately one 
million new cases of colorectal cancer are diagnosed annually and cause half a million 
deaths, commonly in the elderly (Boyle & Leon, 2002). The risk of developing CRC is 
influenced by both environmental and genetic factors. A rise in incidence of young adults 
diagnosed has been reported in the United States of America and Australia linked to an 
increase in common risk factors such as obesity, alcohol consumption and sedentary 
lifestyles (Young et al., 2014). 
Approximately 25% of patients present with metastases at initial diagnosis and almost 50% 
of patients with CRC will develop metastases, contributing to the high mortality rates 
reported for CRC (Van Cutsem, Cervantes, Nordlinger, & Arnold, 2014). Importantly, distant 
metastasis, which may be asymptomatic until reaching an advanced stage, comprises about 
40% of CRC patient deaths due to metastatic complications. 
Even though many of the genetic alterations occurring in colon cancer are now known 
(Fearon & Vogelstein, 1990; Vogelstein et al., 1988), it still remains the second most 
common cause of cancer mortality and current therapeutic approaches still need to be 
improved to increase the effectiveness of the treatment. 
7 
 
1.2.1 Epidemiology 
Colorectal cancer (CRC) is one of the main causes of cancer incidence and death worldwide, 
particularly in developed countries such as Europe, the USA and Australia. It was responsible 
for 215,000 deaths in 2012 in Europe and over 4000 deaths in Australia (Siegel, DeSantis, & 
Jemal, 2014; Young et al., 2014). In the United States, it was estimated that about 71,830 
men and 65,000 women would be diagnosed with colorectal cancer, and 26,270 men and 
24,040 women would die from the disease, in 2014. This data represents about 13.2% and 
12.7% frequency of CRC among all cancer cases, and 11.6% and 13.0% of all cancer deaths in 
men and women, respectively (Siegel et al., 2014). 
Australia remains one of the countries with the highest rates of CRC incidence. CRC was the 
second leading cause of cancer incidence and third leading cause of cancer deaths in 
Australian adults in 2010 (Young et al., 2014). In 2007, 4047 deaths were caused by CRC 
(2191 males; 1856 females), which comprised 10.1% deaths from invasive cancer, the 
second highest after lung cancer. The incidence increased in 2008 with 14,225 people 
diagnosed with this disease (National Bowel Cancer Screening, 2011).  
1.2.2 Colon Carcinogenesis 
Tumourigenesis is a multistep process which involves genetic alterations that have the 
ability to transform normal cells into aggressive malignant cells (Hanahan & Weinberg, 
2000). It has been shown in rodent cells that the transformation process itself includes 
several steps involving genetic changes and acquisition of tumourigenic functions (Hahn et 
al., 1999).  
Hanahan and Weinberg hypothesised that there are six hallmarks of cancer which are 
acquired throughout a multistep process of tumour development. Most cancer cells become 
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capable of producing their own mitogenic growth signals to maintain an active proliferative 
state, they become insensitive to anti-growth signals, they can escape from cell death 
(apoptosis) mechanisms, they cause sustained angiogenesis, they have no limit in replicative 
potential and, lastly, they have the ability to invade other tissues and organs (metastasise) 
(Hanahan & Weinberg, 2000). 
1.3 Tumour Microenvironment and Cancer Stroma 
Tumour stroma or the tumour microenvironment are terms used to describe the mixture of 
connective tissue and stromal cells including inflammatory cells, fibroblasts and vascular 
angiogenic cells that surrounds the tumour cells (Hale, Hayden, & Grabsch, 2013). 
Previously, it was thought that tumour stroma may have acted as a barrier to tumour 
growth and spread, or was a relatively inert tissue that was generated as a reaction to the 
presence of tumour cells and was present in and around tumours, particularly epithelial 
tumours such as lung, colon and breast carcinoma. However, in recent years it has become 
accepted that this microenvironment can favour cancer progression and metastatic spread 
due to cross-talk between tumour cells and stromal cells. This involves recruitment of 
fibroblasts and their transformation into cancer-associated fibroblasts (myofibroblasts), 
immune cell recruitment, matrix degradation and remodelling, and the expansion of 
vascular networks or angiogenesis (Junttila & de Sauvage, 2013). This stroma is known to 
play a role as a key regulator of tumour progression and has also been shown to have an 
association with the efficacy of drug delivery. Recent findings have shown that tumour 
stroma–derived biomarkers can also be used as biomarkers to determine responses to 
chemotherapy and in some cases may be useful as early biomarkers for detection of cancer 
(Hale et al., 2013). 
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The role of tumour stroma in carcinogenesis has been reviewed widely in several studies 
(Bhowmick, Neilson, & Moses, 2004; Quail & Joyce, 2013). Morphological and biochemical 
changes in stromal fibroblasts in response to cancer growth form a ‘reactive stroma’. There 
are abundant expression and diverse types of extracellular matrix proteins present in 
reactive stromal cells associated with alteration of fibroblasts to myofibroblast phenotype, 
including expression of alpha (α) smooth muscle actin (α-SMA), splice variant forms of 
fibronectin, actin bundles, paladin and transforming growth factor-beta (TGF-β1) (Dakhova 
et al., 2009). There is also a direct interaction between reactive stroma and cancer cells in 
promoting cancer development, and the presence of reactive stroma around and within a 
tumour in many cases correlates with poor prognosis for the patient (Tsujino et al., 2007). It 
has also been suggested that tumour progression is controlled by the microenvironment of 
the tumour, not only by the cancer cells themselves (Bissell & Radisky, 2001).  
There are two sequences of events occurring in tumour and stromal cells that involve a 
series of changes which lead to tumour progression. Firstly, transformation of epithelial cells 
to become mesenchymal or stromal cells in the stromata can result in paracrine secretion of 
growth factors and cytokines that regulate tumour cells (Polyak, Haviv, & Campbell, 2009). 
The tumour stroma also consists of several types of cells including blood vessels that 
provide sustained angiogenesis and thus nutrient supply to the tumour cells (Lohela, Bry, 
Tammela, & Alitalo, 2009), and secretion of cytokines and chemokines by immune cells is 
believed to both promote and, under some conditions, suppress tumour progression 
(Mueller-Huebenthal et al., 2009). Secondly, an activated form of fibroblasts, myofibroblasts 
or cancer-associated fibroblasts, are also a key controller between stromal and cancer cells 
in activating paracrine signalling pathways (Lorusso & Rüegg, 2008). These myofibroblasts 
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secrete more extracellular matrix than normal quiescent connective tissue fibroblasts, are 
contractile and can contribute both paracrine growth factors, but also contribute to matrix 
stiffening and enhanced mechanical signalling in the tumour microenvironment. The major 
role of stress fibres is to maintain a balance between contraction and adhesion. This balance 
results in stable actin bundles, which maintain a constant length under tension, especially in 
ventral stress fibres attached to the extracellular matrix on both sides  (Tojkander, Gateva, 
& Lappalainen, 2012). The multistep process of tumour progression suggested in (Hanahan 
& Weinberg, 2000) has been revisited recently and the importance of the tumour 
microenvironment in regulating cancer growth and spread has been acknowledged 
(Hanahan & Weinberg, 2011).  
In the tumourigenic niche, cancer cells may modify the behaviour of fibroblasts, 
macrophages and NK cells so that they acquire tumour-promoting properties. These cells 
have been termed cancer-associated fibroblasts (CAFs) and tumour-associated macrophages 
(TAMs). Inhibition of NK cell cytotoxicity is also frequently observed. TAMs are strongly 
associated with tumour progression, whereas CAFs may potentially initiate tumour 
development, modulate immune responses and promote cancer metastasis (Öhlund, 
Elyada, & Tuveson, 2014). Figure 1.1 indicates changes acquired by stromal cells, such as 
CAFs and TAMs, that can influence tumour cells either directly or indirectly via release of 
several cytokines that lead to promotion of angiogenesis and thus provide a 
microenvironment that favours tumour growth.  
Evolution of multiple stromal cells and extracellular matrix during tumour progression 
creates modifications in cellular organisation and phenotypic characteristics, thereby 
allowing cancer cells to dissociate and disseminate to the metastatic sites (Hanahan & 
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Weinberg, 2011). Cellular interactions between cancer cells and stromal cells in prostate 
cancer in a 3D co-culture system and in mice in vivo studies showed the importance of the 
stroma and tumour microenvironment in cancer progression (Josson, Matsuoka, Chung, 
Zhau, & Wang, 2010). 
 
 
Figure 1.1: Tumour microenvironment support by various types of stromal cells. In the 
local microenvironment, fibroblasts, anti-tumourigenic macrophages and immune cells such 
as NK- and T- cells mediate apoptosis to suppress tumour growth. These stromal cells then 
acquire changes influenced by tumour cells to become CAFs and TAMs, either directly or 
induced by release of several cytokines, leading to promotion of angiogenesis and escape 
from immune surveillance, thus favouring tumour growth (Quail & Joyce, 2013).
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1.4 Cancer Stroma and Wound Healing 
Several cellular and molecular mechanisms are common to wound healing and in cancer 
microenvironments. It was postulated that “tumours are wounds that do not heal” (Dvorak, 
1986) or tumours are wounds that over-healed or fail to resolve (Haddow, 1972) and this 
idea has been revisited more recently where the tumour microenvironment has been shown 
to resemble a site of chronic wound healing (Arwert, Hoste, & Watt, 2012; Barcellos-Hoff, 
Lyden, & Wang, 2013).  
It has been suggested that the composition of tumour stroma is very similar to the chronic 
wound healing involving the formation of granulation tissue which contains differentiated 
myofibroblasts, inflammatory cells and growing blood vessels (Rybinski, Franco-Barraza, & 
Cukierman, 2014). However, in contrast to wound healing, the process in cancer tissue is not 
self-limiting, which results in uncontrolled cellular proliferation, leading to invasion and 
metastasis. It has been proposed previously that tumours trigger a latent wound-healing 
program; however, they do so in a prolonged manner, particularly in epithelial cell tumours 
and/or carcinomas (Schäfer & Werner, 2008).  
Besides the similarities between tumors and wounded tissue, the process of wound healing 
also shows several common characteristics with chronic fibrosis, including similar cell types 
(inflammatory and activated fibroblasts), and soluble and matrix elements that drive wound 
healing (including regeneration) via distinct signalling pathways. It has also been shown that 
chronic fibrosis and tumor progression (Rybinski et al., 2014) have similar characteristics. In 
fact, prolonged healing processes resulting from chronic injury can result in chronic fibrosis 
and eventually tumourigenesis (Schäfer & Werner, 2008; Wynn & Ramalingam, 2012). Both 
tumours and their stroma and chronic fibrosis share several characteristics, as both tissues 
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are characterised by the presence of hyperproliferating cells (Y. Liu, 2011; Noble, 
Barkauskas, & Jiang, 2012), while stromal elements consist of abundant myofibroblasts 
responsible for altered and excessive ECM deposition (Cirri & Chiarugi, 2011). However, 
mutations and epigenetic changes have also been observed in cancer cells which are absent 
in fibrotic tissue. Chronic fibrosis has been shown to influence affected tissues leading to 
development of cancer (Bobba, Holly, Loy, & Perry, 2011; Duell et al., 2012) and also to 
enhanced tumour progression, which is commonly linked with poor prognosis (Gupta et al., 
2011). 
The normal wound-healing process involves three phases, which include clotting and 
inflammation, proliferation (growth of granulation tissue) and tissue remodelling. On injury, 
a platelet plug temporarily seals the wound and provides a rich source of growth factors. 
Subsequently, growth factors and cytokines produced by the inflammatory cells and stromal 
cells stimulate resident cells to form new tissue (Broughton 2nd, Janis, & Attinger, 2006; 
Lazarus et al., 1994). This phase involves cell migration and hyperproliferation of 
keratinocytes, which eventually leads the formation of a reconstituted epidermis. Wound 
contraction occurs due to differentiation of fibroblasts into contractile myofibroblasts, 
which involves transient expression of α-SMA (I. Darby, Skalli, & Gabbiani, 1990). The new 
tissue formed at the wound site is called granulation tissue. Finally, this granulation tissue 
will lay the foundation for mature scar tissue formation, which is characterised by the loss of 
cells and by matrix remodelling (Schäfer & Werner, 2008).  
Velnar et al. 2009 expanded the phases to suggest five major underlying mechanisms of 
action throughout the healing process, which are inflammatory mediators and growth 
factors, interactions between cells and extracellular matrix in mediating cell proliferation, 
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migration and differentiation, re-epithelialisation and angiogenesis associated events, 
wound contraction and then remodelling (Velnar, Bailey, & Smrkolj, 2009). However, this 
process does not resolve in cancer, which then may result in tumourigenesis (Schäfer & 
Werner, 2008). Recently, a WHFC triad has been proposed, which is an interconnection 
between chronic wound healing, fibrosis and cancer (Figure 1.2) (Rybinski et al., 2014). Four 
major components that are common between wound repair, fibrosis and tumour 
development are described in this triad, specifically, cell proliferation, epithelial–
mesenchymal transition (EMT), myofibroblast differentiation and ECM repair.  
 
Figure 1.2: The wound healing, chronic fibrosis and cancer (WHFC) triad. Model illustrates 
the WHFC triad commonalities with wound healing. The triad indicates mechanisms in 
wound healing that facilitate a cycle between fibrosis and cancer without wound resolution. 
Adapted from (Rybinski et al., 2014).  
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1.4.1 Similar characteristics between wounds, chronic fibrosis and tumour stromata 
Both wound and tumour stroma show parallels at the cellular and molecular levels (Schäfer 
& Werner, 2008). There are substantial links showing that the molecules involved in 
inflammation and wound healing are also involved in cancer (Frances Balkwill, Charles, & 
Mantovani, 2005). It has also been shown that patterns of gene-expression in stimulated, 
serum-treated fibroblasts strongly resemble the genes expressed in human carcinomas 
(Chang et al., 2004). Wound-healing factors have also been found to stimulate the 
proliferative capacity of tumour cells and increase tumour-forming capacity in primary head 
and neck cancer cells (Lindgren, Kjellén, Wennerberg, & Ekblad, 2016). In fact, tumour cells 
that express genes which are similar to those in early wounds commonly show a poor 
prognosis, favouring tumour progression and leading to metastasis and potentially to death 
(Chang et al., 2004; Gupta et al., 2011).  
The most common hallmarks in wound healing and tumour progression is the high/ 
increased density of myofibroblastic cells within the tumour microenvironment and EMT 
that occurs in epithelial cells resulting in differentiation and transformation (Cirri & Chiarugi, 
2011). Myofibroblast differentiation, also known as the activation of fibroblasts, is the 
process whereby cells acquire a myofibroblastic phenotype, which occurs in components of 
the stroma such as resident fibroblasts, pericytes, endothelial cells and recruited bone 
marrow–derived mesenchymal cells (Eyden, Banerjee, Shenjere, & Fisher, 2009). 
As mentioned in the previous section, the large populations of myofibroblasts in the tumour 
stroma are referred to as CAFs and pro-fibrotic myofibroblasts are cells that can drive 
tumour progression and chronic fibrosis (Cirri & Chiarugi, 2011; Pietras & Östman, 2010). 
Like myofibroblasts, CAFs are believed to promote tumourigenesis and carcinogenesis 
16 
 
(Hanahan & Weinberg, 2011; Orimo & Weinberg, 2006). They are thought to come from the 
same origin as myofibroblasts and are a heterogenous population of cells that can alter the 
tumour microenvironment, leading to neoplastic changes (Öhlund et al., 2014). Oncogenic 
signalling by neoplastic cells could mimic the normal wound-healing process by releasing 
fibroblast-activating factors, resulting in recruitment and differentiation of the fibroblasts 
similar to that found in wounds. Injured epithelial cells and activated macrophages are also 
shown to secrete these factors (G. Yang et al., 2006). 
In normal stroma, fibroblasts are in an inactive, quiescent state and functionally secrete few 
components of extracellular matrix such as fibronection and collagen, and only in small 
amounts (Brouty-Boye, 2005). In damaged tissues involving tissue remodelling processes 
such as wound healing and fibrosis, fibroblast cells become activated into myofibroblasts, 
which are characterised by the expression of α-SMA, and there are the presence of 
microfilament bundles (contractile stress fibres) and splice variant expression of fibronectin 
(Tomasek, Gabbiani, Hinz, Chaponnier, & Brown, 2002). Myofibroblasts also secrete more 
extracellular matrix proteins that contribute to matrix stiffening and were originally 
described in the granulation tissues of healing wounds (Gabbiani, Ryan, & Majno, 1971). In 
cancer, these myofibroblasts which have escaped apoptosis, are believed to promote 
carcinogenesis (Eyden et al., 2009). It has been shown that physical matrix remodelling by 
myofibroblasts promotes the invasion of cells in squamous cell carcinoma (SCC) (Gaggioli et 
al., 2007). Increased staining for myofibroblasts in the tumour stroma also strongly 
correlates with poor prognosis in lung, pancreatic and colorectal tumours (Erkan et al., 
2008; Maeshima et al., 2002; Tsujino et al., 2007).  
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An increase in ECM stiffness has also been shown in both fibrotic and tumour-associated 
ECM compared to normal stroma (Goetz et al., 2011). ECM changes, such as fibrin and 
fibronectin crosslinking as well as abundant presence of inflammatory cells in the stroma 
during cancer growth and progression, have been confirmed in numerous studies 
((Coussens & Werb, 2002) Schafer et al. 2008; (Solinas, Germano, Mantovani, & Allavena, 
2009). In fact, high deposition of interstitial fibronectin has been shown in liver and 
pancreatic carcinoma, with aggressive progression of tumours observed (Bachem et al., 
2005). Extra domains A and B (EDA and EDB) of fibronectin has also been associated with 
increased tumour growth, angiogenesis and lymphangiogenesis (Sun et al., 2013; Xiang et 
al., 2012). In fact, EDA has also found to promote myofibroblast activation and fibrosis, with 
the presence of TGF- and EDA fibronectin being necessary for fibroblast differentiation to 
the myofibroblast phenotype (Hinz, 2010).  
On the other hand, ECM tension is increased during the wound-healing process due to 
collagen deposition, where collagen I is often found in fibrotic tissue, while abundant 
Collagen I and IV were also commonly observed in activated myofibroblasts (Hinz, 2010). 
The physiological and pathological roles of collagen in wound healing, fibrosis and tumour–
stroma interaction have been recently reviewed (Gullberg, Kletsas, & Pihlajaniemi, 2016). 
Fibrillar collagens are produced by fibroblasts during wound healing, often altering the 
profile of collagen types present in the tissue (Schäfer & Werner, 2008) and this has been 
shown to contribute to tumour growth and metastasis in a breast cancer xenograft models 
(Xiong, Deng, Zhu, Rychahou, & Xu, 2014). Collagen deposition in the tumour tissue may 
also lay down tracks for metastatic tumour cells to move along by rearrangement of the 
collagen linkages (Provenzano, Eliceiri, & Keely, 2009). 
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The predominant inflammatory cells that play a role in wound healing and tumour biology 
are macrophages. Macrophages are associated with the development of tumour-support 
tissues by synthesising growth and angiogenic factors, remodelling extracellular matrix and 
removing apoptotic cells (Condeelis & Pollard, 2006). Therefore, during wound healing 
macrophages are crucial in mediating tissue repair (Coussens & Werb, 2002). Macrophages 
can be divided into two phenotypes depending on the cytokines and growth factors that 
they release and the surface markers that they express. M1 macrophages is predominantly 
present in inflamed non-cancerous tissue, while in tumours tumour-derived cytokines 
induce the polarisation of macrophages into an alternate M2 phenotype. It has been 
suggested that M2 macrophages induce angiogenesis and thus ultimately promote 
tumourigenesis, while also enhancing cancer cell motility and invasion (Allavena, Sica, 
Garlanda, & Mantovani, 2008; Condeelis & Pollard, 2006).  
Angiogenesis is a fundamental process for both wounds and malignant tumours. It is 
defined as the development of blood vessels from an existing vasculature and it is necessary 
in tissue repair to restore blood supply to growing tissues (Crowther, Brown, Bishop, & 
Lewis, 2001). Generally, vascular networks develop via migration, proliferation and 
differentiation of vascular endothelial cells (Carmeliet, 2000). In wound healing, 
angiogenesis functions to restore vascular perfusion in damaged tissues and to assist 
recruitment of inflammatory cells such as neutrophils and macrophages to the site (M. E. 
Wong, Hollinger, & Pinero, 1996). In tumours, the ‘stressed’ microenvironment due to 
hypoxia and high levels of lactate, as a by-product of glycolysis, stimulates tumour cells to 
secrete pro-angiogenic cytokines and enzymes that establish a local vascular supply in the 
tumour, allowing the tumour to progress. Hyperpermeability of wound and tumour blood 
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vessels (capillaries) in the presence of histamine and vascular endothelial growth factor 
(which was originally called vascular permeability factor) also allows the continuous release 
of plasma proteins and the deposition of a fibrin and fibronectin matrix in the stroma. This 
deposition is an acute condition during normal wound repair; however, it is chronic during 
tumour growth (Schäfer & Werner, 2008).  
All of these features are commonly present in wound healing, fibrotic tissue and cancer 
stroma; however, most of these changes are resolved once the wound-healing process is 
complete. For example, in wound granulation tissue, myofibroblasts are lost by apoptosis as 
the wound heals, and scar tissue becomes less cellular and has no transformed fibroblasts 
remaining (Desmoulière, Redard, Darby, & Gabbiani, 1995). Myofibroblasts and EMT cells 
were actively involved in regenerative healing wounds, fibrosis and tumour-associated 
desmoplasia; however, these cells are eventually lost in normal wound repair by the natural 
elimination process of the myofibroblastic cells via apoptosis (Rybinski et al., 2014).  
The cellular and molecular parallels between chronic wound healing and tumour 
progression are summarised in Table 1.1. 
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Table 1.1: Similar cellular characteristics between chronic wound healing and tumour 
progression 
Similarities between chronic wound healing and tumour progression 
 Presence of inflammatory cells including macrophages, neutrophils, mast cells and 
lymphocytes 
 Formation of new vasculature (angiogenesis) 
 Differentiation of fibroblasts into myofibroblasts, creating cancer-associated 
fibroblasts (CAFs) in tumour stroma (which become reactive stroma) 
 Fibronectin and collagen deposition, which contribute to ECM stiffness 
 Transformation of epithelial cells via epithelial–mesenchymal transition (EMT) 
 Release of matrix metalloproteinases, MMPs, which mediate ECM remodelling 
1.5 Local Microenvironment 
In cancer, stroma can be classified as local or distant and, in the case of distant, as the 
metastatic microenvironment. Local microenvironments are heterogeneous, consisting of 
vascular endothelial cells, smooth muscle cells, inflammatory cells, and soluble and 
insoluble extracellular matrix proteins. These cells create a complex cancer stroma in the 
presence of macrophages, platelets, dendritic cells, T and B lymphocytes, and activated 
stroma and then support local cancer growth, progression and distant metastasis (Josson et 
al., 2010). Therefore, the microenvironment surrounding the tumour mass can be 
characterised as containing proliferating tumour cells with local components including 
stromal cells, newly developed blood vessels and inflammatory cell infiltrate associated with 
constant tissue remodelling. Soluble factors secreted by cancer and inflammatory cells such 
as hepatocyte growth factor (HGF) (Ren et al., 2005), epidermal growth factor (EGF) (Chiang, 
Chou, Hsu, Huang, & Shen, 2008; Mendelsohn & Baselga, 2000), PDGF (Donnem et al., 
2008), VEGF (Ai, Lu, Huang, Chen, & Zhang, 2008) and TGF-β (Kitisin et al., 2007; Massagué, 
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2008), induce an activated form of stromal fibroblast or myofibroblast via multiple signalling 
pathways and these have a potent growth-promoting effect on various types of cancer, 
leading to tumour angiogenesis, invasion and metastasis. 
1.6 Metastatic Microenvironment 
Cancer cells have the ability to invade and metastasise to distant sites (Hanahan & 
Weinberg, 2011). Soluble and matrix factors secreted by both cancer cells and cells in 
tumour microenvironment may alter cancer cell adhesion, proliferation and survival 
(Folkman, 2002) and assist in metastasis to other organs such as the lung, liver, brain and 
kidney. There are important events that occur during metastasis, which include dissociation 
from the primary tumour, extracellular matrix remodelling by enzymes that can degrade 
matrix proteins, cell migration and proliferation and angiogenesis within the tumour stroma 
(Wells, 2006). 
Circulating tumour cells (CTCs) undergo several changes to become able to colonise distant 
organs, which include infiltration of distant tissue, the ability to escape from immune 
defence, adaptation to supportive niches, survival of tumour-initiating seeding and 
eventually breaking out to overtake the host tissue (Massagué & Obenauf, 2016). As 
mentioned previously, an early stage of the metastatic cascade involves the invasion and 
migration of cancer cells into tissues and the circulatory system, which is mainly controlled 
by cytoskeletal rearrangements of cancer cells (Hall, 2009), changes to adhesive interactions 
between cells and the secretion of extracellular matrix–degrading metalloproteinases 
(MMPs) allowing destruction of collagen fibres of the ECM (Quail & Joyce, 2013). 
Cancer cells that survive after the infiltrating step are known as disseminated tumour cells 
(DTCs) and later become established in supportive niches (Braun et al., 2005). DTCs are 
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believed to survive in the circulatory system as single cells or clusters of cells coated with 
platelets which then enter a latent state as single cells or micrometastases (Massagué & 
Obenauf, 2016). Finally, cancer cells in supportive niches reinitiate outgrowth and replace 
the local tissue microenvironment.  
Therapeutic strategies have been developed to target different cells in the tumour 
microenvironment, including targeting angiogenesis, inflammation, CAFs and several growth 
factors present, including VEGF, PDGF and HGF, as well as targeting other non-cellular 
components such as the ECM (Joyce, 2005; Sounni & Noel, 2013). The targeting of tumour 
stromata may be crucial since targeting cancer cells alone may be less effective because of 
their capacity to adapt to therapy and due to increasing understanding of the importance of 
the microenvironment (Pietras & Östman, 2010; Quail & Joyce, 2013). Additionally, tumour 
stroma–derived biomarkers are now known to be useful in determining the tumour 
response to chemotherapy, as well as having potential impacts on drug delivery and efficacy 
(Hale et al., 2013). 
Figure 1.3 shows the therapeutic strategies that are available to target different types of 
cells in the tumour microenvironment which actively contribute to cancer development and 
progression.  
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Figure 1.3: Therapeutic approaches targeting the tumour microenvironment. There are 
several possible therapeutic approaches to target stromal cells including inflammatory, 
lymphatic and vascular angiogenic cells in the tumour microenvironment. Adapted from 
(Joyce, 2005). 
1.6.1 Cancer Associated Fibroblasts (CAFs) in metastatic microenvironments 
Fibroblasts located within the extracellular matrix (ECM) are involved in tissue remodelling 
and repair, and the ECM itself acts as a reservoir of important cytokines and growth factors 
that can induce cell differentiation and migration (Öhlund et al., 2014). As described earlier, 
on injury myofibroblasts are found in various inflamed and fibrotic tissues, and in reactive 
tumour stromata (Orimo & Weinberg, 2007). The large population of myofibroblasts in the 
tumor stroma, CAFs and fibrotic myofibroblasts, have the capacity to drive tumor 
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progression and chronic fibrosis (Rybinski et al., 2014). They are also found in 
pseudotumours and close to neoplastic cells within the tumour (Eyden et al., 2009). CAFs 
are defined as fibroblastic, non-epithelial, non-inflammatory, non-vascular and non-
neoplastic cells within a tumour (Kalluri & Zeisberg, 2006; Orimo & Weinberg, 2007). They 
may arise through EMT, which can potentially differentiate them from neoplastic cells. 
However, the heterogeneous populations and different origins of CAFs make it difficult to 
define a specific molecular profile of CAFs.  
CAFs have been reported to augment cancer development by secreting growth factors and 
cytokines which are crucial in the tumour microenvironment. Studies have demonstrated 
that levels of the cytokines CCL7 and CXCL12 are increased in invasive oral squamous cell 
and breast carcinomas, respectively, expressed by stromal fibroblasts (Jung et al., 2010; 
Orimo et al., 2005). Importantly, CAFs have the ability to remodel the ECM such that 
changes in ECM constituents can influence the stiffness of the tissue, which can also favour 
tumour growth by increasing mechanical signalling (Erler & Weaver, 2009). In fact, CAFs can 
also mediate matrix degradation by the production of matrix metalloproteinases (MMPs) 
and contribute to tumour vascularisation (Quail & Joyce, 2013). They can thus facilitate 
tumour invasion and the escape of tumour cells and spread to secondary sites (Zigrino et al., 
2009). Activation of myofibroblasts to cancer-associated (myo) fibroblasts within the stroma 
is commonly correlated with poor prognosis and cancer metastasis (Castelino & Varga, 
2014; Pickup, Mouw, & Weaver, 2014). Recently, more evidence has shown that 
myofibroblasts and CAFs play a role in many types of cancer and targeting CAFs would thus 
be beneficial in regulating fibrosis, scarring and cancer (for review see (I. A. Darby, Zakuan, 
Billet, & Desmoulière, 2016)).  
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Myofibroblasts in the tumour stroma can influence tumour progression and establishment 
of the metastatic niche through the ECM molecules that they secrete (Barcellos-Hoff et al., 
2013). It has been shown that myofibroblasts secrete ECM molecules which can 
mechanically influence signalling and cell adhesion, such as the matricellular protein 
periostin, which can affect tumour growth and establishment of a metastatic niche (I. A. 
Darby & Hewitson, 2016). ECM rigidity and stiffness can also regulate the action and the 
activation of TGF-β signaling including TGF-β-induced apoptosis and TGF-β-induced EMT 
(Leight, Wozniak, Chen, Lynch, & Chen, 2012). In addition, matrix stiffness itself has been 
shown to promote breast cancer progression via mechanoreciprocal induction of Rho-
dependent cell contractility (Levental et al., 2009). 
1.6.2 Epithelial–mesenchymal transition (EMT) in metastatic microenvironment 
EMT and its converse form, MET (mesenchymal–epithelial transition), are essential phases 
in many physiological processes which have been shown to contribute to scar formation and 
fibrosis in response to injury (Stone et al., 2016). At tumour sites, the reverse process of 
MET, which involves the conversion of mesenchymal cells into epithelial derivatives, also 
occurs (J. M. Lee, Dedhar, Kalluri, & Thompson, 2006). As EMT progresses, epithelial cells 
acquire mesenchymal markers and capabilities to evolve towards a mesenchymal 
phenotype, which involves the regulation of several proteins including cadherins (N-
cadherin, E-cadherin), α-SMA, vimentin, integrins, fibronectin and MMPs (Huang, Guilford, 
& Thiery, 2012). 
EMT is crucial in tumour initiation and subsequent invasion of tumour cells into surrounding 
stroma which is a vital event for cancer metastasis (Grünert, Jechlinger, & Beug, 2003). This 
transition involves distinct morphological change whereby the tumour cells switch from a 
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well-differentiated epithelial phenotype to a more invasive mesenchymal phenotype. 
Excessive cell proliferation and angiogenesis are hallmarks of primary epithelial tumour 
growth (Hanahan & Weinberg, 2000) in which EMT-derived migratory cancer cells have 
been shown to establish at distant sites, thus facilitating metastatic dissemination (Kalluri & 
Zeisberg, 2006). EMT has been shown to facilitate metastasis by promoting ECM proteolysis 
and enhancing malignant cell motility, thus conferring the ability to invade (Tiwari, Gheldof, 
Tatari, & Christofori, 2012). In addition, EMT has been found to mediate the metastatic 
stage by colonisation and subsequent MET transition (Kalluri & Weinberg, 2009). 
Furthermore, in the EMT process cancer cells change their adhesive, migratory and invasive 
properties, which involves the reorganisation of the actin cytoskeleton and formation of 
membrane protrusions required for invasive cells (Yilmaz & Christofori, 2009). It has been 
also shown that increased EMT in cancer commonly correlates with late stages of tumour 
progression (Thiery, 2003).  
Recently, increased matrix stiffness in human breast tumours has been shown to induce 
EMT and consequently promote tumour invasion and metastasis (Wei et al., 2015). In 
addition, morphological features of EMT have been shown to resemble many cellular 
changes in matrix stiffness that lead to tumour cell dissemination (J. Yang & Weinberg, 
2008).  
Carcinoma cells can acquire a mesenchymal phenotype and express mesenchymal markers, 
as demonstrated in both in vivo and in vitro studies (J. Yang & Weinberg, 2008). EMT-
derived migratory cancer cells typically establish secondary colonies via a colonisation 
process at distant sites that later resemble the primary tumour as the cells revert to their 
carcinoma phenotype (Massagué & Obenauf, 2016). EMT promotes cell entry into tissue 
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during extravasation and acts as a facilitator of metastatic dissemination, as metastasising 
cancer cells are found to shed their mesenchymal phenotype during secondary tumour 
formation via MET and enter the metastatic microenvironment after extravasation (Kalluri & 
Weinberg, 2009).  
These considerations indicate that induction of an EMT is likely to be a centrally important 
mechanism for the progression of carcinomas to a metastatic stage and implicate MET 
during the subsequent colonisation process, as described in Figure 1.4. 
 
Figure 1.4: EMT in cancer progression. Contribution of EMT to cancer progression involves 
several stages from normal epithelium to invasive carcinoma. Epithelial cells lose their 
polarity and detach from the basement membrane in the invasive carcinoma stage. The 
composition of the basement membrane also changes, altering cell–ECM interactions and 
activating signalling networks. EMT and an angiogenic switch facilitate the malignant phase 
of tumour growth, enabling cancer cells to enter the circulation and exit the bloodstream, 
then undergo MET and thus revert to an epithelial phenotype. Adapted from (Kalluri & 
Weinberg, 2009). 
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1.7 Cancer and Inflammation 
The relationship between inflammation and cancer has been extensively reviewed. 
Inflammation is well known as a critical component in the initiation and progression of 
cancer. Many types of cancer are known to arise from sites of infection (Blaser, Chyou, & 
Nomura, 1995; Shacter & Weitzman, 2002) and sites of chronic inflammation (Coussens & 
Werb, 2002). For example, colon cancer commonly occurs in individuals with inflammatory 
bowel diseases such as Crohn’s disease or chronic ulcerative colitis (Coussens & Werb, 
2002). 
Improving understanding of physiological and pathological changes in wound healing and 
infection is important in developing understanding of the role of inflammation in relation to 
cancer development. Various chemical signals are initiated to regulate the healing process 
on tissue injury, including activation and recruitment of leukocytes such as neutrophils, 
eosinophils and monocytes to the sites of injury (Velnar et al., 2009). Monocytes which then 
differentiate into macrophages are the major source of cytokines and growth factors 
(Osuský, Malik, & Ryan, 1997). ECM remodelling, mediated by secreted proteins such as 
transforming growth factor α and β1 (TGF-α and TGF-β1), platelet-derived growth factor 
(PDGF) and platelet-derived angiogenesis factor, causes proliferation of fibroblasts and 
endothelial cells, which attempt to reconstruct the normal microenvironment (Buckley et 
al., 2001). However, persistent secretion of cytokines and chemokines such as tumour 
necrosis factor-α (TNF-α) and TGF-β1 at inflammatory sites may develop into chronic 
conditions whereby dysregulation initiates neoplastic progression (Coussens & Werb, 2002). 
In chronic inflammatory diseases, TNF-α was originally shown to have toxic effects at higher 
levels; however, animal studies clearly showed that TNF-α can exert tumour-promoting 
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effects (Moore et al., 1999). In fact, activation of a TNF-α signalling pathway mediated by 
malignant and inflammatory cells also contributes to promotion of cell survival, 
angiogenesis and invasion (Charles et al., 2009). 
The presence of inflammatory cells and inflammatory mediators is a prominent hallmark in 
tumour tissues, and numerous studies have demonstrated their important roles in cancer 
development and progression (Candido & Hagemann, 2013; de Visser, Eichten, & Coussens, 
2006; Philip, Rowley, & Schreiber, 2004). There are obvious similar characteristics in tissue 
remodelling and angiogenesis between tumour tissues, chronic inflammatory responses and 
tissue repair (Mantovani, Allavena, Sica, & Balkwill, 2008). ‘Smouldering’ inflammation 
(Frances Balkwill et al., 2005) can also be seen in the tumour without a firm causal 
relationship to inflammation, for example in breast tumours. In addition, epidemiological 
studies have revealed that chronic inflammation correlates to cancer development, with 
colon cancer being one of the typical types of cancer showing a relationship to chronic 
inflammation as mentioned above (de Visser et al., 2006). 
The link between inflammation and cancer can be ascribed to two pathways (Figure 1.5), 
which are, firstly, an extrinsic pathway caused by inflammation that may initiate or promote 
cancer-promoting conditions and, secondly, an intrinsic pathway activated by genetic events 
that cause inflammation and neoplasia such as activation of oncogenes (Figure 1.2) (Candido 
& Hagemann, 2013; Mantovani et al., 2008). Activation of oncogenes such as myc, ras and 
ret or inactivation of tumour suppressors such as p53 and pVHL induce initiated cells to 
produce inflammatory cytokines (Borrello et al., 2005; Soucek et al., 2007). 
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Figure 1.5: Pathways that connect inflammation and cancer. Inflammation and cancer are 
connected by both intrinsic and extrinsic pathways. The intrinsic pathway involves genetic 
mutations that cause neoplasia, which in turn activates production of inflammatory 
mediators, generating an inflammatory microenvironment in tumours. In contrast, 
recruitment of inflammatory cells at the primary site occurs via the extrinsic pathway. Both 
of these pathways converge, thus activating various transcription factors and producing 
inflammatory mediators including cytokines and chemokines. Adapted from (Mantovani et 
al., 2008). 
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Inflammatory cells can potentially direct malignant transformation processes as they are 
potent producers of reactive oxygen species (ROS) and reactive nitrogen species, which can 
directly damage DNA and also alter proteins that regulate DNA repair, act in cell-cycle 
checkpoint controls or are involved in regulation of apoptosis (Allavena et al., 2008). 
Inflammatory mediators such as cytokines, chemokines, arachidonic acid, and free radicals 
and cellular effectors are important components of the local microenvironment of tumours 
(Candido and Hagemann 2013). Release of these potent soluble mediators during immune 
responses has been found to regulate cell migration, proliferation, angiogenesis, 
remodelling of ECM and effects on metabolism (Tlsty & Coussens, 2006). Complex 
interactions between the cell types and these mediators in this microenvironment favour 
tumour growth and angiogenesis, leading to cancer progression and metastasis (Fran 
Balkwill, 2005).  
1.7.1 Macrophage functions in cancer 
Inflammatory responses in the tumour microenvironment involve various types of immune 
cells, and macrophages are key players (Libby, Ridker, & Maseri, 2002). Macrophages are 
important in the innate and adaptive immune responses towards pathogens and are also 
critical mediators in the inflammatory response. Macrophages derived from the bone 
marrow enter the blood circulation as immature monocytes before undergoing 
differentiation into resident macrophages in the tissue (Siveen & Kuttan, 2009). 
Macrophages execute a multitude of functions which are essential for tissue remodelling (D. 
O. Adams & Hamilton, 1984), inflammation and immunity, including phagocytosis, 
cytotoxicity (Nathan & Hibbs Jr, 1991) and the secretion of various cytokines, growth 
factors, lysozyme and complement components (Ross & Auger, 2002).  
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In order to respond to injury or infection, monocytes and endothelial cells are upregulated 
or activated by E- and P-selectin to induce production of cytokines and chemokines such as 
IL- 1β, TNF-α and interferon gamma (IFN-γ) which trigger recruitment of other immune cells 
(Fran Balkwill, 2004; Fox, Turner, Gatter, & Harris, 1995). Macrophages are involved in the 
regulation of angiogenesis in both normal and diseased tissues (Leek, Harris, & Lewis, 1994). 
This observation is based on early studies indicating the presence of wound macrophages in 
wound fluid associated with angiogenic activity (Greenburg & Hunt, 1978). The importance 
of macrophages in wound angiogenesis has been shown in mouse models comparing aged 
and young mice in which macrophages in aged mice produced less VEGF than in younger 
mice, resulting in reduced angiogenesis and delayed wound healing in older mice (Crowther 
et al., 2001). Unless activated, macrophages are not tumouricidal for tumour cells, while 
activation can stimulate anti-tumour functions via direct and indirect cytotoxicity towards 
tumour cells (Siveen & Kuttan, 2009).  
Macrophages can, however, contribute to tumour growth and progression. In some cancers 
macrophages represent up to 50% of the tumour mass (Solinas et al., 2009). It has also been 
shown that macrophages may comprise up to 80% of the tumour mass in breast carcinoma. 
In these cases macrophages may actually behave as a tumour promoter. Macrophages serve 
as a source for many pro-angiogenic factors, including vascular endothelial factor (VEGF) as 
mentioned above, tumour necrosis factor-alpha (TNF-alpha), granulocyte macrophage 
colony-stimulating factor (GM-CSF), Interleukin 1 (IL-1) and Interleukin 6 (IL-6) (Lin et al., 
2006), contributing further to tumour growth. Macrophages infiltrate into many tumour 
types. The quantity of infiltrated macrophages then correlates with poor prognosis in many 
types of cancers such as breast, cervix, bladder and brain cancers (Bingle, Brown, & Lewis, 
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2002). The association of macrophages in human and murine tumours called TAMs has been 
further reviewed in many cancers where their numbers correlate significantly with tumour 
angiogenesis, such as in pulmonary adenocarcinoma (Takanami, Takeuchi, & Kodaira, 1999), 
endometrial carcinoma (Salvesen & Akslen, 1999) and malignant melanoma (Torisu et al., 
2000). Recently, macrophage infiltration during wound healing was found to promote skin 
carcinogenesis by stimulation of epidermal cell proliferation (Weber et al., 2016). 
 Macrophage polarisation 1.7.1.1
Macrophages have a pleotropic biological function and show different phenotypes based on 
the specific environmental stimuli that they are exposed to (Frances Balkwill et al., 2005). 
Figure 1.6 shows a schematic diagram of macrophage polarisation. The M1 phenotype or 
M1 macrophages are classical activated macrophages that have the ability to kill 
microorganisms and tumour cells and to produce high levels of immunostimulatory 
cytokines. In contrast, in the presence of tumour-derived anti-inflammatory molecules such 
as IL-4, IL-10, IL-13 and transforming growth factor β1, macrophages show an M2 
phenotype. These cells are adapted to cell scavenging, promoting angiogenesis and 
repairing and remodelling damaged tissues (Mantovani, Sozzani, Locati, Allavena, & Sica, 
2002). In addition, angiogenesis and ECM breakdown stimulated by these cells may promote 
tumourigenesis (Allavena et al., 2008). Production of MMPs by macrophages at the invading 
front of a tumour may also enhance cancer-cell motility and invasion (Condeelis & Pollard, 
2006). 
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Figure 1.6: Polarisation of macrophage function. Macrophages can be polarised based on 
their environmental stimuli. They are primarily of the M1 phenotype in normal inflamed 
tissue. Increased levels of reactive oxygen species (ROS) and inflammatory cytokines provide 
potent antimicrobial, immunostimulatory and tumour cytotoxic effects on the cells. In 
tumours, tumour-derived cytokines induce differentiation of macrophages into the M2 
phenotype, which favours tumour growth (Solinas et al., 2009). 
 Tumour-associated macrophages (TAM) 1.7.1.2
Macrophages are known to exhibit either pro- or anti-inflammatory responses depending on 
the stage of disease and the type of signals they are exposed to in the microenvironment. In 
the tumour microenvironment TAMs, which resemble M2 macrophages (Sica, Schioppa, 
Mantovani, & Allavena, 2006), have diverse functions and have the ability to affect 
neoplastic tissues, which includes promotion of angiogenesis and vascularisation, stroma 
formation and ECM dissolution, and enhancement or in some cases inhibition of tumour cell 
growth (Mantovani, Bottazzi, Colotta, Sozzani, & Ruco, 1992).  
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Both primary lesions and metastases of solid tumours are infiltrated by enormous numbers 
of tumour-associated leukocytes. The heterogeneous populations of these cells consist of a 
variable subset of T-cells (helper, suppressor and cytotoxic), B-cells, natural killer (NK) cells 
and macrophages (Bingle et al., 2002). 
 
Figure 1.7: Tumour-associated macrophages in cancer progression. TAMs play a role in 
cancer progression, where they influence several important cellular functions including 
proliferation, matrix remodelling and angiogenesis (Siveen & Kuttan, 2009). 
TAMs have been associated with several stages of tumour progression, as well as tumour 
proliferation, angiogenesis and tissue remodelling, metastasis and immune suppression, as 
shown in Figure 1.7. TAMs also promote cancer metastasis via all of these mechanisms, 
including enhancement of cell proliferation, migration and invasion. Several studies have 
demonstrated that TAMs induced tumour cell invasion via a paracrine signalling loop with 
the involvement of tumour-derived colony stimulating factor 1 (CSF-1) and macrophage-
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derived epidermal growth factor (EGF) in glioma and breast cancers (Coniglio et al., 2012; 
Goswami et al., 2005). Interactions within the tumour microenvironment enable ECM 
breakdown and promote cell motility (Condeelis & Pollard, 2006). Modulation of the 
microenvironment by TAMs has been shown to increase neovascularisation and stroma 
formation (Crowther et al., 2001). 
1.8 Cytokines in Inflammation and Cancer 
Cytokines are major mediators of communication between cells in the inflammatory tumour 
microenvironment (Fran Balkwill, 2004). Neoplastic cells commonly over-express pro-
inflammatory cytokines, such as migratory inhibitory factor (MIF) (Verjans et al., 2009; 
Wilson et al., 2005), TNF-α (Charles et al., 2009; Maniati et al., 2011), IL-6 (Lesina et al., 
2011), IL-17 (Charles et al., 2009; Numasaki et al., 2003; L. Wang et al., 2009), IL-12, IL-23, IL-
10 and TGF-β (Candido & Hagemann, 2013), and these have been shown in various types of 
cancers in both experimental animal models and human cancers. Furthermore, growth 
factors released by tumour cells such as granulocyte macrophage colony-stimulating factor 
(GM-CSF), platelet-derived growth factor (PDGF), VEGF, TGF-α and other monokines lead to 
the activation of macrophages, which then have the capability to influence angiogenic 
processes (Ueno et al., 2000). 
These anti-inflammatory cytokines provide a link between inflammation and cancer. 
Inflammatory cytokines which are produced by stromal and cancer cells may functionally 
promote or potentially suppress tumours (Mueller-Huebenthal et al., 2009). It has been 
clearly shown that both TNF-α and IL-17 can act as tumour suppressors at the beginning of 
tumour development, while later they are seen to promote tumour growth (Mumm & Oft, 
2008; Murugaiyan & Saha, 2009). Apart from angiogenesis to help maintain cell survival, 
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TNF-α has been shown to suppress the function of T-cells and associated macrophages, 
which then impairs immune surveillance (Kiessling et al., 1999). Stimulation of genotoxic 
ROS and RNS by TNF-α also may help to initiate tumour growth (Charles et al., 2009).  
In addition, both IL-6 and IL-10 are highly expressed in inflammatory bowel disease (IBD) 
and colitis-associated colon cancer (CAC) (Mudter et al., 2008), and in diffuse large B-cell 
lymphoma (Lech-Maranda et al., 2006), respectively. IL-6 is commonly shown to target 
important genes which regulate cell cycle progression and suppress apoptosis; therefore, it 
has been suggested as promoting cell survival and tumour development (Bommert, Bargou, 
& Stühmer, 2006). 
1.9 Tumour Growth and Proliferation 
Tumour growth is determined by three main factors, which are regulation of the cell cycle, 
the amount of cell proliferation and the amount of cell loss (Quinn & Wright, 1990). The cell 
cycle consists of four phases: Gap1 (G1), S, Gap2 (G2) and mitosis (Figure 1), where DNA 
synthesis takes place in the S phase, followed by mitosis. The G1 and G2 phases allow cell 
preparation before entering DNA synthesis and mitosis, respectively. However, most of the 
cells in normal tissue are in a quiescent state (G0), having a range of normal metabolic 
activities outside the cell cycle (Tachibana, Gonzalez, & Coleman, 2005). 
Normal tissues have the ability to control the cell cycle process by regulating growth signals, 
while in tumour cells, acquired damage to cell cycle regulatory genes such as p53 and 
retinoblastoma protein (Rb) (Staunton & Gaffney, 1998), and deregulation of these signals, 
can result in uncontrolled cell growth and inappropriate cell survival. Since tumour cells are 
heterogeneous and diverse, they can acquire the ability to proliferate beyond the growth 
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restrictions in normal tissue, which then results in an uncontrolled growth rate in tumours 
(Evan & Vousden, 2001). 
Numerous studies have shown that higher tumour proliferation rates, as assessed by 
various established techniques, commonly correlate with higher risk of metastasis and 
increased number of malignancies, as seen for example in breast and lung cancer patients 
(Kawai et al., 1994; Rudas et al., 1994). Inhibiting cell proliferation could delay 
tumourigenesis and limit cancer spread, currently widely applied using various drugs for 
treatment and intervention (Mabuchi et al., 2007; So, Guthrie, Chambers, Moussa, & Carroll, 
1996; Tsuchiya et al., 2011). 
Proliferating cell nuclear antigen (PCNA) is one of the proliferation markers that has a role in 
normal DNA replication and repair, chromatin remodelling and cell cycle regulation 
(Stoimenov & Helleday, 2009; Strzalka & Ziemienowicz, 2011). Based on that fact, PCNA has 
been found to be an effective marker for cell proliferation and has been very useful to 
determine tumour status, including histological staging, prognosis and cancer relapse 
(Mayer et al., 1993; S.-C. Wang, 2014). A study showed that serosal invasion and metastasis 
to lymph nodes were correlated with a high PCNA labelling index in gastric adenocarcinoma 
(Elpek, Gelen, Aksoy, Karpuzoğlu, & Keles, 2000). Furthermore, high levels of expression of 
PCNA have also been shown in more aggressive oral tumours (Tsuji et al., 1995). 
Additionally, survival time was found to be inversely related to the percentage of PCNA-
positive cells in primary tumours and lymph node metastases (Mayer et al., 1993). 
Even though PCNA is widely used as a tumour proliferation marker, researchers are still 
concerned with sometimes conflicting results in the correlation between PCNA expression 
and cancer prognosis. Evidence shows that in several types of cancer, PCNA was highly 
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expressed in tumours which are associated with poor survival rates (Ebina, Steinberg, 
Mulshine, & Linnoila, 1994; L.-F. Wang et al., 2006). However, there were variations in the 
distribution and intensity of PCNA staining in cancer tissues (Ebina et al., 1994). In addition, 
a few studies have claimed that expression of PCNA and Ki-67 were not correlated with 
cancer prognosis and survival rates (Bukholm, Bukholm, Holm, & Nesland, 2003; Grossi et 
al., 2003; Haerslev, Jacobsen, & Zedeler, 1996), even though expression may be associated 
with larger tumour size and poor tumour cell differentiation (Haerslev et al., 1996). 
1.10 Cell Motility and Adhesion 
Cell motility is one of the characteristics of invasive tumours which facilitate migration into 
adjacent tissues or transmigrate through basement membranes and ECMs. Invasive tumour 
cells have frequently been demonstrated to show dysregulated cell motility in response to 
extracellular signals from growth factors and cytokines. Previous findings suggest that this 
growth factor receptor–mediated motility is one of the most common aberrations in tumour 
cells leading to increased invasiveness and may represent an altered cellular behaviour 
during migration (Wells, 1999). 
After cellular differentiation, most cells are non-motile (with the exception of wounded 
keratinocytes and sprouting capillaries in wounded tissue) due to attachments, via 
membrane proteins such as integrins, to the ECM scaffold and these attachments limit 
locomotion (Peter Friedl & Wolf, 2003). In contrast, during invasion reorganisation of the 
cytoskeleton occurs via actin protrusions, producing lamellipodia and invadopodia that help 
the cell to invade across basement membranes. Additionally, EMT may occur and this has 
been widely described in cancer cell dissemination (Grünert et al., 2003). The changes of the 
cytoskeleton result in changes of the cell shape that equip the cell for migration and 
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extravasation (Wells, 2006). This may be accompanied by a loss of lateral attachments to 
other cells, which is a hallmark of EMT and is characterised by a loss of cadherin expression. 
Cell movement involves the extension of lamellipodia at the leading edge of the migrating 
cells which allow protrusion towards the motogenic signal, attachment, contraction and 
detachment at the rear of the cells (Ridley et al., 2003). In addition there are filopodia, 
described as membrane projections that consist of gathered actin filaments to form tight 
bundles and have the ability to respond to cell migration signals (Mattila & Lappalainen, 
2008). The biophysical processes involved in cytoskeletal reorganisation are described in 
Figure 1.8. Limitation of cell motility and tumour invasion could be achieved by inhibiting 
one of these processes (Kassis, Lauffenburger, Turner, & Wells, 2001). Chemokinesis or 
chemotaxis towards released growth factors and cytokines can influence cell movement, 
and these are directly related to tumour progression (Wells, 2006). Targeting tumour cell 
motility will be crucial for future therapeutic approaches to enhance effectiveness in limiting 
tumour progression and in preventing metastasis to secondary sites. 
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Figure 1.8: Cytoskeleton reorganisation in migration. The process involves protrusion of 
lamellopodia, anterior adhesion, cellular contraction and posterior detachment of the cell. 
Figure indicates the integrating molecules for each process; those involved in adhesion and 
growth factor–driven motility (black) and those activated during the enhanced movement 
due to growth factor receptor activation (blue italics). Abbreviations: ERK, extracellular 
signal-regulated kinase; PKCδ, protein kinase Cd; PLCγ, phospholipase Cγ. Adapted from 
(Wells, Grahovac, Wheeler, Ma, & Lauffenburger, 2013). 
Adhesiveness of the cells may also influence the invasion process. Cell adhesion is very 
closely related to important cellular processes such as cell proliferation, migration and 
motility, differentiation and death (Thiery, 2003). Cell adhesion molecules such as cadherins, 
integrins and immunoglobulin-like cell adhesion molecules (Ig-CAMs) were found to directly 
mediate signal transduction pathways which are involved in diseases as well as cancer 
development (Cavallaro & Christofori, 2004). Adhesion signalling also frequently enhances 
signalling from growth factors and acts in a synergistic fashion. Cellular movement and cell-
matrix binding can be controlled by complexes of integrins, adaptor proteins and the actin 
cytoskeleton termed the cytoplasmic cell-adhesion complex (CCC) which is involved in 
potential cell signalling pathways such as RTK and Wnt signalling (Hynes, 2002). Moreover, 
adhesion sites also influence the maintenance of an adhesive interaction between cells and 
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the basement membrane via specialised junctions including tight junctions, adherens 
junctions, gap junctions, desmosomes and hemidesmosomes (Thiery, 2003). 
The ability of malignant cancer cells to dissociate from the primary tumour site and 
metastasise to other distant organs indicates changes in the adhesive properties of the 
tumour cell to basement membrane components that thus facilitate tumour progression 
(Cavallaro & Christofori, 2004). Invasive cells are less adhesive and become highly mobile, 
with additionally higher mitotic activity compared to normal cells. They are also increasingly 
metabolically active and have the ability to secrete proteolytic enzymes that can change 
their motility (Turner & Sherratt, 2002) by degrading adjacent ECM molecules. 
1.10.1 Focal adhesion proteins 
Cell spreading and migration are driven by focal complexes in which focal adhesion (FA) 
proteins adhere to the ECM (Zaidel-Bar, Milo, Kam, & Geiger, 2007). FAs are specialised 
cellular domains that provide networking junction between the cell cytoskeleton and the 
ECM (Burridge, Fath, Kelly, Nuckolls, & Turner, 1988). The formation of lamellipodia and the 
reorganisation of cell adhesion proteins enable the attachment and detachment of actin 
filaments throughout the cycle (Mohammad et al., 2012; Vicente-Manzanares, Choi, & 
Horwitz, 2009). 
In most adhesion sites, extracellular domains of the integrin receptors mediate the binding 
to the ECM, which then either directly mediates or strengthens the mechanical linkage 
between the ECM and the cytoskeleton, or participates in adhesion-mediated signalling 
(Zamir & Geiger, 2001). FAs commonly located at the periphery of the cell possess specific 
FA proteins such as paxillin, vinculin and β-subunits of integrins, such as αvβ3 integrin, 
which are then associated outside the cell with matrix molecules such as fibronectin fibrils 
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(Zaidel-Bar, Ballestrem, Kam, & Geiger, 2003). Tyrosine phosphorylation of FA via Rho 
signalling pathways allows the assembly and turnover via those FA proteins, mediated by 
activation of focal adhesion kinase (FAK) (Panetti, 2002). Focal complexes (FXs) are 
temporary structures that assemble under the lamellipodium in a hierarchical manner, 
being activated by Rho A and resulting in force-dependent transformation into FAs (Zaidel-
Bar et al., 2003). These structures are then associated with actin- and myosin-containing 
stress fibres (Zamir & Geiger, 2001).  
Figure 1.9 (adapted from (Sandbo & Dulin, 2011)) shows the connection signalling between 
matrix stiffness, contraction of FA and formation of stress fibre during actin cytoskeletal 
regulation of myofibroblasts. Involvement of actin cytoskeleton in this bidirectional 
signalling was shown to increase ECM organisation, FA turnover and contraction, resulting in 
the regulation of transcriptional proteins, which are vital processes in wound repair and 
fibrogenesis (Sandbo & Dulin, 2011).  
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Figure 1.9: The role of the actin cytoskeleton in modulating myofibroblast functions. The 
actin cytoskeleton regulates several mechanical functions during myofibroblast 
differentiation (focal adhesion formation, contraction and matrix remodelling), which 
controls the transcription and translation of several genes simultaneously that are involved 
in these same mechanical functions. The actin stress fibre amplifies the signals leading to 
myofibroblast differentiation and contributes to matrix stiffness, focal adhesion formation 
and contractility of stress fibre formation. Adapted from (Sandbo & Dulin, 2011). 
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Cell adhesions, connecting cells to their surrounding stroma, have been shown to influence 
tumour malignancy via their role in regulating the rigidity and reorganisation of the ECM, 
thus regulating tumour cell survival and favouring metastasis. Activation of both growth 
factor pathways and FA proteins such as paxillin, Hic-5 and leupaxin has been shown to 
correlate with poor prognosis and aggressive cancera (Jianxin, Deakin, & Turner, 2009; Short 
et al., 2007). Cortactin, paxillin and PKCm have been shown to form a complex associated 
with invadopodial membranes that enables the cell to extend into the matrix, which 
produces cellular protrusions via matrix degradation and an invasive phenotype in invasive 
breast cancer cells MDA-MB-231 (Bowden, Barth, Thomas, Glazer, & Mueller, 1999). 
 Paxillin 1.10.1.1
Paxillin is characterised as a 68-kDa FA protein involved in cell adhesion assembly and 
turnover via tyrosine phosphorylation, and has been identified as a novel binding partner 
for the FA and actin-binding protein vinculin (279). The paxillin family comprises three 
proteins: paxillin, hydrogen peroxide inducible clone-5 (Hic-5) and leupaxin, which functions 
as a molecular scaffold protein. Paxillin comprises multiple discrete protein-binding 
modules, including numerous tyrosines as well as Ser/Thr phosphorylation sites. Many of 
these phosphorylated forms have been detected in tumour samples and/or cancer cell lines, 
and are expressed in a variety of invasive/metastatic cancers, including but not limited to 
breast, lung and prostate tumours (Deakin, Pignatelli, & Turner, 2012). Paxillin family 
expression in human cancers varies, as shown in Table 1.2 (based on mRNA expression in 
tumour samples compared to normal tissue). 
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Table 1.2: Variability of paxillin expression in human cancers. Variability of paxillin 
expression in human cancers as indicated by a number of studies which determined 
expression in tumour tissues compared to normal tissue. Adapted from (Deakin et al., 2012). 
Cancer Type Paxillin Hi-5 Leupaxin 
Increased Decreased Increased Decreased Increased Decreased 
Bladder cancer    3   
Brain and CNS cancer 5  4 1  1 
Breast cancer 1 6 2 3 3 1 
Cervical cancer 2 1  1 1  
Colorectal cancer   3 4 5  4 
Oesophageal cancer 5  1    
Leukaemia  10 2 2 1 1 
Ovarian cancer 6      
Pancreatic cancer 1  2    
Prostate cancer    4 1 1 
 
Paxillin phosphorylation has been shown to increase lamellopodia protrusions, while non-
phosphorylated paxillin is crucial for fibrillar adhesion formation (Zaidel-Bar et al., 2007). 
Paxillin phosphorylation was also shown to promote invadopodia dynamics by expansion of 
an invadopodia ring which allows invadopodia disassembly (Badowski et al., 2008). 
However, there is contradictory evidence on the role of paxillin phosphorylation in 
remodelling integrin adhesion and cell migration that leads to membrane protrusion (Zaidel-
Bar et al., 2007); phosphorylation was shown to increase migration in some cell types 
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(Iwasaki et al., 2002), whereas it was reported to inhibit cell migration in another study 
(Yano et al., 2000). The dynamic adhesion process may depend on the proportions of 
phosphorylated and non-phosphorylated paxillin. It has been demonstrated that 
overexpression of a phosphomimetic paxillin mutant enhances lamellipodial projection 
associated with formation of FA complexes (Zaidel-Bar et al., 2007). Recently, increased 
levels of paxillin have been shown to reduce cell migration and invasion from the primary 
tumour to metastatic sites due to the inability to disassemble of FAs (Mowers, Sharifi, & 
Macleod, 2016). 
 Vinculin 1.10.1.2
Vinculin is a 116 kDa actin-binding protein which localises to integrin-mediated cell–matrix 
interactions in the FA complex and cadherin-mediated cell–cell junctions (Ziegler, 
Liddington, & Critchley, 2006). It has been shown to bind with talin to the actin cytoskeleton 
of the cytoplasmic domain of β-integrin, and is required for integrin activation and FA 
stabilisation (Nayal, Webb, & Horwitz, 2004).  
Vinculin acts as a key regulator of FAs and regulates cell migration depending on the 
availability of paxillin in the system (DeMali, 2004; Zaidel-Bar et al., 2007). Depletion of 
vinculin reduced cell adhesion to different substrates of the ECM and increased cell 
migration (Saunders et al., 2006). Expression of vinculin also is correlated with local 
protrusion of the cell membrane and lamellopodia formation (Humphries et al., 2007). 
Similarly, overexpression of vinculin reduces cell migration, while downregulation of vinculin 
enhances cell motility, supporting findings that vinculin knockout cells are less adherent but 
more motile and associated with fewer and smaller FAs, also showing elevated expression 
of both FAK and paxillin (Ziegler et al., 2006). Induction of cell motility associated with lower 
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vinculin expression is thought to enhance tumour metastasis (Carisey & Ballestrem, 2011). 
Tyrosine phosphorylation of vinculin has been confirmed to be involved in the regulation of 
cell spreading (Z. Zhang et al., 2004). Vinculin has also been claimed to act as a tumour 
suppressor, as it has been shown to be involved in apoptosis-signalling pathways, leading to 
increased cell survival (Subauste et al., 2004; Ziegler et al., 2006). 
1.11 Tumour Cell Migration 
Cell migration can be defined as the ability of cells to migrate and change their positions 
within tissue or organs, a non-destructive process (Kramer et al., 2013) and crucial for tissue 
repair and immune function (Ridley et al., 2003). In contrast, invasion involves penetration 
through tissue barriers, which allows malignant cells to pass through the basement 
membrane and infiltrate into interstitial tissues. Therefore, in order to invade, tumour cells 
require migration, adhesion, proteolysis and remodelling of the ECM (Peter Friedl & Wolf, 
2010). A cell cannot invade without migration, but can move without invasion (Kramer et al., 
2013). Disruption of this motility behaviour contributes to pathological conditions such as 
atherosclerosis (Heldin & Westermark, 1999), as well as tumour progression and metastasis 
(Hood & Cheresh, 2002). 
The migration cycle consists of cell polarisation and protrusion before the cell can migrate in 
a certain direction (Ridley et al., 2003). Actin filaments are polarised, commonly via actin 
polymerisation that drives membrane protrusion. It also involves formation of lamellipodia 
or filopodia, and adherence to the ECM via transmembrane receptors that are linked inside 
the cell to the actin cytoskeleton (Welch & Mullins, 2002) via adaptor proteins.  
Cells can migrate in several ways, including single cell, amoeboid, chain and collective 
migration (Peter Friedl & Wolf, 2003). Commonly, the shape and structure of migrating cells 
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are both changed, allowing cell protrusion at the edge of the cells, followed by cell 
adherence to the substrate before forward translocation of the cells finally occurs 
(Lauffenburger & Horwitz, 1996). It has been described that tumour cells collectively 
migrate via protrusion sheets and strands at the primary site or site of local invasion, and 
then detachment from the cluster, becoming a ‘nest’ of cells, which is then responsible for 
metastasis. The migration mechanism used by tumour cells has been found to be most likely 
similar to that of normal cell migration, such as that seen in morphogenesis, immune 
responses and wound repair (P Friedl & Bröcker, 2000). 
In addition, extrinsic controls regulated by chemokines and growth factors can also 
influence cell migration. Epidermal growth factor (EGF) and insulin-like growth factor 1 are 
known factors that enhance cell migration (Brooks et al., 1997). Moreover, chemokines have 
been shown to promote cell metastasis by increased cell migration via CXCR4-signalling 
pathways (Wells et al., 2013). 
1.12 Tumour Invasion and Metastasis 
Most cancer morbidity and mortality occurs on spread of the tumour from an original 
localised tumour site. This is termed tumour dissemination and is responsible for about 90% 
of cancer deaths. Therefore, key molecular controls that enable this process must be 
identified in order to prevent metastatic spreading. Understanding the mechanisms of 
inhibition of migration, invasion and metastasis will likely lead to the development of novel 
therapeutic approaches. 
Tumour dissemination involves invasion and the metastasis process. Multistage processes 
are involved in metastasis, including infiltration of cells through ECM, migration of cells 
through blood and lymphatic vessels – termed invasion – and establishment of malignant 
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cells at secondary sites (Kramer et al., 2013). Adaptation by aggressive cancer cells to 
particular tissue microenvironments creates favourable surroundings which allow tumour 
cells to survive and exploit new environments. In order to spread to distant sites, cancer 
cells need to survive in the circulation prior to intravasation; this leads to ‘cell seeding’ at 
the target organ, successful parenchymal extravasation and persistent cell proliferation at 
the distant site (Joyce & Pollard, 2009). 
Different cellular characteristics of the dissemination process are observed in both invasion 
and metastasis, as listed in Table 1.3. At the primary sites, tumour cells need to separate 
from the primary mass, reorganise and penetrate the basement membrane barrier so as to 
migrate through it and survive among neighbouring cells (Wells et al., 2013). Sustained 
angiogenesis and stable adhesion are crucial at this stage to provide support to the tumour 
cells, since without angiogenesis growth is limited (Kienast et al., 2010). Metastatic seeding 
then occurs by extravasation of surviving cancer cells at the distant sites and establishment 
of distinct secondary or metastatic tumours (Klein, 2008). 
While much is known about cellular contractility and traction forces of cells including cell 
adhesion, migration and actin remodelling (Lemmon, Chen, & Romer, 2009) in 2D, force 
generation in more physiologically-relevant 3D environments has not been well 
characterised. There are differences in cell–matrix adhesions and cytoskeletal organization 
(Rhee, Jiang, Ho, & Grinnell, 2007) between 2D and 3D microenvironments which can alter 
cell morphology, proliferation and migration (Fraley et al., 2010). In contrast, study on the 
role of the cytoskeleton in 2D and 3D was showed no difference in modulating cell force 
(Kraning-Rush, Carey, Califano, Smith, & Reinhart-King, 2011). As for the advantage of 3D 
microenvironment, it has been shown that multiple modes of 3D migration, including 
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lamellipodial, lobopodial and amoeboid and collective migration were involved that 
influence the mode of cell motility and migration (Peter Friedl, Sahai, Weiss, & Yamada, 
2012).  
In vivo, tumour cells move through three dimensional matrices, meaning two-dimensional 
models in vitro have limitations compared to tumour invasion and metastasis in animal 
models (Wells, Chao, Grahovac, Wu, & Lauffenburger, 2011). Transcellular contractility/cell-
substratum adhesion was found to be dependent on the 3D environment, including changes 
in actin polymerisation which allow cell protrusion and also potentially allow differences in 
matrix stiffness (Wells et al., 2013). In fact, ECM stiffness, density and fibre orientation have 
been shown to modulate cell adhesion and reorganisation of the actin cytoskeleton (Peter 
Friedl & Wolf, 2010). 
 
Table 1.3: Properties needed for invasion and metastasis 
 
Property acquired Invasion Metastasis 
Dissociate from tumour mass Partial Full 
Reorganize/remodel matrix At invasion site At metastasis site 
Migrate Major Limited to major 
Recognize endothelial cells N/A Limited to major 
Proliferate within ectopic stroma TBD Major 
N/A – not necessary, TBD – to be determined 
Adapted from (Wells, 2006). 
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1.12.1 Invadopodia mechanisms 
In order for tumour cells to disseminate from the primary tumour sites, they must degrade 
the surrounding ECM–basement membrane barrier to escape into surrounding tissues, and 
subsequently metastasise and be sustained at the distant sites. These protrusion membrane 
structures are called lamellipodia and are usually associated with dynamic membrane ruffle 
formation, characterised by the co-localisation of many proteins that are found in FAs and 
lamellipodia, as well as membrane-trafficking proteins and proteases (Buday & Downward, 
2007; Yamaguchi, Wyckoff, & Condeelis, 2005).  
Invadopodia and podosomes are highly dynamic and specialised adhesive structures 
associated with finger-like protrusions that can degrade ECM in order to invade into and 
across tissue boundaries (Yamaguchi et al., 2005). There are three stages of invasive cancer 
cells needed to cross the ECM: perforation of the ECM by invadopodia formation, followed 
by invadopodia elongation and maturation, then finally the cells’ entry into tumour 
stromata and establishment in a new microenvironment (Figure 1.10). In addition, the 
elongation of invadopodia is commonly dependent on filopodial actin formation associated 
with establishment of microtubule and vimentin filament networks for further growth 
(Schoumacher, Goldman, Louvard, & Vignjevic, 2010). 
These structures are crucial in tumour cell invasion, as they cause focal disruption of the 
dense meshwork of ECM barriers through localised activity of membrane binding, and 
release of soluble MMPs, which are responsible for degradation of constituents of the ECM 
and thus able to promote tumour cell dissemination (Curran & Murray, 2000). Degradation 
of the ECM that is present in the basement membrane and tumour stroma is essential for 
local invasion and formation of metastatic sites by malignant cancer cells (Kessenbrock, 
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Plaks, & Werb, 2010) and this capacity is useful in determining the invasiveness of the 
cancer cells (Artym, Yamada, & Mueller, 2009). MMPs have also been shown to interact 
with cell-matrix adhesion molecules such as integrins to promote cell migration and matrix 
degradation, and EMT has been shown to further enhance these processes by increasing the 
expression of MMP-2 and MMP-9 (Bourboulia & Stetler-Stevenson, 2010). 
In many ways invadopodia are similar to lamellipodia, having branched actin cytoskeleton 
into membrane protrusions that are present at the leading edge of migratory or invasive 
cells. Lamellipodia instead could be thought of as an initiating event for invadopodia 
formation (Baldassarre et al., 2006). However, their structures differ in the formation of FA 
complexes and FAK, which are found only in podosomes but not in invadopodia (Bowden et 
al., 2006). In addition, significant differences in the key regulatory proteins, such as Nck1 
and Mena, was observed in tumor cell invadopodia compared to pedosomes (Sibony-
Benyamini & Gil-Henn, 2012). 
Recently, invadopodia were shown to be a major contributor to and hallmark of tumour 
cells that undergo systemic dissemination and metastasis due to oncogenic mutations in 
tumour cells, driving tumour initiation in the tumour microenvironment (Eddy, Weidmann, 
Sharma, & Condeelis, 2017). In addition, a range of signals from tumour microenvironments, 
such as ECM stiffness, mitogenic and angiogenic growth factors, cell contact-mediated 
signalling and hypoxia, have all been shown to influence invadopodia functions in vivo (Eddy 
et al., 2017). 
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Figure 1.10: Stages of invadopodium maturation. Stage 1 or early precursor stage: invadopodia initially form as non-degradative precursors 
that consist of a core structure containing actin, cortactin, cofilin, N-WASp, Tks5 and other proteins. Stage 2 or late precursor stage involves 
activation of kinases, recruitment of β1 integrin and talin, and Tks5 anchors the precursor. Stages 3–4, which are the maturation of 
invadopodium stage: Stage 3 involves activation of actin polymerisation by stimulation of the NHE-1-cofilin pathway, and actin polymerisation 
drives invadopodial elongation and stabilisation. In Stage 4, microtubule and intermediate filament recruitment facilitates further elongation 
of the protrusion, and matrix proteases are recruited to degrade the ECM. Adapted from (Beaty & Condeelis, 2014). 
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1.12.2 Cortactin as invadopodia marker 
Cortactin is an actin-binding protein that was originally identified as a substrate for the 
protein kinase Src (Roncucci, Stamp, Medline, Cullen, & Robert Bruce, 1991). It contains an 
N-terminal acidic region (NTA) that binds to and activates the Arp2/3 complex. The major 
function of cortactin is to regulate the actin cytoskeleton through promotion and 
stabilisation of the Arp2/3-induced branch-chained actin networks, suggesting that cortactin 
facilitates actin network formation (Weaver, 2008). 
Cortactin is distributed in the cytoplasm and enriched in the front of the extending 
lamellipodia at the adhering side of cultured cancer cells (L.-H. Zhang et al., 2006). In 
invadopodia, cortactin is involved in the activation and stabilisation of the branched actin 
assembly to form an Arp2/3 complex, which allows cellular protrusion (Clark & Weaver, 
2008) by projection of lamellipodia (Yamaguchi & Condeelis, 2007) and pedosomes (Tehrani, 
Faccio, Chandrasekar, Ross, & Cooper, 2006). Dynamic regulation of pedosomes has been 
shown to result in differentiation into invadopodia, which are specialised actin-rich 
protrusions in metastatic tumour cells and in most transformed cells, where they play 
crucial roles in ECM degradation and invasion (Artym, Matsumoto, Mueller, & Yamada, 
2011).  
In addition, cortactin has been suggested to act directly to promote actin assembly at 
invadopodia puncta (Yamaguchi & Condeelis, 2007). Importantly, the plasma membrane 
delivery of MT1-MMP, which can activate the proteases MMP-2 and MMP-9, is correlated 
with the level of expression of cortactin (Clark, Whigham, Yarbrough, & Weaver, 2007). The 
role of cortactin in vesicular trafficking and dynamic branched actin assembly is thought to 
be a potential mechanism to mediate ECM degradation associated with invadopodia by 
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releasing proteases (Clark & Weaver, 2008). The secretion of MMPs has been found to be 
correlated closely with cortactin expression levels. 
In humans, the amplification of segment 11q13 on chromosome 11 – a region that includes 
the CTTN gene – and the associated overexpression of cortactin have been linked to many 
cancers, including head and neck squamous cell carcinomas (HNSCC), oral SCC, lung SCC, 
gliosarcoma, breast cancer, colorectal cancer and melanoma (Akervall et al., 1995; Cai et al., 
2010; Campbell et al., 1996; Chen et al., 2010; Faoro et al., 2010; Schuuring et al., 1993; 
Schuuring et al., 1992; van Damme et al., 1997; Xu et al., 2010; Yamada et al., 2010). 
Cortactin is commonly overexpressed in several human cancers, including breast and 
squamous cell carcinomas of the head and neck (Buday & Downward, 2007). It has been 
well documented that cortactin is overexpressed in several human cancers, including 
hepatocellular carcinoma, where the expression of cortactin correlated with metastatic level 
(Chuma et al., 2004) and increased phosphorylation of cortactin has been shown to induce 
metastasis in a mouse cancer model (Y. Li et al., 2001).  
Overexpression of cortactin has also been linked to invasive cancers, including melanoma, 
colorectal cancer and glioblastoma, making cortactin an important biomarker for invasive 
cancers (Hirakawa et al., 2009; Kirkbride et al., 2011; Rothschild et al., 2006; Weaver, 2008; 
Xu et al., 2010). 
Since cortactin is an important regulator in cell motility and invasion, it is frequently used as 
an invadopodia marker, based on its localisation to sites of focal ECM degradation (Weaver, 
2008). 
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1.13 Apoptosis and Necrosis 
Apoptosis, or programmed cell death, is defined as a genetically encoded cell-death 
program which can be differentiated from necrosis, or accidental cell death, based on 
distinct morphological and biochemical characteristics (Vermes, Haanen, & 
Reutelingsperger, 2000). Thus, necrosis occurs due to biological changes in the cell’s 
environment (Nanji & Hiller-Sturmhöfel, 1997). Apoptosis involves an elimination process of 
unwanted, damaged, transformed or infected cells, and plays a fundamental role in the 
maintenance of tissue homeostasis in the adult organism, while dysregulation of apoptosis 
results in pathological conditions including cancer, autoimmune and neurodegenerative 
diseases (Ola, Nawaz, & Ahsan, 2011). Morphological signs of apoptosis are characterised by 
cellular shrinkage, membrane blebbing, nuclear condensation and fragmentation, and it can 
be distinguished from necrosis by these unique events (Vermes et al., 2000).  
It has been shown that aggressive tumours commonly show obvious signs of apoptosis, but 
this may be offset by proliferation, since there are significant linear correlations between 
apoptotic and cell division (mitotic) indices in many tumours types (Staunton & Gaffney, 
1998). A high level of proliferating cells correlates with aggressive tumours in various types 
of cancer; however, many tumours grow relatively slowly due to a high rate of cell loss, 
which involves apoptosis (Arends, McGregor, & Wyllie, 1994). Therefore, in certain tumour 
types increased levels of both apoptosis and mitotic activity may reflect aggressive tumour 
growth. 
Excessive apoptosis can also lead to immune deficiency (Saito et al., 1999) depending on the 
cell type undergoing apoptosis. Since resistance to apoptosis is a hallmark of some cancer 
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types, it is important to understand the mechanisms underlying apoptosis and how it might 
impact on tumour growth. 
1.13.1 Molecular mechanisms of apoptosis 
The sequence of events of apoptosis are well characterised (Rich, Watson, & Wyllie, 1999). 
Apoptosis starts when cells undergo nuclear and cytoplasmic condensation, with blebbing of 
the plasma membrane and finally creation of apoptotic bodies containing portions of 
nucleus and solid organelles (Figure 1.11). Phagocytes then ingest and degrade these 
apoptotic bodies, and apoptosis typically does not therefore induce inflammation and 
scarring (Jacobson, Weil, & Raff, 1997). In contrast, necrosis is an accidental mode of cell 
death stimulated by several conditions such as hyperthermia, metabolic poisons, toxic 
stimuli and cell trauma. In some pathological conditions, a combination of necrosis and 
apoptosis may be present, and hypoxic and poorly perfused areas in tumours often contain 
necrotic cells (Fadeel & Orrenius, 2005). 
 
Figure 1.11: The various phases of apoptosis. These images are visualised via confocal laser 
scanning microscopy of cells undergoing early and late apoptosis with production of 
apoptotic bodies (Vermes et al., 2000). 
The coordinated activation of subsets of enzymes called caspases and subsequent cleavage 
of specific cellular proteins lead finally to nuclear DNA fragmentation and consequently 
induce cell death (Hengartner, 2000). 
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Apoptosis may be initiated via the mitochondrial or intrinsic pathway. The outer 
mitochondrial membrane has pores formed in it during apoptosis which allow the release of 
the pro-apoptotic factor cytochrome c, which leads to the activation of initiator caspases 
such as caspase-3, caspase-6 and caspase-7 in the cytosol. Subsequently, effector caspases 
are activated by pro-caspase-9, which is proteolytically processed via apoptosome activation 
(Bremer, van Dam, Kroesen, de Leij, & Helfrich, 2006). This pathway is regulated by the B-
cell leukemia/lymphoma 2 (BCL-2) family of pro- and anti-apoptotic proteins (Breckenridge 
& Xue, 2004), which may either block pore formation in the mitochondrial membrane or 
promote pore formation.  
The second main pathway for apoptosis is the death receptor–mediated or extrinsic 
pathway. This pathway plays a maintenance role in tissue homeostasis. Association of the 
death-inducing signalling complex (DISC) leads to activation of initiator and effector 
caspases and subsequently results in apoptotic cell death (Bremer et al., 2006). 
Hyperactivation of proliferating signals, for example involving RAS and MYC oncoproteins, 
which would result in corresponding increases of cancer cell proliferation and thus tumour 
growth, has also been shown to be able to induce cell senescence and/or apoptosis (Collado 
& Serrano, 2010). 
Many cancers are characterised by inactivating mutations in pro-apoptotic proteins, mainly 
in the tumour suppressor protein p53, which is very important in the activation of the 
mitochondrial pathway of apoptosis (O’Brate & Giannakakou, 2003). Tumour cells generally 
lose p53 function through either mutation or silencing, whereby the normal function of the 
protein in suppressing transformed cell proliferation and inducing cell cycle arrest and 
apoptosis is lost (Woods & Vousden, 2001). Anti-apoptotic proteins such as Bcl-2 and Bcl-xL 
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are also often found to be overexpressed in several tumour types, which then leads to 
resistance to apoptosis (Soengas et al., 2001). Conversely, activation of several downstream 
pro-apoptotic pathways by growth-deregulating oncoproteins such as Myc seems to 
promote apoptosis. Myc is found to have effects on mitochondria that can trigger 
cytochrome release and caspase-9 activation (Evan & Vousden, 2001). 
1.14 Flightless I 
Flightless I (FliI) is a member of the gelsolin family of proteins, which regulates actin 
polymerisation and depolymerisation, and consists of gelsolin, adseverin, capG, villin, 
advillin and supervillin (Figure 1.12). These proteins are involved in cell motility, contraction 
and adhesion, and have been hypothesised to mediate other protein interactions (Cowin et 
al., 2007). 
 
Figure 1.12: Family members of gelsolin protein. The core domain, which is repeated six 
times, is shown: leucine-rich repeat (LRR), headpiece (HP), nuclear translocation (NT) 
domain. Adapted from (Kwiatkowski, 1999). 
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Originally, the FliI protein was identified as a gene mutation in the fruit fly, Drosophila 
melanogaster, where mutations in this gene cause irregular actin organisation and defects in 
the flight muscles (H. Campbell et al., 1993), hence causing the flightless phenotype. The 
human homologue of the FliI gene was discovered four years later (H. D. Campbell et al., 
1997). Drosophila FliI and the human homolog FliI has shown to contain the classic 6-fold 
gelsolin segmental repeats and an amino-terminal extension of 16 tandem leucine-rich 
repeats (LRR) (Y.-T. Liu & Yin, 1998). 
FliI is a cytoskeletal-remodelling protein crucial in early stages of development. It has been 
shown that homozygous knockout of FliI in mice is embryonically lethal with gastrulation 
and cellularisation defects (H. D. Campbell et al., 2002), but heterozygous knockout mice 
survive and express lower levels of the FliI protein. The flightless and cellularisation 
phenotypes suggest that FliI is required for actin organisation as defective cellularisation of 
the syncytial blastoderm is associated with a disorganised cortical actin cytoskeleton during 
myogenesis and embryogenesis (Straub, Stella, & Leptin, 1996). The human flightless I (FLI) 
locus has been mapped to a region deleted in the Smith-Magenis syndrome, which is 
associated with a spectrum of developmental and behavioral abnormalities (H. D. Campbell 
et al., 1997). 
The protein structure is characterised by leucine-rich repeat (LRR) domains, a protein-
interacting domain, and six gelsolin-like segmental repeats in the C-terminal tail, as 
illustrated in Figure 1.13 (Z. Kopecki & Cowin, 2008). The FliI gene encodes a protein with 
1256 amino acids and an estimated molecular weight of 143,672 Da which is characterised 
by the fusion of these LRR domains and gelsolin-like domains in the subdivision 19F on the X 
chromosome (Davy, Ball, Matthaei, Campbell, & Crouch, 2000). In cells, FliI is localised at the 
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periphery, where it co-localises with the GTP-binding proteins ras, cdc42 and rhoA, which 
are important regulators of cytoskeletal reorganisation (Ben-Ze'ev, 1997). In this respect, FliI 
may stabilise the cytoskeleton and thereby inhibit turnover of adhesions, as it likely 
interacts with adaptor proteins on the cytosolic side of the FA, as shown by its co-
immunoprecipitation with paxillin. 
The difference between FliI and other family members is that FliI contains 6 repeat gelsolin 
domains and 11 LRR domains which are not present in the other gelsolin members. As a 
multifunctional protein, FliI distribution was expected and found to be present in multiple 
cellular compartments, including the nucleus, cytosol and lysosomes (Z. Kopecki & Cowin, 
2008; Lei et al., 2012), as well as being secreted from the cell.  
 
Figure 1.13: Schematic diagram of FliI structure. The FliI protein contains gelsolin domains 
and unique leucine-rich repeat (LRR) domains. Adapted from (Z. Kopecki & Cowin, 2008). 
FliI also has the ability to act as a transcription factor. FliI acts as a co-activator of GRIPI and 
CARM1, and has been shown to bind with oestrogen and thyroid hormone receptors. In 
addition, FliI is involved in regulating hormone-stimulated gene expression through binding 
of its gelsolin region to the oestrogen receptor (Y.-H. Lee, Campbell, & Stallcup, 2004).  
The actions of FliI defined to date relate to intracellular FliI; however, the protein has been 
shown to be secreted via endosomes and is measurable in serum (Davy, Campbell, Fountain, 
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de Jong, & Crouch, 2001). Studies done by Cowin, Adams et al. 2007 also confirm that FliI is 
secreted. Recent findings suggest that FliI might not be secreted through the classical 
pathway (Lei et al., 2012), which involves trafficking proteins from the endoplasmic 
reticulum to the cell surface via the Golgi complex (Bonifacino & Glick, 2004). The non-
classical pathway of secretion involves protein transport to the cell surface via late 
endosomes/lysosomes and it has been shown that FliI may be secreted via this pathway (Lei 
et al., 2012). 
1.14.1 Role of Flightless I in wound healing 
Generation of mice that overexpress or underexpress FliI has enabled studies on FliI 
function during skin wound repair. FliI-overexpressing mice (FliI Tg/Tg), which have two extra 
copies of human FliI, have impaired healing, with larger, less-closed wounds and reduced 
cell proliferation, and delayed epithelial migration, which also resulted in excessive scar 
formation (Cowin et al., 2007). This could be due to the ability of FIiI to inhibit turnover of 
cell adhesions and thus affect cell migration. Changes in cell adhesion and migration could 
also possibly occur due to effects on the linkage between the actin cytoskeleton and ECM 
mediated by FliI, since FliI has also been suggested to interact with linker proteins found 
close to FAs (Zlatko Kopecki, Ruth Arkell, Barry C Powell, & Allison J Cowin, 2009). In 
addition, FliI was observed to impair hemidesmosome formation and regulate adhesion in 
keratinocytes and fibroblast cells in wound healing (Zlatko Kopecki et al., 2009). It has been 
shown that cell adhesion was improved in heterozygous FliI+/− fibroblasts, while significantly 
impaired in transgenic FliITg/− keratinocytes in scratch wound assay (Cowin et al., 2007; 
Zlatko Kopecki et al., 2009). 
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In contrast, FliI heterozygous knockout mice (FliI+/−), which have reduced expression of FliI, 
showed improved wound healing, with increased epithelial migration and enhanced wound 
closure (Cowin et al., 2007). Cells typically found in wounds including fibroblasts and 
keratinocytes, show different rates of cell migration depending on their level of FliI 
expression, with those expressing less FliI migrating faster in two-dimensional models of 
scratch wound healing in vitro.  
1.14.2 Role of Flightless I in inflammation 
In recent years, a number of studies have suggested that FliI may have an important role in 
dampening immune response interaction with Toll-like receptors (Dai et al., 2009; Lei et al., 
2012; J. Li, Yin, & Yuan, 2008; T. Wang et al., 2006). FliI contains LRR domains which are 50% 
similar to LRR domains of the immune-related receptor and toll-like receptor 4 (TLR4) (Lei et 
al., 2012). Excessive activation of TLR receptors leads to increased and prolonged 
inflammatory responses and can induce tissue damage, which can then impair the wound-
healing process, as well as potentially inducing tumour formation in certain chronic 
environments. Inhibition of TLR-signalling pathways and reduction of cytokine secretion 
have been shown as possibly due to the interaction of FliI with nucleoredoxin and the TLR 
adaptor protein MyD88 in macrophages. In addition, a reduction in endogenous FliI 
enhanced the activation of NF-ΚB and its downstream cytokine production (Dai et al., 2009; 
T. Wang et al., 2006).  
FliI also binds to pro-inflammatory caspase 1, acting as a pseudosubstrate of caspase-1 and 
caspase 11, which would then reduce caspase-1–mediated interleukin 1β maturation and 
secretion (J. Li et al., 2008). Recently, FliI has also been shown to mediate caspase-1 
inhibition by the interaction of the leucine-repeat FliI-interacting protein 2 (LRRFIP2), which 
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negatively regulates NLRP3 inflammasome activation. This is supported by evidence that 
knockdown of FliI significantly promotes NLRP3 inflammasome activation, whereby 
interaction between FliI and caspase-1 facilitates an inhibitory effect of FliI on caspase-1 
activation (J. Jin et al., 2013). Thus, several studies have shown possible mechanisms for FliI 
to play a role in dampening inflammation. Therefore, further analysis of this negative 
regulator of wound repair in prolonged conditions of inflammation, which have been shown 
to be one of the possible causes of tumour initiation, is warranted. 
Apart from the intracellular functions of FliI, it has been shown that FliI secreted by 
macrophages may also have effects on inflammatory responses or innate immunity. Recent 
data showed that macrophages secrete FliI via the late endosome/lysosome pathway 
regulated by Rab7 and Stx11, so the secreted form of Flil might then be upregulated on 
wounding (Lei et al., 2012). It is therefore possible that FliI exerts effects either via 
intracellular mechanisms, such as regulation of adhesion and migration or activation of 
inflammatory pathways, or via a possible role of the secreted form of FliI on inflammatory 
cells such as macrophages. 
1.14.3 Role of Flightless I in cell adhesion and migration 
Cell migration can be defined as the ability of cells to migrate and change their positions 
within tissue or organs, a non-destructive process (Kramer et al., 2013) which is crucial for 
tissue repair and immune functions (Ridley et al., 2003). FliI associates with β-actin, so FliI 
can contribute to the actin remodelling and polymerisation processes, and regulate cell 
adhesion to matrix proteins that are associated with changes in cell arrangement and 
motility. During the adhesion process, protein complexes bind to the ECM, then trigger a 
linkage signal between integrin receptors and the actin cytoskeleton to form an active FA 
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site (Hehlgans, Haase, & Cordes, 2007). It is further suggested that FliI mediates cell 
migration via localisation and maturation of FA proteins (Mohammad et al., 2012). FliI 
stabilises FAs and its overexpression leads to a decrease in the hemidesmosome component 
CD151, laminin-332 and altered expression of laminin integrin receptors α3β1 and α6β4 (Z. 
Kopecki, R. Arkell, B. C. Powell, & A. J. Cowin, 2009).  
In addition, FliI has been shown to co-localise with talin, paxillin and vinculin, which are also 
important in regulating cell adhesion (Mohammad et al., 2012). It has been shown that cell 
adhesion was increased in heterozygous FliI+/− while significantly impaired in transgenic 
FliITg/− keratinocytes and fibroblasts on different substrates (Zlatko Kopecki et al., 2009). 
Wound-healing models used in the same study also demonstrated that overexpression of 
FliI increased FA complexes, leading to actin stabilisation with elevated expression of α-
actinin. Reduction of paxillin activity was also shown in FliI-overexpressing fibroblasts via 
inhibition of paxillin tyrosine phosphorylation signalling pathways mediated by the adhesion 
molecules Src and p130cas (Z. Kopecki, O'Neill, Arkell, & Cowin, 2011). It has been suggested 
that paxillin phosphorylation increases the formation of focal complexes associated with 
lamellipodia formation (Zaidel-Bar et al., 2007), which in turn increases the cell’s ability to 
migrate. Consequently, increased expression of FliI has been shown to impair cellular 
spreading, with a reduction in active Rac1 and Cdc42, and enhanced formation of fibrillar 
adhesions, suggesting that the effect of FliI is Rac1-dependent (Z. Kopecki et al., 2011). 
1.14.4 Role of Flightless I in cancer invasion and metastasis 
Several studies have shown that the expression levels of actin-remodelling proteins are 
affected during tumour progression, and development of therapies targeting those proteins 
may thus inhibit cell motility and invasion (Baig et al., 2013; Dong, Asch, Ying, & Asch, 2002; 
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K. W. Jeong, 2014; A. Van den Abbeele et al., 2007). FliI has been identified as a tumour 
promoter with transcriptional activity in vitro in several types of cancer cell, including 
colorectal, breast and hepatocellular carcinomas (K. W. Jeong, 2014; L. Wu et al., 2013). FliI 
has been found to negatively regulate ChREBP functions in cancer cells via the ChREBP 
transcriptional complex, where ChREBP has been shown to enhance glucose-stimulated 
proliferation in cancer cells (Lifang Wu et al., 2013).  
Knockdown of endogenous FliI in the breast cancer cell line MCF-7 has been shown to 
significantly inhibit cell proliferation (K. W. Jeong, 2014). It is important to highlight that FliI 
has been suggested to exert most of its effects at the cellular level, to mediate tumour 
progression via its ability to influence cell migration, adhesion and proliferation. FliI could 
also affect proliferation via interactions with calmodulin-dependent protein kinase type II 
(Seward, Easley, McLeod, Myers, & Tombes, 2008) and inflammation and cytokine 
production via caspase activation and maturation of IL-1b (J. Li et al., 2008).  
A recent study by our collaborator’s laboratory showed that FliI-overexpressing mice 
(FliITg/Tg) with a chemically induced cutaneous SCC developed more invasive tumours as 
compared to FliI+/− mice. Additionally, FliI negatively regulated apoptosis due to inhibition of 
annexin V and caspase-1 expression (Z Kopecki et al., 2015). Intradermal injection of FnAb 
was shown to be effective in reducing tumour size and SCC progression (Z Kopecki et al., 
2015; Z Kopecki et al., 2014). Similarly, in vitro findings demonstrated less three-dimensional 
invasion in MET-1 SCC keratinocytes when FliI expression was reduced, as well as co-
localisation of FliI and the invadopodia marker cortactin (Z Kopecki et al., 2015). Invasive 
cells are generally less adhesive and become highly mobile, with additionally higher mitotic 
activity compared to normal cells. They are also metabolically active and have an ability to 
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secrete proteolytic enzymes that can change their motility (Turner & Sherratt, 2002) by 
degrading adjacent ECM molecules. The effect of FliI on tumour progression and invasion 
was suggested to be mainly due to its ability to regulate cell adhesion and migration, thus 
favouring tumour growth. This is in contrast to FliI’s suggested role in wound repair, where 
at least in two-dimensional models FliI appears to negatively regulate motility. The tumour 
microenvironment may also serve as an important factor in influencing FliI activity and this 
needs to be further investigated.  
Table 1.4 summarises FliI functions at the cellular level, including cytoskeletal 
reorganisation, transcription, and FliI regulation in wound healing, inflammation, cell 
adhesion and migration, and cell invasion. 
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Table 1.4: Summary of Flightless I cellular functions 
FliI Cellular Functions Mechanism Associated Molecules References 
Cytoskeletal reorganisation Inhibit turnover of adhesion by interaction 
with adaptor proteins integrin, paxillin 
FliI co-localised with GTP-binding 
proteins ras, cdc42 and rhoA 
(Ben-Ze'ev, 1997) 
Transcription Bind to oestrogen and thyroid hormone 
receptors 
Co-activator of GRIPI and CARM1 (Y.-H. Lee et al., 2004) 
Wound healing Impaired wound healing, reduced cell 
migration and proliferation, and increased 
scar formation 
Interacted with linker proteins of focal 
adhesion proteins (CD151 and laminin-
binding integrins α3, β1, α6 and β4) and 
regulated hemidesmosome formation 
(Zlatko Kopecki et al., 
2009) 
Inflammation 
1) Reduced immune response via 
toll-like receptors 
2) Promoted NLRP3 inflammasome 
3) Regulated inflammatory pathway 
by macrophages 
 
1) Activation of NF–KB pathway 
2) Interaction with leucine-repeat 
FliI-interacting protein 2 
(LRRFIP2), leading to caspase-1 
activation 
3) Regulation of Rab7 and Stx11 
(Lei et al., 2012), (Dai et 
al., 2009), (J. Jin et al., 
2013) 
Cell adhesion and migration Associates with cell adhesion proteins in 
cell adhesion, regulating cell arrangement 
and motility 
Co-localised with β-actin, talin, paxillin, 
vinculin and α-actinin 
(Mohammad et al., 
2012), (Zlatko Kopecki 
et al., 2009) 
Cell invasion and metastasis Known as tumour promoter with 
transcriptional activity in vitro and 
promotes cutaneous squamous cell 
carcinoma model in vivo 
1) Affected proliferation via 
interactions with calmodulin-
dependent protein kinase type II 
via caspase activation 
2) Co-localised with invadopodia 
marker cortactin  
(J. Li et al., 2008) 
(Z Kopecki et al., 2015) 
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1.15 Hypotheses 
The hypotheses in this research study are: 
1) Similarities between cellular functions in wound healing, fibrosis and cancer, including 
cell migration, proliferation, apoptosis and cytokine release, lead to the investigation of 
the role of FliI in tumour growth and metastasis. We hypothesise that FliI inhibition will 
reduce tumour growth and establishment of secondary tumours. 
2) FliI regulates cell invasion and adhesion associated with adhesion complexes and 
invadopodia formation, which mediates tumour development and spread to distant 
sites. 
3) FliI expression enhances tumour growth and spread, and therefore FliI inhibition by 
using FliI knockdown (siRNA in cancer cells) will reduce tumour growth and lung seeding. 
4) The therapeutic effects of a FliI-neutralising antibody will reduce lung seeding in an 
animal cancer model via effects on the tumour microenvironment. 
1.15.1 Specific aims of the project 
The aims of this research study are: 
1) To determine the effects of FliI on cell migration, proliferation and apoptosis, and on the 
levels of cytokine secretion in CT26 and HT29 (mouse and human colon carcinoma cell 
lines). Additionally, to examine the effects of knockdown of FliI (siRNA FliI) in CT26 and 
HT29 cells and administration of exogenous recombinant FliI on these cells. 
2) To determine the role of FliI in cell invasion and adhesion using a 3D culture model in 
CT26 WT and siRNA FliI CT26 colon carcinoma cells. Expression of FA proteins vinculin 
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and paxillin, and expression of the invadopodia marker cortactin will be further 
evaluated to elucidate the mechanisms affected by FliI in these cellular processes. 
3) To determine the role of FliI in modulating cancer growth, lung seeding and 
establishment of lung nodules in murine colon-tumour models in wild type and 
underexpressing FliI mice. Additionally, to examine tumour growth using cancer cells 
that have FliI expression reduced via siRNA knockdown. 
4) To determine the therapeutic effects of a FliI-neutralising antibody (FnAB) in 
establishment of lung nodules in murine colon-tumour models and tumour spheroid 
invasion assay in vitro.  
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Chapter 2 Materials and Methods 
2.1 Materials and Methods for in vitro study 
2.1.1 Cell lines 
The human colon carcinoma cell line (HT29) (ATCC HTB-38), murine colon carcinoma cell line 
(CT26 H2kd) (ATCC CRL-2638), mouse leukaemic monocyte macrophage cell line (RAW 
264.7), human embryonic kidney cells line (HEK 293T) and primary mouse fibroblasts were 
obtained from ATCC and were available in the Cancer and Tissue Repair Laboratory, RMIT 
University. HT29 and CT26 H2kd adherent epithelial colon cancer cells were used in this 
study, as they are compatible (from the same mouse strain) for animal studies.  
2.1.2 Mammalian and murine cell cultures 
Human colon carcinoma cell line HT29 cells were cultured in 10% fetal bovine serum (FBS) in 
McCoy’s Medium 5A with L-Glutamine (Life Technologies, USA) and penicillin-streptomycin 
(Life Technologies, USA), and murine colon carcinoma cell line (BALB/c background), CT26 
H2kd (mouse) cells were cultured in 5% FBS in RPMI-1640 with L-Glutamine (Life 
Technologies, USA), 1% (v/v) HEPES buffer solution (Life Technologies, USA) and 1% (v/v) 
penicillin-streptomycin. These cells were incubated at 37 °C in a tissue culture incubator 
with humidified air, supplemented with CO2 to 5%. Adherent cells were grown in 75 cm
2 and 
125 cm2 vented tissue-culture flasks up to 80% confluence until required for experimental 
use. 
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2.1.3 Administration of exogenous recombinant Flightless I (rFliI) 
Recombinant mouse protein Flightless I homologue (rFliI) (Cusabio, USA) was used in in vitro 
studies at a final concentration of 1µg/ml. Full-length Flightless I protein is not currently 
available.  
2.1.4 RNA extraction 
Total RNA was extracted from WT mice and transfected with HT29 and CT26 using TRIzol 
reagent (Invitrogen, USA). Contaminating DNA was removed using DNase Turbo (Ambion, 
USA). cDNA was synthesised from 1 µg RNA using SuperScript III First Strand Synthesis 
Supermix (Invitrogen, USA). 
2.1.5 Real-time quantitative polymerase chain reaction (qPCR) 
A 25 µl reaction was set up containing 1 µg cDNA template, 125 ng of each primer and 12.5 
µl SYBR Green Supermix (Invitrogen and Roche, USA). A polymerase chain reaction (PCR) 
was then run using the following program, and reaction parameters and PCR amplification 
products were generated using the following primers (Invitrogen, USA): 
Table 2.1: PCR program and cycle reactions 
Cycle/s Process HIF1α 
1 Pre-incubation 
(initial denaturation) 
95 °C, 5 minutes and 30 seconds 
42 Denaturation 95 °C,15 seconds 
Annealing 60 °C, 30 seconds 
Extension 72 °C, 1 minute  
1 Final extension 55 °C, 10 seconds 
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Table 2.2: List of primers sequences for qPCR 
Name 
Sequence (5’-3’) 
FliI human forward 
CCT CCT ACA GCT AGC AGG TTA TCA AC 
FliI human reverse 
GCA TGT GCT GGA TAT ATA CCT GGC AG 
RPL32 human forward 
GGC AGC CAT CTC CTT CTC GGC 
RPL32 human reverse 
TGC CTC TGG GTT TCC GCC AGT 
FliI mouse forward (1) 
AAG GGT GGC TAC TTC CCT GA 
FliI mouse reverse (1) 
GTT GTG GCT CAC AGA CAG GT 
FliI mouse forward (2) 
GGG TGG CTA CTT CCC TGA GA 
FliI mouse reverse (2) 
GTG GTC AGA TGG TTG TGG CT 
18S mouse forward 
AGT TCG CTC ACA CCC GAA AT 
18S mouse reverse 
AGT GCG TTC GAA GTG TCG AT 
 
Fold changes were calculated by normalising the value to housekeeping gene 18S and using 
the ∆∆Ct formula to compare transfected cells to control samples (WT cells). 
2.1.6 Cell lysis and immunoblotting 
Treated or non-treated cells, WT and transfected cells, were lysed in a lysis buffer for whole-
cell protein isolation on ice for 10 minutes, scraped and the cell suspension collected into a 
pre-cooled microfuge tube. The cell suspension was then centrifuged at 12000xg for 20 
minutes to remove cell debris. Cell lysates were mixed with 4X SDS sample buffer, boiled at 
95°C for 5 minutes and either used immediately or stored at −20 °C. Proteins were resolved 
by SDS-PAGE and immunoblotted for the desired protein. 
Up to 30 μl of whole-cell lysates were loaded into each well on SDS-PAGE gels covered with 
1x running buffer and migrated through the gel using 100 V for approximately 2 hours. After 
electrophoresis, proteins were transferred from the gel onto a nitrocellulose membrane 
using a semi-dry transfer system (Invitrogen, USA). For immunodetection, membranes were 
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then blocked in 5% milk/TBS-Tween for 1 hour at room temperature, with rocking to 
prevent non-specific antibody binding. Then the membrane was washed in TBS-T and 
incubated with primary antibodies overnight at 4 °C with agitation by roller.  
Following three washes in TBS-Tween for 10 minutes, the blots were incubated with the 
appropriate horseradish peroxidise-conjugated (HRP) (Dako, Denmark) secondary 
antibodies for 1 hour at room temperature. After three more washes with TBS-T for 10 
minutes, immunoprobed proteins were visualised by Enhanced Chemiluminescent Reagents 
(GE Healthcare, Australia) using the ChemiDoc XRS System (Biorad, USA). To re-probe the 
membrane with another primary antibody, membranes were incubated in a stripping buffer 
twice for 15 minutes, followed by 5 minutes with PBS-Tween at room temperature, then 
blocked again in 5% milk or BSA in TBS-T for 1 hour and incubated overnight with new 
primary antibodies at 4 °C.  
2.1.7 Quantification of blots 
To quantify the protein levels, protein bands exposed onto ECL films were scanned onto a 
computer and saved as TIF files. The intensity of each protein band was determined using 
Image J software, and from this the FliI protein expression was calculated and normalised to 
the WT cells. 
2.1.8 Transformation of E. coli cells 
E. coli cells were transformed with DNA plasmids via a heat shock protocol. Competent E. 
coli cells stored at −80 °C were thawed out slowly on ice prior to the addition of 1–10 μg of 
plasmid DNA. Bacteria with the added plasmid DNA were incubated on ice for 30 minutes, 
placed at 42 °C for 40 seconds and then quickly returned to the ice. S.O.C medium (Thermo 
Fisher Scientific, USA) was added to the transformed bacteria and incubated at 37 °C with 
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shaking for 1 hour. The bacteria were then plated onto LB-agar plates supplemented with 
the required antibiotic, kanamycin, and incubated overnight at 37 °C.  
2.1.9 Purification of plasmid DNA 
A Maxi-prep kit (Invitrogen, USA) was used to isolate and purify plasmid DNA from E. coli 
cells. Transformed bacteria from a single colony were inoculated into L-broth supplemented 
with the required antibiotic, kanamycin (50 g/ml), grown in 200 ml of LB broth at 37 °C 
overnight with shaking. A Maxi-prep kit was used to isolate up to 500 μg from 200 ml of 
broth. Plasmid DNA was eluted in TE Buffer from Invitrogen columns. Concentration and 
purity of the plasmid were determined using nanodrop. DNA plasmid was then stored at −20 
°C prior to use. 
2.1.10 Stable transfection using Lipofectamine 2000 
Lipofectamine 2000 transfection reagent (Invitrogen, USA) was used to transfect full-length 
FliI pEGFP plasmid into HT29 and CT26 cells. Cells were plated the day before transfection to 
allow them to adhere overnight. Prior to transfection, complete growth medium was 
replaced with antibiotic-free growth medium. Between 6–8 hours after the transfection mix 
was added to the cells, the medium was replaced with fresh complete growth medium. 
Transfected cells were selected using resistance to Geneticin (G418) (Santa Cruz 
Biotechnology, USA) up to 1 mg/ml. The trypsinised G418-resistant cells were then further 
analysed to determine the expression of FliI. 
2.1.11 siRNA transfection 
CT26 and HT29 cells were seeded at 2x105 cells/ml in 2 ml antibiotic-free normal growth 
medium supplemented with  serum, then allowed to adhere for 24 hours to attain 60–80% 
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confluence. 6 µl mouse or human Flil I siRNA oligonucleotide duplex (at 10 µM), Flil I siRNA 
mouse (m): sc-35387 and Flil I siRNA human (h): sc-35386 (Santa Cruz Biotechnology, USA) 
were added to 94 µl of transfection medium (Opti-MEM) (Life Technologies, USA) to make 
up a total volume of 100 µl. A separate tube was then prepared by adding 6 µl of 
Lipofectamine 2000 (Invitrogen, USA) to 94 µl of transfection medium (Opti-MEM), then 
gently mixed with the diluted siRNA and incubated for 45 minutes to allow the formation of 
transfection complexes.  
Subsequently, the complexes were added to the washed cells with PBS containing 1 ml of 
transfection medium. Cells were further incubated for 5–7 hours at 37 °C in a tissue culture 
incubator. Medium containing the transfection complexes was aspirated, then replaced with 
medium containing double the normal concentration of serum and antibiotics. Expression of 
the knockdown gene was then measured using RT-PCR and immunofluorescence staining. 
Universal negative control siRNA (Sigma, USA) was used as the transfection control.  
2.1.12 Scratch motility assay 
WT and knockdown CT26 and HT29 cells (silencing of FliI) were seeded in 6-well culture 
plates and allowed to create a confluent monolayer of cells. Monolayer cells were scraped 
in a straight line to create a ‘wound’ using a yellow (p200) pipet tip. Debris was removed 
and cells were washed once with 1 ml of growth medium and then replaced with 3 ml of 
reduced serum culture medium (1% of serum for CT26 cells and 2% of serum for HT29 cells). 
The scratches were observed and images taken at 0, 24 and 48 hours interval time points 
using phase contrast microscopy on an inverted microscope (3 images per well in 
triplicates). The same field of images were photographed in each condition at the same 
point by marking reference points on the culture plate close to the scratch. Images were 
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analysed using a Scratch Assay Analyser (MiToBo) in Image J Software. The distance of cell 
migration (distance of the scratch gap) was determined via measuring the scratch gap of 
images generated by Image J by subtracting the value from the initial gap (0 hour) in each 
condition.  
2.1.13 Apoptosis assay 
Apoptosis assay was carried out using a BD Pharmingen PE Annexin V Apoptosis Detection 
Kit (BD Bioscience, USA) (Catalogue number: 559763). Cells were seeded at 2x105 cells/ml in 
2 ml and were maintained overnight in medium containing a normal percentage of serum. 
The next day, the culture medium was replaced with a fresh medium and subsequently 
exogenous recombinant FliI was added to the medium and then further incubated for 6, 24 
and 48 hours. The cells were collected by trypsinisation and washed with phosphate 
buffered saline (PBS). The cells at a concentration of 1x106 cells/ml were resuspended in 1X 
Binding Buffer. 100 µl of the solution containing 1x105 cells/ml were transferred into 
microcentrifuge tubes according to conditions. Controls, which were unstained cells and 
cells stained with either PE Annexin V or 7-AAD, were prepared to set up compensation and 
quadrants. 5 µl of PE Annexin V and/or 7-AAD were added into the solutions, then 
incubated for 15 minutes in the dark. 400 µl of 1X Binding Buffer were added into the 
solutions and then transferred into flow cytometry tubes. The percentages of cell death, 
early apoptosis and necrosis were analysed using flow cytometry.  
Viable cells with intact membranes exclude 7-AAD, whereas the membranes of dead and 
damaged cells are permeable to 7-AAD (7AAD+, Annexin V-). Cells that stain positive for PE 
Annexin V and negative for 7-AAD are undergoing early apoptosis (Annexin V+, 7AAD-) and 
cells that stain positive for both PE Annexin V and 7-AAD are either in the end stage of 
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apoptosis, are undergoing necrosis or are already dead (Annexin V+, 7AAD+). The 
percentages of cells undergoing early apoptosis and necrosis were determined from the 
flow cytometry dot plots. 
2.1.14 Proliferation assay 
Indirect intracellular staining was performed to determine cell proliferation using the 
proliferation marker, proliferating cell nuclear antigen (PCNA) (Dako, Denmark), a mouse 
monoclonal antibody that detects cells in stages S and G2 of the cell cycle. Cells were fixed 
with 2.5% paraformaldehyde and permeabilised with 0.5% saponin in PBS for 15 minutes. 
Cell suspensions were centrifuged at 250xg for 5 minutes and the pellets were washed with 
PBS and then subsequently resuspended in 0.5% (w/v) bovine serum albumin (BSA) (Sigma, 
USA) in PBS. Cells were adjusted to a concentration of 1x106 cells/ml and aliquoted into 
tubes following conditions including negative control. The required concentration of primary 
antibody for FliI (ab109015) (Abcam, UK) was added to the cells in a buffer containing 0.5% 
(w/v) BSA/PBS and incubated for 30 minutes at room temperature. Cell suspensions were 
centrifuged at 250xg for 5 minutes and then the supernatant removed without disturbing 
the pellet. Fluorochrome-conjugated secondary antibody (Alexa 488) at 1:200 dilution was 
added to the resuspended pellets and incubated for 30 minutes on ice. The centrifugation 
step was repeated and the pellets were resuspended in 500 µl FACS fix buffer. Tubes were 
then stored in the dark for prior to analysis using flow cytometry. 
2.1.15 Cell cycle analysis using propidium iodide staining 
Cellular DNA content can be quantitatively measured using flow cytometry by measuring 
the fluorescence signal produced by cells stained with propidium iodide (PI) (Sigma, USA), 
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which is proportional to the amount of DNA. Four distinct phases could be recognised in the 
cell population, which were G1, S (DNA synthesis phase), G2 and M phase (mitosis).  
Cells were harvested and cell suspensions were prepared in a wash buffer. Cells were 
washed twice and resuspended at 2x106 cells/ml in PBS. Cell suspensions were centrifuged 
at 250 g for 5 min and cold (−20 °C) absolute ethanol was added to the pellet to fix the cells 
for at least 1 hour or preferably overnight. Cell suspensions were then centrifuged at higher 
speed (1000xg) and washed twice with PBS. Cell pellets were resuspended in 1 ml of PI 
staining solution (40 µg/ml in PBS), which was added to the cell pellets and vortexed to 
resuspend. 50 µl of RNase A (10 µg/ml) (New England Biolabs Inc, USA) was added into the 
mixture and incubated at 37 °C for 20 minutes. Data was acquired from flow cytometry, as 
stained cells triggered the PI signal detected. For the gating, a secondary gate was placed 
around the single-cell populations and then represented as histograms. The measurements 
of cell cycle parameters were analysed using FlowJo software. 
2.1.16 3D cell invasion assay 
Chemotatic cell invasion assay was performed using pre-coated 24-well plates of BD 
Matrigel Invasion Chamber (BD Biosciences, USA) with 8 µm pores in the membrane 
according to the manufacturer’s instructions. Each lower chamber of the transwell was filled 
with 750 µl culture medium containing 5% FBS as a chemoattractant. Prior to addition of the 
cell suspension, the layer of Matrigel matrix was rehydrated with a culture medium without 
serum for 2 hours in a tissue culture incubator. Cell suspensions in the presence or absence 
of exogenous recombinant FliI were prepared and seeded at a concentration of 5x104 (500 
µl) in serum-free culture medium into each transwell. Subsequently, transwells were 
transferred to the chamber containing the chemoattractant and incubated for 22 hours in a 
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humidified tissue culture incubator, at 37 °C with 5% CO2 atmosphere. Cells remaining in the 
upper surface of the membrane were completely removed by gentle swabbing. Cells on the 
lower surface of the membrane were fixed and stained with cold absolute methanol and 1% 
Toluidine blue, respectively. The percentages of cell invasion and the invasion index were 
determined based on the equations below.  
(A) Determine the percentage of invasion: 
% Invasion = Mean number of cells invading through the Matrigel insert membrane 
 _______________________________________________________ x 100 
 Mean number of cells migrating through the control insert membrane 
(B) Determine the invasion index:  
 
 % of invasion test cells 
___________________ 
 % of invasion control cells 
 
2.1.17 Cell adhesion assay 
Poly-L-Lysine (Sigma, USA) and laminin-coating substrates were used to coat 96-well plates 
at 37 °C for 1 hour. The coated wells were blocked with medium containing 2% BSA and 
washed with PBS. Cell suspensions in serum-free medium were seeded into each well at a 
concentration of 5x104 and incubated with or without exogenous FliI at 37 °C for 15 and 30 
minutes. At each time point, non-attached cells in the medium were removed by rinsing. 
Attached cells were fixed with ethanol and stained with 0.5% (w/v) crystal violet in 10% (v/v) 
ethanol for 5 minutes. Excess staining of crystal violet was washed and removed. Stained 
adherent cells were counted in 5 fields of view in each well and the cell adhesion indices 
were calculated in comparison to WT cells. The adhesion index was determined based on 
the equation below.  
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Adhesion index:  
 % of adhesion test cells 
________________________ 
 % of adhesion control cells 
 
2.1.18 ELISA 
The levels of cytokines and growth factors for human tumour necrosis factor alpha (TNF-α), 
mouse and human vascular endothelial growth factor (VEGF), human interleukin 10 (IL-10) 
and human interleukin 6 (IL-6) in culture medium (24 hours incubation) of CT26 WT and/or 
HT29 WT cells were measured by enzyme-linked immunosorbent assay (ELISA) according to 
the manufacturer’s instructions, respectively (eBioscience (USA), PeproTech (USA), 
eBioscience (USA) and MABTech (Germany)).  
2.1.19 Immunoperoxidase staining 
Pre-incubated cells with or without exogenous recombinant FliI were cultured on 6-well 
plates and fixed in 4% (w/v) paraformaldehyde for 20 minutes, then, after washes, 
permeabilised with 0.5% (v/v) Triton x-100 for 15 minutes followed by washing steps. A 
blocking step was performed by incubation with 3% (v/v) hydrogen peroxide for 5 minutes. 
Cells were then incubated with primary antibodies (1:200 dilution of anti-PCNA and 1:100 
dilutions of anti-α-SMA) (Dako, Denmark) for 1 hour at room temperature followed by 
washes. Dual link peroxidase (α-mouse/α-rabbit) was applied to the cells for 15 minutes and 
they were washed again. As a final step, DAB reagent was used to develop the colour on the 
slides and then cell nuclei were counterstained with haematoxylin and further analysed. 
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2.1.20 Immunocytochemistry 
Pre-incubated cells with or without exogenous recombinant FliI were cultured on 8-well 
glass slide chambers, then washed briefly with PBS, fixed in 3% (w/v) formaldehyde in PBS 
for 10 minutes at room temperature, and again washed with PBS. For permeabilisation and 
blocking, the cells were treated with 10% (v/v) goat serum in 5% (w/v) BSA in PBS containing 
1% FBS, 0.1% (v/v) Triton X-100 for 2 hours, followed by five washes in PBS. The cells were 
then incubated with primary antibody diluted in antibody diluent (Dako, Germany), 0.1% 
(w/v) BSA in PBS overnight at 4 °C in the dark, followed by washing steps. Rabbit monoclonal 
anti-Flil (ab108594; 1:100), anti-vinculin (ab73412; 1:200), anti-Ki-67 (ab92742; 1:200), anti-
paxillin (ab32084; 1:100) and anti-cortactin (ab81208; 1:100) were used in this study based 
on previous experiments performed in the laboratory.  
The cells were further incubated with corresponding either anti-mouse or anti-rabbit 
secondary fluorescence antibodies Alexa 488 and 594 (Molecular Probes Life Technologies, 
USA), then diluted 1:1000 in PBS containing 0.1% BSA for 1 hour. An additional wash was 
performed and cell nuclei were counterstained with Hoechst 33342, Trihydrochloride, 
Trihydrate (Life Technologies) or DAPI nuclei staining (Sigma, USA) diluted at 1:500 dilution. 
Glass slide chambers were removed and slides were coverslipped using an aqueous 
mounting medium. Cells were viewed using a Nikon D-Eclipse C1 confocal microscope 
(Nikon, Langen, Germany), using oil immersion and 40x objective. Positive stained cells were 
calculated in 5 fields of the microscope area of each well for each cell. Fluorescence 
intensity was measured based on the corrected total cell fluorescence (CTCF) using Image J 
software (McCloy et al., 2014). 
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2.1.21 Isolation of primary fibroblasts 
Primary fibroblasts were isolated from mice skin using modified explant culture methods 
(Seluanov, Vaidya, & Gorbunova, 2010). Tissue fragments were cut into small pieces and 
transferred onto the scratched surfaces of 6-well plates (the wells were scratched using a 
scalpel). 300 µl of DMEM supplemented with 10% serum and a double concentration of 
penicillin/streptomycin was added into each well and placed in a humidified 37 °C, 5% CO2 
incubator for 24 hours. After 24 hours, 1 ml of complete medium was added into the wells 
and the cells allowed to grow. Cells’ growth was observed after 6–8 days and established in 
the wells after 2 weeks (about 14–20 days). Cells were trypsinised using 0.25% of Trypsin-
EDTA for seeding and were then ready to co-culture assay. 
2.1.22 Co-culture with primary fibroblasts 
Primary fibroblasts and either WT or knockdown of FliI of CT26 cells were co-cultured at a 
1:1 ratio (30,000 cells for each cell type) in DMEM medium for 1 week (Bakhtyar et al., 
2013). Fibroblast cells were seeded in 6-well plates and allowed to grow for 4 days, after 
which WT and knockdown of FliI of CT26 cells were co-cultured with the fibroblast cells for 
another 2 days. Cells were harvested for real-time PCR (qPCR) analysis to determine the 
expression of FliI in the system. Transwell coated with Matrigel was used in this system to 
separate different type of cells to further evaluate the expression of the myofibroblast 
marker, α-SMA, affected by FliI. 
2.1.23 Tumour spheroid invasion assay 
Spheroid tumour formation was established by seeding 1x104 either WT CT26 or knockdown 
of FliI cells in 96-well low-adherent plates. Tumour spheroids were treated in medium 
containing 50 µg/ml of unspecific IgG (control) or 50 µg/ml of FnAb. Images were captured 
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at day 2, 5 and 10 using an inverted microscope at 10X magnification and the diameters of 
the spheroids were measured using Image J software.  
2.1.24 Live/dead cell staining 
Spheroids were then stained for live/dead staining using Calcein AM (Abcam, UK) and 
propidium iodide (Sigma, USA) with 45 minutes’ incubation at 37 °C in the dark. The images 
and stacking properties of the spheroids were obtained using an A1 confocal microscope 
(Nikon, New York). Live cells were visualised with calcein AM (green) and dead cells were 
detected by propidium iodide (red). 
2.2 In vivo Animal Study 
Animal ethics approval for this study was obtained from the RMIT University Animal Ethics 
Committee (RMIT AEC # 19061). 
In the ethics approval, part of the animal monitoring process included identifying signs of 
distress, panting or breathing difficulty, and/or major weight changes in the mice. Any 
elevated levels of these changes would result in animals being euthanised. 
All mice were obtained at the same age, at 6 weeks old. It is important to record the initial 
body weight before tumour inoculation procedure; however variation weight between WT 
BALB/c mice and FliI +/- mice was not predicted. 
2.2.1  Tumour nodules in the lung of CT26-induced colon cancer in animal models with 
different levels of expression of Flil I 
Flil I heterozygous knockout (FliI+/−) and WT BALB/c mice at 6 weeks old were kindly 
provided by A/Prof Allison Cowin from the Mawson Institute, UniSA, Adelaide. Mice 
genotyping has been previously described: in mice lacking one copy of the Flil gene, the 
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double knockout is embryonically lethal (H. D. Campbell et al., 2002; Cowin et al., 2007). All 
experimental mice were acclimatised in the RMIT animal facility for 48 hours on arrival. To 
established tumour nodules in the lung, 12 mice (n=6 from each genotype) were used. 
Firstly, each mouse was placed under a heat lamp for no more than 5 minutes. Restrained 
mice were injected intravenously with 100 µl of CT26 cells (2x106) in PBS via the tail vein. 
The mice were monitored for up to 4 hours post-injection. On day 14, the mice were killed 
by a C02 inhalation procedure. The lungs were collected for further analysis. Mice were bled 
via cardiac puncture, and serums were processed and stored at −80 °C for further cytokine 
analysis. 
2.2.2 Effect of Flil I gene knockout on primary tumour growth 
siRNA FliI CT26 cells with disruption of the FliI gene (FliI −/− cells) were used in tumour 
inoculation studies. BALB/c WT mice (n=20) at 6 weeks old were shaved on the right flank 
area and injected with either 100 µl WT CT26 cells (2x106) or siRNA FliI CT26 cells in PBS (10 
mice for each condition). Mice were monitored up to 1 hour post-injection. Sizes of 
subcutaneous tumours were monitored and measured daily using electronic callipers. Mice 
were killed by a C02 inhalation procedure once the tumour reached a size of 1000 mm
3 (10 
mm width x 10 mm length x 10 mm depth) or a maximum of day 21 post-injection. Primary 
tumours were surgically excised and fixed in 4% (w/v) paraformaldehyde (PFA) in PBS for 
further analysis.  
2.2.3 Effect of Flil I gene knockout on metastatic tumour growth 
siRNA FliI CT26 cells with disruption of the FliI gene (FliI −/−) were also used in this metastatic 
model. Each BALB/c WT mouse was placed under a heat lamp for no more 5 minutes and 
restrained mice were injected intravenously with either 100 µl of WT CT26 cells (2x106) or 
87 
 
siRNA FliI CT26 cells in PBS via the tail vein. Each experimental group included 10 mice 
(n=10). The mice were monitored for up to 4 hours post-injection. After 14 days, mice were 
killed according to a C02 inhalation procedure. The lungs were collected for further analysis. 
Mice were bled via cardiac puncture, and serums were processed and stored at −80 °C for 
further cytokine analysis. 
2.2.4 Therapeutic effects of Flil I–neutralising monoclonal antibody on lung tumour 
growth 
In this particular animal model, a FliI-neutralising monoclonal antibody (FnAb) was 
administered via intranasal injection at a concentration of 50 µg/ml in 50 l volume per 
mouse. FnAb was kindly prepared and provided by our collaborator, A/Professor Allison 
Cowin (UniSA). Rabbit anti-FliL FnAB was raised against the LRR domain of the FliI protein. 
Twenty WT BALB/c mice including a vehicle control group at 6 weeks old were used in this 
experiment. Each mouse was placed under a heat lamp for no more 5 minutes and 
restrained mice were injected intravenously with 100 µl of CT26 cells (2x106) in PBS via the 
tail vein. The mice were monitored for up to 4 hours post-injection. On days 4 and 8, mice 
were administered with 20 µl FliI-neutralising monoclonal antibody (50 µg/ml) in PBS or 
unspecific IgG (50 µl) via intranasal injection using an isofluorane anaesthesia inhalation 
procedure. A control group received the antibody without the tumour cell inoculation 
procedure. After 14 days, mice were killed according to a C02 inhalation procedure. The 
lungs were dissected for histology analysis. Mice were bled via cardiac puncture, and serums 
were processed and stored at −80 °C for further cytokine analysis.  
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2.2.5 Haematoxylin and eosin staining 
Paraffin-embedded sections of the primary tumours and organs were cut (4 µm) and the 
histological sections were stained with a standard haematoxylin and eosin (H&E) staining 
procedure. Histological images were analysed to determine the number of metastatic 
nodules in the lung.  
2.2.6 Immunohistochemical staining (IHC) 
Expression of Flil I, α-SMA, PCNA and cortactin (Abcam, UK) were quantified using the IHC 
technique. Histological sections were deparaffinised and heated in a microwave oven for 10 
minutes in a pH 6.0, 0.1M citrate buffer for antigen retrieval. Subsequently, sections were 
blocked for endogenous peroxidase with 0.3% (v/v) H2O2 and for non-specific protein 
binding with 0.2% gelatin in BSA/PBS. Slides were immunostained with rabbit monoclonal 
anti-Flil (ab108594) (Abcam, UK), α-SMA (Dako, Denmark), anti-PCNA (Dako, Denmark) and 
anti-cortactin (ab81208) (Abcam, UK) monoclonal antibodies that were used in this study. 
After washing steps, slides were incubated with either anti-rabbit or anti-mouse secondary 
antibody (Dako, Denmark) for 30 minutes. Finally, DAB reagent was used to develop the 
colour on the slides and then cell nuclei were counterstained with haematoxylin. Images 
were analysed using the Image-Pro Plus Program (Media Cybernetics, USA) to quantify the 
expression of proteins of interest.  
 Immunoreactive score 2.2.6.1
Immunohistological sections were further scored to determine the level of expression of 
each tumour marker. The immunoreactive score (IRS) system was used, considering the 
percentage of positive cells and the intensity of the staining (Fedchenko & Reifenrath, 
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2014). IRS is mainly used for intracellular staining and in this study a slight modification was 
adopted for extracellular staining, which determines the percentage of the immuno-positive 
area within the tumour.  
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Table 2.3: The immunoreactive score (IRS) for immunohistology 
A (percentage of positive cells/ 
area in tumour) 
B (intensity of staining) IRS score (multiplication of A x B) 
0 = no positive cells/area 0 = no colour reaction 0–1 = negative 
1 = <10% of positive cells/area 1 = mild reaction 2–3 = mild 
2 = 10–50% positive cells/area 2 = moderate reaction 4–8 = moderate 
3 = 51–80% positive cells/area 3 = intense reaction 9–12 = strongly positive 
4 = >80% positive cells/area Final IRS score (A x B) = 0–12 
Adapted and modified from (Fedchenko & Reifenrath, 2014). 
2.2.7 Statistical analysis 
All results are presented as mean ± SEM, N indicates the number of experiments performed 
for in vitro and in vivo. The effects between the groups were analysed using Student’s 
unpaired t-test and one-way or two-way ANOVA, with post hoc analysis using Tukey’s or 
Dunnet’s multiple comparison test as appropriate; p<0.05 was considered statistically 
significant.  
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Chapter 3 Flightless I Regulates Cell 
Migration, Proliferation and 
Apoptosis 
3.1 Introduction 
Metastasis is the major cause of death in cancer patients therefore much research is 
required into therapeutic targeting of both tumour cell dissemination and inhibition of 
secondary tumour establishment in distant sites. Tumour dissemination involves invasion 
and metastasis, and research commonly focuses on the key regulators of tumour 
progression at a cellular level (Wells et al., 2013). In fact, the invasive and migratory 
capabilities of tumour cells and the support of stromal cells have become crucial factors in 
the management of cancer prognosis and treatment (Kramer et al., 2013). It is also 
important to provide a better understanding of the mechanisms involved in metastasis, 
which will allow targeting of cancer cells and stromal cells for anti-metastatic drug 
development.  
Cell migration is a fundamental cellular function that underlies numerous diverse biological 
processes, including morphogenesis, gastrulation (Keller, 2005), tissue repair and immune 
response (Peter Friedl & Weigelin, 2008). It also contributes to pathological conditions such 
as tumour progression and cancer metastasis when there is deregulation of cell movement 
(Hood et al., 2002; Kramer et al., 2013). Migration and invasion involve cyclical changes in 
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cell morphology driven by the constant remodelling of the actin cytoskeleton into structures 
that coordinate cell migration. FA proteins are also involved and these are spatiotemporally 
regulated (Gardel, Schneider, Aratyn-Schaus, & Waterman, 2010; Tojkander et al., 2012). In 
order to migrate in response to extracellular signals, cells first assemble actin at the cell 
front, driving the extension of membrane protrusions called lamellipodia and filopodia 
(Partridge & Marcantonio, 2006). FliI associates with β-actin, so FliI is likely able to affect 
actin remodelling and to be involved in regulating cell adhesion to matrix proteins. Both of 
these phenomena are associated with changes in cell arrangement and motility. The tissue 
microenvironment, in relation to either cellular or non-cellular components, can affect cell 
motility by influencing the organisation and stiffness of the ECM (Erler & Weaver, 2009). The 
non-cellular components of the stroma, including growth factors and cytokines and changes 
in organisation of the ECM, have been shown to promote tumour cell motility and invasion 
(Tlsty & Coussens, 2006). 
Several cellular changes have been found to occur in tumourigenesis, including alterations in 
cell proliferation, the cell cycle and apoptosis that also favour tumour cell survival and 
dissemination. These cancer hallmarks have been discussed widely, including deregulation 
of proliferative signals in cancer cells enabling uncontrolled cell proliferation and altered 
apoptosis/survival signalling that can influence cell survival (Hanahan & Weinberg, 2011). 
In order to metastasise, cells must alter their attachment to the ECM, activate degradation 
of the ECM and penetrate into the basement membrane and also surrounding connective 
tissues, then intravasate into vessels and extravasate through the blood vessels at distant 
metastatic sites (Wells, 2006). Additionally, the tumour cell must escape immune 
surveillance. This complex process is mediated by the crucial first step of tumour cell 
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invasion. The ability of tumour cells to migrate and invade through ECM barriers determines 
the metastatic potential of these cells (Wells, 2006).  
Monolayer scratch motility assays are an effective technique to determine cell migration 
properties (Nobes & Hall, 1999) and cell polarity (Etienne-Manneville & Hall, 2003), although 
this two-dimensional model may not necessarily provide information about tumour cell 
invasion through the ECM. In this chapter, the differences between the scratch motility 
behaviour of WT cells, FliI knockdown and cells overexpressing FliI are examined. In 
addition, flow cytometry is used to examine cell proliferation, apoptosis and cell cycles in 
these cells. Downstream functions of cytokines that play roles in promoting tumours are 
also investigated. Therefore, this chapter discusses the role of FIiI in affecting cell migration, 
proliferation, apoptosis and cell cycle by comparing WT cells and knockdown of FliI, and the 
effect of exogenous recombinant FliI.  
3.2 Results 
3.2.1 Expression of FliI 
 Expression of FliI in different types of cell lines 3.2.1.1
The expression of FliI was analysed in mouse and human colon carcinoma cell lines (CT26 
WT and HT29 WT), mouse leukaemic monocyte macrophage cell lines (RAW 264.7), primary 
mouse fibroblasts and human embryonic kidney cells line (HEK 293T) by quantitative PCR 
analysis. Figure 3.1 show the levels of FliI expression in CT26 WT cells, HT29 WT cells and 
RAW 264.7 as compared to the mouse fibroblast cell lines and HEK 293T cells in vitro. HEK 
293T and mouse fibroblast cells were used as positive control cells for FliI expression for 
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human and mouse cells, respectively. mRNA was quantified using the qPCR threshold cycle 
and normalised to a housekeeping 18S mRNA expression to correct for loading differences. 
These results show that there is a readily detectable expression of FliI in both murine and 
human colon cancer cells and macrophages in comparison to the respective positive control 
cells. In mouse cells, CT26 WT and RAW cells showed similar levels of FliI compared to the 
positive mouse fibroblasts cells. Similarly, HT29 WT cells showed comparable expression 
levels of FliI to HEK293T cells. Interestingly, the overall expression of FliI was lower in the 
human cells compared to the mouse cells. A higher expression of FliI was observed in CT26 
WT cells as compared to human colon cancer and normal cells, HT29 WT and HEK293T 
(p<0.001) (Figure 3.1). 
 
 
 
 
 
 
 
 
Figure 3.1: Quantitative PCR analysis showing expression of FliI in different cell lines. 
Expression of FliI in CT26 WT, RAW, primary mouse fibroblasts, HT29 WT and HEK 293T cell 
lines in vitro. Results are shown as expression of FliI normalised to 18S ± SEM (n=3). 
***p<0.001 significantly different compared to CT26 WT (Tukey’s multiple comparison test).  
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 Expression of FliI in wild type, siRNA FliI and FliI-overexpressed CT26 and HT29 cells 3.2.1.2
Figures 3.2 and 3.3 show the expression of the FliI gene in WT, siRNA FliI and FliI-
overexpressing CT26 and HT29 cells. FliI overexpressed in CT26 showed three-fold higher 
levels of FliI (p<0.01), while there was a marked reduction in the expression of FliI in siRNA 
FliI-treated CT26 cells (p<0.05). An unrelated gene Siah2 was used as a transfection control 
gene as a reference (Figure 3.2). The same pattern was also seen in FliI-overexpressing and 
siRNA FliI HT29 cells (Figure 3.3). HT29 cells showed similar three-fold increases in the level 
of FliI compared to mouse CT26 cells. There was a three-fold increase in the expression of 
FliI in FliI-overexpressing cells compared to HT29 WT cells (p<0.05), while reduced FliI 
expression was seen in siRNA FliI HT29 cells (Figure 3.3). 
 
 
 
 
 
 
 
 
Figure 3.2: Quantitative PCR analysis showing expression of FliI in CT26 WT, FliI-
overexpressing CT26, siRNA FliI CT26 and transfection control cells. Results are shown as n-
fold change in expression of FliI ± SEM (n=3). **p<0.01 and *p<0.05 significantly different to 
control CT26 WT cells (Tukey’s multiple comparison test). 
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Figure 3.3: Quantitative PCR analysis showing expression of FliI in HT29 WT and HT29 
transfected with FliI (FliI-overexpressing HT29) and siRNA FliI (siRNA FliI HT29). Results are 
shown as n-fold change of expression of FliI normalised to 18S (n=3). *p<0.05 significantly 
different to control HT29 WT cells (Tukey’s multiple comparison test). 
 Detection of FliI expression by immunofluorescence 3.2.1.3
Expression of FliI was also detected in CT26 WT and siRNA FliI CT26 cells using 
immunofluorescence staining. Results show that the expression of FliI was reduced in siRNA 
FliI-treated CT26 cells compared to CT26 WT cells, as shown in Figure 3.4. Lower 
fluorescence intensity (green) was obtained in siRNA FliI CT26 cells showing less FliI 
expression, while increased fluorescence intensity in CT26 WT cells indicates abundant FliI 
expression in these cells. FliI was localised in both the nucleus and the cytoplasm associated 
with the actin-rich cytoskeleton (green fluoresecence) (Figure 3.4).  
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Figure 3.4: Immunofluorescence staining of FliI in CT26 cells expressing different levels of FliI. Immunofluorescence micrographs show 
expression of FliI in (A) CT26 WT and (B) siRNA FliI CT26 cells. Cells were immunostained for FliI (anti-FliI antibody) (green) and counterstained 
with Hoechst (blue). Images were taken using an A1 Confocal Microscope (Nikon) at 400X magnification.  
Hoechst FliI Overlay 
A 
B 
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3.2.2 Effect of FliI on cell migration 
 FliI regulates cell migration in vitro 3.2.2.1
Scratch assays were performed to study the migration properties of cancer cells expressing 
different levels of FliI in vitro. Results showed that treatment with siRNA FliI in CT26 cells 
significantly increased cell migration (90%) by reducing the area of the scratch as compared 
to CT26 WT (p<0.01) (75%) after 24 hours. In contrast, FliI-overexpressing CT26 cells showed 
reduced migration, with only 60% of the scratch closure compared to CT26 WT (p<0.05) 
(Figure 3.5). 
Representative images of scratches in CT26 cell monolayers at 0 and 24 hour time points are 
shown in Figure 3.6, and image analysis was performed using a Scratch Assay Analyser 
(MiToBo program). Increased cell migration was observed in siRNA FliI-treated CT26 cells 
with an increase in scratch closure seen in images of segmentation analysis using Scratch 
Assay Analyser software. In contrast, reduced cell migration and less scratch closure were 
observed in FliI-overexpressing CT26 cells compared to CT26 WT cells. 
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Figure 3.5: Cell migration in colon cancer cells expressing different levels of FliI in vitro. 
Percentages (%) of cell migration after 24 hours’ incubation time with different levels of FliI 
expression in CT26 cells are shown as the scratch gap at 24 hours subtracting the value from 
the initial gap at 0 hour ± SEM (n=5).** p<0.01 and p<0.05 significantly different to control 
cells CT26 WT (Dunnett’s multiple comparison test).  
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Figure 3.6: Monolayer scratch images in CT26 cells expressing different levels of FliI in vitro. Representative photographs of monolayer 
scratch images of CT26 WT, siRNA FliI CT26 cells, FliI-overexpressing CT26 and transfection control cells (siRNA Siah2 CT26) at 0 hour and 24 
hours’ incubation time. Images were taken using an inverted light microscope at 20X magnification. Images of segmentation analysis using the 
MiToBo program show the scratch gap (white area) and migratory cells (black area) of CT26 WT, FliI-overexpressing CT26, siRNA FliI CT26 cells 
and transfection control cells.  
0 
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 Exogenous recombinant FliI has no effect on cell migration in vitro 3.2.2.2
Scratch assays were also used to determine the effect of exogenous recombinant FliI (1 
µg/ml) on CT26 cells, again using cells with different levels of FliI expression. Cell migration 
was measured in CT26 WT and siRNA FliI CT26 cells after treatment with recombinant FliI (1 
µg/ml) in vitro. As with previous results, siRNA FliI CT26 cells showed significantly increased 
cell migration compared to CT26 WT cells after 24 hours (p<0.05) (Figure 3.7). The addition 
of recombinant FliI to CT26 WT and siRNA FliI CT26 cells had no significant effect on cell 
migration; however, there was a significant decrease in cell migration in the transfection 
control cells as compared to CT26 WT cells (p<0.05). Representative images of the scratch 
motility assay with the addition of exogenous FliI are shown in Figure 3.8. 
 
 
 
 
 
 
 
 
Figure 3.7: Colon cancer cell migration after exogenous FliI treatment in vitro. Percentages 
(%) of cell migration of CT26 WT and siRNA FliI CT26 cells with (rFliI 1 µg/ml) or without 
(untreated control) treatment with recombinant FliI (rFliI). Results are shown as % cell 
migration ± SEM (n=5). *p<0.05 significantly different to control cells CT26 WT (Dunnett’s 
multiple comparison test). 
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Figure 3.8: Images of CT26 cells in scratch assay after exogenous FliI treatment in vitro. 
Representative images of CT26 WT cells with (rFliI 1 µg/ml) or without (untreated control) 
treatment with recombinant FliI (rFliI) at 0 and 24 hours. Images show the scratch gap 
before treatment (0 hour) and after treatment with rFliI (24 hours). Images were taken using 
an inverted light microscope at 20X magnification. 
3.2.3 Effect of exogenous FliI on cell apoptosis 
 Exogenous recombinant FliI increases apoptosis in CT26 cells 3.2.3.1
Stages of apoptosis, cell death and necrosis in CT26 colon cancer cells expressing different 
levels of FliI were measured by flow cytometry using 7AAD/Annexin V staining. Cells were 
treated with recombinant FliI for three different time periods (6, 24 and 48 hours) and then 
flow cytometry was carried out to look at apoptosis, cell death and necrosis. Findings 
Untreated cells (control) Treated cells (1µg/ml rFliI) 
0 
hour 
24 
hours 
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showed that adding exogenous recombinant FliI (1 µg/ml) to CT26 cells significantly 
increased the percentage of apoptosis at 24 hours post-incubation in vitro (p<0.05) (Figure 
3.9). However, there was no difference in the percentage of cell death/necrosis in CT26 WT 
cells treated with exogenous recombinant FliI compared to the control cells (untreated) at 
the other time points examined (Figure 3.9). 
Representative flow cytometry dot plots of early apoptosis, cell death and necrosis are 
shown in Figure 3.10. Untreated CT26 cells and cells treated with exogenous recombinant 
FliI (1 µg/ml) for 24 hours were collected and analysed by flow cytometry (Figure 3.10). Dot 
plots represent (A) Control (7AAD-, Annexin V-), (B) Cell death (7AAD+, Annexin V-), (C) Early 
apoptosis (7AAD-, Annexin V+) and (D) late apoptosis or necrosis (7AAD+, Annexin V+). Flow 
cytometry dot plots show that 15% of control CT26 cells underwent early apoptosis and this 
increased to 25.3% after incubation with exogenous recombinant FliI; 4.4% cell death and 
6.1% cell necrosis were recorded in control CT26 cells and similarly, approximately 5.7% cell 
death and 6.3% necrotic cells were counted in CT26 cells treated with exogenous 
recombinant FliI. 
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Figure 3.9: FliI effect on apoptosis in CT26 colon cancer cells in vitro. Induction of apoptosis, necrosis and cell death after treatment with 
exogenous recombinant FliI (rFliI; 1 µg/ml) shows percentages of (A) cell death (7AAD+, Annexin V-), (B) early apoptosis (Annexin V+, 7AAD-) 
and (C) necrosis (Annexin V+, 7AAD+) in untreated or treated (rFliI 1 µg/ml) CT26 cells over 6, 24 and 48 hours. Results are shown as mean ± 
SEM (n=3).*p<0.05 significantly different to untreated (control) cells (Tukey’s multiple comparison test). 
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Figure 3.10: Representative flow cytometry dot plots showing apoptosis of CT26 colon cancer cells treated with exogenous FliI treatment in 
vitro. CT26 colon cancer cells were treated with recombinant FliI (1µg/ml) or control medium. Dot plots represent (A) control (7AAD−, Annexin 
V−) (Q3-1), (B) cell death (7AAD+, Annexin V−) (Q1-1), (C) early apoptosis (7AAD−, Annexin V+) (Q4-1) and (D) late apoptosis or necrosis (7AAD+, 
Annexin V+) (Q2-1). Flow cytometry analysis was collected on a FACSCanto (BD Biosciences) and analysed using FACS Diva Software (BD 
Biosciences). 
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 No difference on cell apoptosis in knockdown of FliI using siRNA FliI in CT26 cells  3.2.3.2
To study the effects of knockdown of FliI (using siRNA) and addition of exogenous 
recombinant FliI (rFliI; 1 µg/ml), apoptosis was analysed by flow cytometry in untreated 
CT26 WT and siRNA FliI CT26 cells and/or cells treated with exogenous recombinant FliI 
(rFliI; 1 µg/ml). There is no significant change observed in the percentage of apoptotic cells 
(Annexin V+/ 7AAD−) between the control scrambled siRNA and the FliI siRNA treated cells 
without or with treatment with exogenous rFliI (Figure 3.11).  
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Figure 3.11: Apoptosisanalysis via flow cytometry in CT26 colon cancer cells expressing 
different levels of FliI and with recombinant FliI treatment (rFliI 1µg/ml) in vitro. 
Percentages (%) of (A) cell death (7AAD+, Annexin V−), (B) early apoptosis (Annexin V+, 
7AAD−) and (C) necrosis (Annexin V+, 7AAD+) in CT26 WT, siRNA FliI CT26 and transfection 
control cells (scrambled siRNA) with and without exogenous recombinant FliI (rFliI) 
treatment. Results are shown as mean ± SEM (n=3).****p<0.0001 and ***p<0.001 
significantly different to control cells CT26 WT (Tukey’s multiple comparison test). 
 
(A) 
(C) 
(B) 
C
T
2
6
 W
T
C
T
2
6
 W
T
 +
 r
F
li
I
s
iR
N
A
 F
li
I
s
iR
N
A
 F
li
I  
+
 r
F
li
I
S
c
ra
m
b
le
 s
iR
N
A
S
c
ra
m
b
le
 s
iR
N
A
 +
 r
F
li
I
0
1 0
2 0
3 0
4 0
%
 c
e
ll
 d
e
a
th
 C
T
2
6
 W
T
C
T
2
6
 W
T
 +
 r
F
li
I
s
iR
N
A
 F
li
I
s
iR
N
A
 F
li
I  
+
 r
F
li
I
S
c
ra
m
b
le
 s
iR
N
A
S
c
ra
m
b
le
 s
iR
N
A
 +
 r
F
li
I
0
2 0
4 0
6 0
%
 a
p
o
p
to
s
is
***
****
C
T
2
6
 W
T
C
T
2
6
 W
T
 +
 r
F
li
I
s
iR
N
A
 F
li
I
s
iR
N
A
 F
li
I  
+
 r
F
li
I
S
c
ra
m
b
le
 s
iR
N
A
S
c
ra
m
b
le
 s
iR
N
A
 +
 r
F
li
I
0
1 0
2 0
3 0
%
 n
e
c
r
o
s
is
108 
 
 No difference in cellular apoptosis in knockdown of FliI in siRNA FliI HT29 cells  3.2.3.3
We found similar results in the reduction of apoptosis in siRNA HT29 cells as observed in 
CT26 cells (Figure 3.12). Apoptosis assays were carried out in untreated HT29 WT and siRNA 
FliI HT29 cell and cells treated with exogenous recombinant FliI (1 µg/ml). There was no 
significant change observed in the percentage of apoptotic cells (Annexin V+/ 7AAD−) 
between the control scrambled siRNA and the FliI siRNA treated cells without or with 
treatment with exogenous rFliI (Figure 3.12). Results also show no difference in the 
percentages of cell death and necrosis in siRNA FliI HT29 cells as compared to scrambled 
siRNA cells with addition of exogenous recombinant FliI.  
Representative flow cytometry dot plots representing early apoptosis, cell death and 
necrosis are shown in Figure 3.13. Untreated CT26 WT and siRNA FliI HT29 cells and cells 
treated with exogenous recombinant FliI (1 µg/ml) for 24 hours were collected and analysed 
by flow cytometry (Figure 3.13). Dot plots represent (A) control (7AAD−, Annexin V-), (B) cell 
death (7AAD+, Annexin V−), (C) early apoptosis (7AAD−, Annexin V+) and (D) late apoptosis or 
necrosis (7AAD+, Annexin V+). Flow cytometry dot plots show 37.7% of CT26 WT cells 
underwent early apoptosis and this decreased to 24.6% in siRNA FliI CT26 cells. There was 
no difference observed in the percentages of cell death and necrosis in CT26 WT cells 
(26.8% cell death and 27.1% cell necrosis) and in siRNA FliI CT26 cells (19.7% cell death and 
19.8% necrotic cells). 
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Figure 3.12: Apoptosis analysis via flow cytometry in HT29 colon cancer cells expressing 
different levels of FliI and with exogenous FliI treatment (rFliI 1µg/ml) in vitro. 
Percentages (%) of (A) cell death (7AAD+, Annexin V−), (B) early apoptosis (Annexin V+, 
7AAD−) and (C) necrosis (Annexin V+, 7AAD+) in HT29 WT, siRNA FliI HT29 cells and 
transfection control cells (scrambled siRNA) with and without exogenous recombinant FliI 
(rFliI). Results are shown as mean ± SEM (n=3). ***p<0.05 significantly different to control 
cells HT29 WT (Tukey’s multiple comparison test). 
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Figure 3.13: Representative flow cytometry dot plots showing apoptosis of CT26 colon cancer cells expressing different levels of FliI treated 
with exogenous FliI (rFliI 1µg/ml) in vitro. CT26 WT and siRNA FliI CT26 cells were treated or left untreated with recombinant FliI. Dot plots 
represent (A) control (7AAD−, Annexin V−) (Q3-1), (B) cell death (7AAD+, Annexin V−) (Q1-1), (C) early apoptosis (7AAD−, Annexin V+) (Q4-1) and 
(D) late apoptosis or necrosis (7AAD+, Annexin V+) (Q2-1). Flow cytometry analysis was performed on a FACSCanto (BD Biosciences) and 
analysed using FACS Diva Software (BD Biosciences). 
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3.2.4 Effect of FliI on cell proliferation 
 Knockdown of FliI increased cell proliferation in vitro 3.2.4.1
Intracellular PCNA expression in human colon cancer HT29 cells was assessed by flow 
cytometry to determine the effect of FliI on cell proliferation in vitro. Our results show that 
knockdown of FliI significantly increased cell proliferation (MFI = 65.80 ± 7.607) as compared 
to HT29 WT cells (MFI = 34.87 ± 5.080) (p<0.05). Addition of exogenous recombinant FliI 
(rFliI) to HT29 cells had no significant effect on cell proliferation compared to HT29 WT 
control cells after 24 hours (Figure 3.14). The expression of PCNA in HT29 WT and siRNA FliI 
HT29 cells treated with exogenous rFliI slightly increased in HT29 WT cells (MFI = 54.60 ± 
4.392) while it decreased in siRNA HT29 cells (MFI = 47.40 ± 4.339); however, this is not a 
statistically significant difference compared to HT29 WT control cells.  
Representative flow cytometry histograms show PCNA expression in (A) HT29 WT, (B) HT29+ 
rFliI (1 µg/ml), (C) siRNA FliI HT29 and (D) siRNA FliI HT29 + rFliI (1 µg/ml) cells (Figure 3.15). 
37.7% proliferation in HT29 WT cells was counted and the percentage increased to 67.3% in 
siRNA FliI HT29 cells. Adding exogenous recombinant FliI increased PCNA expression in HT29 
WT cells (57.9%) while siRNA FliI HT29 cell showed reduced PCNA expression (44.1%) (Figure 
3.15). 
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Figure 3.14: PCNA expression in HT29 cells expressing different levels of FliI and after 
treatment with exogenous recombinant FliI (rFliI) analysed by flow cytometry. Intracellular 
expression of PCNA in HT29 WT and siRNA FliI HT29 cells treated with or without rFliI (1 
µg/ml). PCNA expression is shown as PCNA mean fluorescence intensity (MFI) ± SEM (n=3). 
*p<0.05 indicate statistical significance between each experimental group (Tukey’s multiple 
comparison test). 
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Figure 3.15: Representative flow cytometry histograms showing PCNA expression in HT29 
cells expressing different levels of FliI or with added FliI protein. Representative flow 
cytometry histograms show PCNA expression in (A) HT29 WT, (B) HT29 WT+ rFliI (1 µg/ml), 
(C) siRNA FliI HT29 and (D) siRNA FliI HT29 + rFliI (1 µg/ml). Histograms on the left represent 
control (secondary antibody alone) and on the right represent cells stained intracellularly for 
PCNA with secondary FITC-labelled antibody. Results were analysed by flow cytometry 
(FACSCanto, BD Biosciences) and analysed using FACSDiva Software (BD Biosciences). 
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Immunoperoxidase staining of PCNA in HT29 WT and siRNA FliI HT29 with and without 
recombinant FliI treatment showed an increased number of positive cells stained with PCNA 
in siRNA FliI HT29 compared to HT29 WT cells (Figure 3.16). The number of proliferating 
cells (nucleus stained brown) also increased after the addition of exogenous recombinant 
FliI (1 µg/ml rFliI) in HT29 WT cells. However, a reduction in PCNA-positive cells was 
observed after the addition of exogenous recombinant FliI (1 µg/ml rFliI) in siRNA FliI HT29 
cells (Figure 3.16). 
 
 
 
 
 
 
 
 
 
 
Figure 3.16: PCNA expression in HT29 cells expressing different levels of FliI with and 
without treatment with exogenous recombinant FliI (rFliI) analysed by immunoperoxidase 
staining. Representative images of immunoperoxidase staining of PCNA in (A) HT29 WT, (B) 
siRNA FliI HT29, (C) HT29 WT + exogenous recombinant FliI (rFliI; 1 µg/ml) and (D) siRNA FliI 
HT29 + exogenous recombinant FliI (rFliI; 1 µg/ml). Images taken using an inverted light 
microscope at 20X magnification. 
A 
D B 
C 
115 
 
  FliI regulates Ki-67 expression in colon cancer cells in vitro 3.2.4.2
In order to determine the effect of FliI on cell proliferation in mouse colon cancer cells, CT26 
WT and siRNA FliI CT26 cells were immunostained against an additional proliferation 
marker, Ki-67. Ki-67 positive CT26 cells were counted using Image J software. Similar to the 
immunofluorescence staining of PCNA, there showed an increased positive staining of Ki-67 
in siRNA FliI CT26 cells compared to CT26 WT cells (p<0.01) (Figure 3.17). Positive stained 
cells were counted in 5 fields per well from three independent experiments. 
Figure 3.18 shows representative images of immunofluorescence staining of Ki-67 in CT26 
WT and siRNA FliI CT26 cells. There were more cells positive for Ki-67 (green fluorescence) in 
siRNA FliI CT26 cells compared to the staining seen in CT26 WT cells. 
 
 
 
 
 
 
 
 
Figure 3.17: Quantification of Ki-67 expression in CT26 cells expressing different levels of 
FliI. Number of positive cells stained by immunoperoxidase with proliferation marker Ki-67 
in CT26 WT and siRNA FliI CT26 cells were counted using Image J software in 5 fields per well 
from three independent experiments. Results are shown as mean ± SEM (n=3). **p<0.01 
indicates statistical significance compared to control cells CT26 WT (Student’s unpaired t-
test). 
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Figure 3.18: Immunofluorescence staining of Ki-67 in CT26 cells expressing different levels 
of FliI. Representative images of immunofluorescence staining of Ki-67 expression (green) in 
(A) CT26 WT and (B) siRNA FliI CT26 cells counterstained with DAPI (blue). Photos taken 
using an A1 confocal microscope at 60X magnification. 
3.2.5 Effect of FliI on cell cycle 
 FliI showed no effect on the cell cycle of CT26 colon cancer cells in vitro 3.2.5.1
Cell cycle analysis of CT26 colon cancer cells expressing different levels of FliI was performed 
using propidium iodide (PI) staining and flow cytometry. Analysis was also performed on 
CT26 WT and siRNA FliI-treated CT26 cells with or without addition of exogenous 
recombinant FliI (1 µg/ml). Cells were treated with 1 µg/ml of rFliI for 24 and 48 hours, and 
stained with PI staining for cell cycle analysis using flow cytometry (Figure 3.19). Cell counts 
in each cell cycle phase were measured using FlowJo software analysis.  
A 
B 
Ki-67 Ki-67/ DAPI DAPI 
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There was no difference in the cell count in the different phases of the cell cycle at 24 and 
48 hours’ incubation time between CT26 WT cells and siRNA FliI CT26 cells regardless of 
exogenous recombinant FliI treatment. No significant difference in the cell count was 
observed in the GI phase (DNA preparation for synthesis phase), S phase (DNA synthesis and 
replication) or G2M phase (cell growth and mitosis) at 24 and 48 hours’ incubation time 
(Figure 3.19).  
Representative flow cytometry dot plots and histogram of cell cycle analysis using PI staining 
are shown in Figure 3.20.  
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Figure 3.19: Cell cycle analysis using in CT26 cells expressing different levels of FliI with or 
without treatment with exogenous recombinant FliI (rFliI 1µg/ml) in vitro. Effect of FliI on 
phases of the cell cycle in CT26 WT, siRNA FliI CT26 and transfection control cells (siRNA 
Siah2 CT26), (A) and (B) G1 phase, (C) and (D) S phase, and (E) and (F) G2M phase at 24 (A, 
C, E) and 48 (B, D, F) hours’ incubation time. Phases were determined using propidium 
iodide staining and flow cytometry. Results are shown as mean ± SEM (n=3). *p<0.05 
indicates statistical significance to control CT26 WT cells (Dunnet’s multiple comparison 
test). No significant differences were observed in any treatment. 
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Figure 3.20: Representative cell cycle dot plots using flow cytometry analysis in vitro. (A) 
gated cell populations (P1) of the basis of FSC and SCC scatter, (B) selected within another 
gate (P2) and (C) applied to a histogram analysing PI fluorescence. The histogram shows the 
markers for identifying cells in P3 (non-dividing), P4 (G1 phase), P5 (S phase) and P6 (G2M 
phase). Results were obtained using flow cytometry (FACSCanto, BD Biosciences) and 
analysed using FACSDiva Software (BD Biosciences).  
3.2.6 Effect of FliI on colon cancer cell cytokine secretion 
 Knockdown of FliI reduced while exogenous recombinant FliI increased the levels 3.2.6.1
of TNF-α, VEGF and IL-10 in vitro 
Analysis of cytokines that play a role in cancer progression and potential roles in 
inflammation or inhibition, such as TNF-α, VEGF, IL-6 and IL-10, were determined in colon 
cancer cell supernatants using ELISAs (Figure 3.21). Colon cancer cell supernatants were 
obtained from HT29 WT and siRNA FliI-treated HT29 cells without and with addition of 
exogenous recombinant FliI (1 µg/ml) after 24 hours’ incubation. Levels of TNF-α (p<0.01), 
(A) 
(C) 
(B) 
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VEGF (p<0.05) and IL-6 (p<0.01) were significantly reduced in siRNA FliI-treated HT29 cell 
supernatants compared to the levels in HT29 WT cells. However, no difference was 
observed in the levels of IL-10 in any of the conditions. It was also found that addition of 
exogenous recombinant FliI significantly increased the secretion of TNF-α in HT29 WT cell 
supernatants (p<0.05) and increased the level of IL-6 in siRNA FliI HT29 cell supernatants 
(p<0.001).  
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Figure 3.21: Cytokine levels in HT29 cell culture supernatants from cells expressing 
different levels of FliI and after treatment with exogenous recombinant FliI (rFliI 1µg/ml). 
Supernatants from human HT29 colon cancer cells expressing different levels of FliI as well 
as after treatment with recombinant FliI (1 µg/ml) were analysed for (A) TNF-α, (B) VEGF, 
(C) IL-6 and (D) IL-10 by ELISA assay. Results are shown as mean (pg/ml) ± SEM (n=3). 
***p<0.001, **p<0.01 and *p<0.05 indicate statistical significance between experimental 
groups (Tukey’s multiple comparison test). 
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3.3 Discussion 
3.3.1 Role of FliI in cell migration 
To enable investigation into the role of FliI in colon cancer growth and metastasis, it is 
important to establish baseline mRNA levels of FliI in the cell lines used in experiments. PCR 
results showed that there was detectable expression of FliI in mouse and human colon 
carcinoma cell lines (CT26 and HT29 cells) that were higher than in control cultured cells, 
mouse fibroblasts and HEK 293T cells, respectively. FliI in both cell lines was then knocked 
down using FliI siRNA or overexpressed using transfection with a FliI expression plasmid and 
expression confirmed with qPCR analysis. This enabled us to begin studies to determine the 
role of FliI in cell migration, proliferation, invasion and cell cycles, and its effect on cytokine 
release. 
As a member of the actin-remodelling family of gelsolin-like proteins, FliI is involved in cell 
motility, adhesion and contraction (Davy et al., 2000). It is worthwhile to emphasise the 
difference between migration and invasion in order to perhaps explain the mechanism of 
FliI in affecting the migration and invasion of cancer cells (which will be the basis of later 
chapters). Based on their definition, migration occurs on 2D surfaces in the absence of any 
obstructive fibre network (ECM), while invasion involves movement of cells through a 3D 
matrix in which cells must modify their shape and remodel the ECM to enable them to 
protrude through the cell membrane (as lamellipodia or invadopodia) and move through the 
matrix. Therefore, invasion requires cell attachment and adhesion to successfully invade the 
matrix (Kramer et al., 2013).  
Cell migration is crucial in determining cell motility, and deregulation of this process could 
contribute to pathological conditions such as tumour angiogenesis and metastasis (Ridley et 
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al., 2003). In this study, it has been confirmed that knockdown of FliI in the cell increased 2D 
migration while overexpression of FliI reduced cell migration. Studies done previously 
(Cowin et al., 2007) showed that FliI deficiency (using siRNA knockdown) in fibroblast 
monolayers derived from mice skin increased the rate of wound closure in a scratch assay as 
compared to WT and FliI overexpressing fibroblasts. Our studies confirm that this 
mechanism seems to apply in the tumour cell lines used in this study. In addition, the same 
study also showed that FliI-deficient (FliI+/−) mice showed improved wound healing in vivo 
via increasing epithelial migration and proliferation. A previous study by Mohammed et al. 
(Mohammad et al., 2012) suggested that actin filament ends are not capped in migrating 
cells where FliI has been knocked down, and that FliI retards the turnover of actin filaments 
and thus can be associated with slower migration. They further suggested that FliI mediated 
cell migration via FA-regulated actin-capping activity. In vivo studies show a significant 
increase in CD151, integrin β1 protein and laminin protein expression in Flil heterozygous 
mice. Increases in these factors are associated with the escalation of cellular migration and 
contraction (Zlatko Kopecki et al., 2009). Conversely, the overexpression of FliI decreased 
the expression of integrin receptors, causing a reduction in cell migration and proliferation, 
and the atypical removal of ECM proteins (Zlatko Kopecki et al., 2009). 
3.3.2 FliI affects cell apoptosis and cytokine release 
The importance of programmed cell death by apoptosis in acting to prevent or suppress 
cancer progression has been well established in previous studies (de Bruin & Medema, 
2008; Hanahan & Weinberg, 2000; Lowe, Cepero, & Evan, 2004). Resistance to apoptosis 
can allow tumour cells to survive and undergo tumour progression. However, there are also 
findings pointing to the ability of cancer cells to switch their susceptibility to apoptosis, and 
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this may play a key role in tumour development (J. Adams & Cory, 2007; Lowe et al., 2004). 
It has been shown that activation of a number of downstream pro-apoptotic effector 
pathways via growth-deregulating oncoproteins was likely to induce apoptosis (Evan & 
Vousden, 2001). In this study, we found that adding of exogenous FliI to WT cells increased 
apoptosis, while knockdown of FliI significantly decreased the percentage of cells 
undergoing apoptosis. Cancer cells can undergo evolution to escape from this destructive 
machinery and suppression of apoptosis mechanisms is common in many tumour cells (Evan 
& Vousden, 2001). However, the mechanisms underlying this process are still unclear.  
In contrast to apoptosis, necrotic cell death has been commonly shown to release pro-
inflammatory factors into the tumour microenvironment that can promote tumour 
progression (Hanahan & Weinberg, 2011) and areas of tumour necrosis are often an 
indicator of poor prognosis. Necrotic cells have also been shown to enhance recruitment of 
immune cells which are capable of promoting tumour development and inducing 
angiogenesis (Galluzzi & Kroemer, 2008; Grivennikov, Greten, & Karin, 2010). In addition, by 
releasing regulatory factors such as IL-1α cells undergoing necrosis may directly stimulate 
adjacent viable cells to proliferate and thus potentiate neoplastic progression (Grivennikov 
et al., 2010).  
Even though these findings show that knockdown of FliI reduced cellular apoptosis and 
increased cell proliferation, which are suggestive of FliI having an anti-tumour activity, we 
also show that these cells produced less TNF-α, VEGF and IL-6, which are known to have 
potent effects in promoting cancer progression. It has been shown that cells can have an 
immediate response on stimulation of growth factors which actively trigger cell migration 
(Maheshwari et al., 1999; Ware et al., 1998). Furthermore, addition of exogenous 
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recombinant FliI increased apoptosis and also showed an increase in the level of 
inflammatory cytokines measured in this study.  
3.3.3 Effect of Flil on cell proliferation and cell cycle 
Our data suggests that knockdown of FliI increased cell proliferation, as shown by nuclear 
staining of the proliferation markers PCNA and Ki-67. FliI has previously been found to 
regulate cell proliferation via FliI localisation to β-tubulin-based structures which are then 
involved in cell division (Davy et al., 2001). Studies by collaborators (Cowin et al., 2007) have 
shown that siRNA knockdown of FliI in fibroblasts and keratinocytes increased cell 
proliferation, similar to our results. Reduced proliferation and migration were also observed 
in fibroblasts overexpressing FliI, resulting in impairment of the healing process. In fact, it 
has been postulated that FliI negatively regulates cell proliferation and migration via an 
actin-severing function (Cowin et al., 2007).  
PCNA is widely used as a tumour marker, but there are conflicting results in the correlation 
between expression of PCNA and tumour progression and prognosis (S.-C. Wang, 2014). In 
addition to having a role in proliferation, PCNA is also required for DNA repair, which is also 
involved in tumour progression (Toschi & Bravo, 1988). A high percentage of proliferating 
cells often correlates with aggressive tumours in various types of cancer, while other 
tumours grow relatively slowly due to a high rate of cell loss via apoptosis (Arends et al., 
1994). This indicates that in certain tumour types, increased levels of both apoptosis and 
mitotic activity may reflect aggressive tumour growth.  
Despite some of the differences observed in this study, there are a number of limitations 
that need to be considered. Overexpression of FliI in tumour cells was only partially 
established, since the cells did not produce the expected large increases in levels of FliI 
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expression. Other laboratories, including our collaborators’ laboratory and that of Dr 
Rachael Murray (QUT), have also experienced problems with FliI overexpression, which 
seem to relate to correct processing of the protein in cells that have incorporated the FliI 
plasmid. This aspect of the project requires further study. The establishment of cell lines 
that significantly overexpress the FliI gene will greatly aid in further studies in this area. 
3.4 Conclusion 
In this chapter we have explored a number of in vitro experimental approaches in order to 
elucidate the role Flil may play in the regulation of four well-established tumour growth 
promoters: cell migration, proliferation, apoptosis and the secretion of tumour-enhancing 
cytokines. The effects observed remain difficult to interpret, as Flil appears to regulate both 
pro- and anti-tumour functions, and it is evident that there are complexities involved in the 
functions of Flil that demand further and extensive examination. Similar findings have been 
made in relation to wound healing, in that FliI can correlate with enhanced adhesion and 
reduced migration, which would both tend to be seen as tumour inhibiting. However, the in 
vitro findings thus far continue to support the hypothesis that Flil may play a potential role 
in tumour growth and progression, and so provide a rationale for further exploration. The 
cellular effects of Flil on two other important tumour-regulating factors, cell adhesion and 
invasion, will be discussed in Chapter 4. In conjunction with the findings reported in this 
chapter, this work provides motivation to pursue these investigations via an in vivo cancer 
model. 
  
127 
 
Chapter 4 Flightless I Mediates Cell 
Invasion and Adhesion 
4.1 Introduction 
Cancer cell migration and invasion into adjacent tissues and extravasation into 
blood/lymphatic vessels are necessary for metastasis, and acquisition of a migratory 
phenotype of invasive carcinoma cells has been shown in several types of human cancers 
(W. Wang et al., 2005). Invasion and metastasis are dependent on the ability of tumour cells 
to modify and degrade the constituents of the ECM around them (Hoon et al., 2006). 
Metastasis then involves two major phases, the physical translocation of tumour cells from 
the primary tumour microenvironment to distant tissues and then the establishment of 
secondary tumours at these sites (Chaffer & Weinberg, 2011). Protrusions of the cell 
membrane into the ECM by invading cells, invadopodia, are important in this process since 
several pro-invasion activities are centred at these sites. These activities include branched 
actin assembly close to the membrane, cell-signalling molecules and adhesion sites for the 
ECM, and secretion of proteases that lead to degradation and remodelling of the ECM 
(Weaver, 2006).  
Invadopodia formation has been observed in highly invasive cancer cells and has therefore 
been implicated in tumour cell metastasis (Yamaguchi et al., 2005). Since invadopodia are 
enriched in actin regulatory proteins, adhesion molecules, signalling/adaptor proteins, 
membrane-remodelling proteins and matrix-degrading proteases, it was considered 
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worthwhile to further investigate the possible role of FliI in modifying important FA proteins 
which may affect the dynamics of FA complexes and so have an impact on invadopodia 
formation.  
In this study, because of the limitations of using 2D cell-culture systems showing cell 
migration, a more physiological 3D culture environment was used to obtain a better 
understanding of the possible regulation by FliI of cell invasion and adhesion. A co-culture 
system was also used in conjunction with transwell invasion assays using ECM-coated 
surfaces overlaid with a porous filter (Kramer et al., 2013). This assay was used to determine 
whether changes in FliI influence on invasiveness of the cancer cells had an impact on FA 
protein expression and to look for the involvement of invadopodia. Therefore, this chapter 
discusses the effect of intracellular expression levels and the exogenous addition of FliI in 
the regulation of cell invasion and adhesion in order to further elucidate the involvement of 
FA proteins and regulation of invadopodia in promoting cancer progression and metastasis. 
4.2 Results 
4.2.1 Effect of FliI expression on cell invasion 
 Knockdown of FliI reduced cell invasion and exogenous FliI increased invasiveness of 4.2.1.1
cancer cells 
The effect of FliI in inducing the invasiveness of cancer cells was determined using a 
Matrigel invasion assay. CT26 WT and siRNA FliI CT26 cells treated with or without 
exogenous recombinant FliI (rFliI; 1 µg/ml), were analysed. Results show that knockdown of 
FliI greatly inhibited cell invasion, while addition of exogenous FliI increased the percentage 
of cells invading through the membrane in both WT and siRNA knockdown cells. The data 
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shown in Figure 4.1 is represented in two ways; (A) indicates the percentage of cell invasion 
and (B) the invasion index (ratio of invading cells compared to control cells). 
 
 
 
 
 
 
Figure 4.1: 3D cell invasion of CT26 colon cancer cells expressing different levels of FliI and 
after recombinant FliI treatment in vitro. Quantification of cell invasion (determined as % 
mean of invading cells in FliI-treated cells compared to the mean in control cells) in CT26 WT 
and siRNA FliI CT26 cells with or without recombinant FliI. Results are shown as mean ± SEM 
(n=3). Significant differences from control cells (WT CT26) shown as ****p<0.0001, 
(Dunnett’s multiple comparison test). 
Images from an inverted microscope at 40X magnification show that there were few 
knockdown-treated cells invading through the Matrigel matrix and membrane as compared 
to WT cells, while the addition of exogenous FliI appeared to increase the invasiveness of 
cells (Figure 4.2). 
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Figure 4.2: Toluidine blue staining of invading colon cancer cells expressing different levels 
of FliI and after exogenous FliI treatment. Representative phase micrographs of cells (A) 
CT26 WT and (B) siRNA FliI CT26, (C) CT26 with exogenous recombinant Flil and (D) siRNA 
FliI CT26 with exogenous recombinant Flil. Invading cells were fixed in 2.5% 
paraformaldehyde and stained with toluidine blue (40X magnification). 
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4.2.2 Effect of FliI on invadopodia marker expression 
 Knockdown of FliI downregulates invadopodia marker cortactin in colon cancer cells 4.2.2.1
in vitro 
Total cell fluorescence after immunofluorescence staining for cortactin was used as the 
main marker of invadipodia and was determined in CT26 WT and siRNA FliI CT26 cells. 
Higher expression levels of cortactin was found in CT26 WT cells compared to siRNA FliI-
treated CT26 cells, which showed a significantly lower level of cortactin fluorescence. 
Graphs showing total fluorescence intensity for cortactin in WT and siRNA FliI-treated CT26 
cells are shown below (Figure 4.3).  
Immunofluorescence photomicrographs showing expression of cortactin are shown in 
Figure 4.4 comparing CT26 WT and siRNA FliI CT26 cells. 
  
 
 
 
 
 
Figure 4.3: Cortactin expression in colon cancer cells expressing different levels of FliI. 
Expression of the invadopodia marker cortactin, based on total fluorescence in CT26 WT and 
siRNA Flil CT26 cells. Results are shown as corrected total cell fluorescence mean ± SEM 
(n=3). **** shows p<0.0001 is statistically significant between experimental groups 
(Student’s unpaired t-test). 
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Figure 4.4: Cortactin staining in CT26 colon cancer cells expressing different levels of FliI detected by immunofluorecsence. Representative 
immunofluorescence micrographs showing expression of cortactin in (A) CT26 WT and (B) siRNA FliI CT26 cells. Cells were immunostained for 
invadopodia marker cortactin (red) and counterstained with DAPI (blue) to show nuclei. Images were taken using an A1 confocal microscope 
(Nikon) at 600X magnification. 
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4.2.3 Effect of FliI expression on cell adhesion 
 Knockdown of FliI increased cell adhesion 4.2.3.1
Cell adhesion assays were performed to determine the possible effect of FliI expression 
levels in regulating cell adhesiveness. Results showed that knockdown of FliI using siRNA 
increased the ability of the cells to adhere to both types of coating matrix that were used to 
mimic ECM, which were poly-L-lysine (Figure 4.5(A)) and laminin (Figure 4.5(B)). Adhesion 
was determined at 15 and 30 minutes after cell seeding. Addition of exogenous FliI 
decreased cell adhesiveness of siRNA FliI-treated CT26 cells at 15 and 30 minutes’ 
incubation time on laminin; however, there was no effect on cell adhesion of the poly-L-
lysine substrate. Representative images of phase-contrast micrographs of adherent cells 
(CT26 WT and siRNA FliI CT26) on the poly-L-lysine substrate, in the presence and absence 
of exogenous FliI, are shown in Figure 4.6. 
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Figure 4.5: Cell adhesion assay in colon cancer cells expressing different levels of FliI and 
after exogenous FliI treatment. Cell adhesion index using (A) poly-L-lysine and (B) laminin 
coating materials at 15 and 30 minute time points in CT26 WT and siRNA FliI CT26 cells with 
and without exogenous recombinant FliI. Results are shown as mean ± SEM (n=3). 
***p<0.001, **p<0.01, *p<0.05 show significant difference to control cells (CT26 WT) using 
Dunnett’s multiple comparison test. 
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Figure 4.6: Toluidine blue staining of adherent colon cancer cells expressing different 
levels of FliI and after recombinant FliI treatment. Representative phase micrograph of 
adherent cells (A) CT26 WT and (B) siRNA FliI CT26, (C) CT26 WT with exogenous 
recombinant Flil and (D) siRNA FliI CT26 with exogenous recombinant Flil on poly-L-lysine 
substrate. Adherent cells were fixed in 2.5% formaldehyde, stained with toluidine blue and 
viewed under a light microscope at 20X magnification. 
4.2.4 Effect of FliI on focal adhesion protein expression 
 Knockdown of FliI upregulates FA protein paxillin in colon cancer cells in vitro 4.2.4.1
Immunofluorescence staining of the FA protein paxillin showed an upregulation of the 
expression of this FA protein in siRNA Flil-treated CT26 cells compared to CT26 WT cells 
(Figure 4.7). Statistical analysis of paxillin expression levels showed a highly significant 
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difference (p<0.001) in comparison to CT26 WT cells. Representative images of 
immunofluorescent staining for paxillin are shown in Figure 4.8. 
 
 
 
  
 
 
 
Figure 4.7: Paxillin expression in CT26 colon cancer cells expressing different levels of FliI 
in vitro. Expression of FA protein paxillin, based on total cell fluorescence, comparing CT26 
WT and siRNA FliI-treated CT26 cells. Results are shown as mean corrected cell fluorescence 
± SEM (n=5). ****p<0.0001, significant difference to control cells CT26 WT (Student’s 
unpaired t-test). 
 
C T 2 6  W T  s iR N A F liI  C T 2 6
0
1 0 0 0 0
2 0 0 0 0
3 0 0 0 0
4 0 0 0 0
C
o
r
r
e
c
te
d
 t
o
ta
l 
c
e
ll
 f
lu
o
r
e
s
c
e
n
c
e
 (
C
T
C
F
)
****
137 
 
 
  
 
 
 
 
 
 
 
 
Figure 4.8: Paxillin staining in CT26 colon cancer cells expressing different levels of FliI determined by immunofluorecsence. Representative 
immunofluorescence micrographs showing expression of paxillin in (A) CT26 WT and (B) siRNA FliI CT26 cells. Cells were immunostained for FA 
protein paxillin (red) and counterstained with DAPI (blue). Images were taken using an A1 confocal microscope (Nikon) (400X magnification). 
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 Knockdown of FliI upregulated vinculin expression in colon cancer cells in vitro 4.2.4.2
Immunofluorescence staining for the FA protein vinculin also showed a higher level of 
expression in siRNA FliI-treated CT26 cells compared to CT26 WT cells (Figure 4.9). 
Respresentative images of immunofluorescence staining for vinculin in CT26 WT and siRNA 
FliI-treated CT26 cells are shown in Figure 4.10. 
 
 
 
 
 
 
 
Figure 4.9: Vinculin expression in CT26 colon cancer cells expressing different levels of FliI. 
Expression of FA protein vinculin, based on total cell fluorescence, in comparing CT26 WT 
and siRNA FliI-treated CT26 cells. Results are shown as mean corrected cell fluorescence ± 
SEM (n=5). *p<0.05 shows significant difference to control cells (CT26 WT) (Student’s 
unpaired t-test). 
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Figure 4.10: Immunofluorescence staining of vinculin in CT26 colon cancer cells expressing different levels of FliI. Representative 
immunofluorescence images showing expression of vinculin in CT26 WT (A) and siRNA Flil-treated CT26 cells (B). Cells were immunostained for 
vinculin (green) and counterstained with DAPI (blue). Images were taken using an A1 confocal microscope (Nikon) at 600X magnification.
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4.2.5 Co-culture system with primary fibroblasts 
A number of stromal cells in the tumour microenvironment can enhance growth and 
facilitate the ability of cancer cells to metastasise to distant organs. Stromal cells have the 
ability to create a surrounding microenvironment that favours tumour growth and spread to 
secondary sites. In order to obtain a better understanding of the effect of fibroblasts within 
the tumour microenvironment and the role of FliI in this microenvironment, co-culture 
systems with primary fibroblasts (FIB) were established and the expression of FliI in the 
system was determined. A 1:1 ratio of cancer cells (either CT26 WT or siRNA FliI CT26) and 
FIB were co-cultured for 24 hours. Controls, which were CT26 WT and FIB only, were also 
included. The expression of FliI in the co-culture system was determined using quantitative 
RT-PCR. There was an approximate four-fold increase in the expression of FliI in the co-
culture of WT and primary fibroblasts in comparison to single cultures of either CT26 WT or 
fibroblast cells (Figure 4.11). 
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Figure 4.11: FliI expression in co-cultures of primary fibroblasts with colon cancer cells 
expressing different levels of FliI. Quantitative PCR analysis showing expression of FliI in co-
cultures of primary fibroblasts (FIB) with and without CT26 WT and siRNA FliI CT26 cells 
compared to single cultures. Results are shown as FliI expression (n-fold change) ± SEM (n=3). 
****p<0.0001 significant difference to control cells (WT CT26) (Tukey’s multiple comparison 
test). 
Expression of the myofibroblast marker α-SMA was also evaluated to determine whether the 
expression of FliI had an effect on the differentiation of fibroblasts into their activated form, α-
SMA-positive myofibroblasts. Transwells coated with Matrigel were used in these experiments 
to separate the two types of cells in the co-culture system. Interestingly, there was a significant 
decrease in the number of α-SMA-positive cells in the siRNA FliI CT26 co-cultures, suggesting 
fewer myofibroblasts were activated in the presence of CT26 cells with reduced FliI expression 
(Figure 4.12). Greater α-SMA expression was observed in CT26 WT cell co-cultures, as shown in 
representative images of the immunostaining (Figure 4.12). 
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Figure 4.12: α-SMA expression in primary fibroblasts (FIB) co-cultured with colon cancer cells 
expressing different levels of FliI detected by immunoperoxidase staining. Co-cultures of 
primary fibroblasts with (A) CT26 WT and (B) siRNA FliI CT26 cells were stained with anti-α-SMA 
antibody. (C) Negative control of α-SMA of primary fibroblasts cells. Results are shown as α-
SMA-positive cells ± SEM (n=3). *p<0.05 significant difference to control cells (CT26 WT) 
(Student’s unpaired t-test). 
4.3 Discussion 
4.3.1 Role of FliI in cell invasion 
3D matrix invasion assays are an established method to determine the capacity of particular 
cells to invade the ECM and these assays have been frequently used in studies of cancer cell 
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invasion, for example colon cancer (F. Zhang et al., 2013) and human melanoma cell invasion 
(Kreiseder et al., 2013). In this assay, ECM is coated onto a membrane that has pores of a size 
that block non- or less invasive cells from migrating through the membrane. However, invasive 
cells can move through the ECM layer by degrading the matrix, then penetrate the 8 m pores 
and adhere to the bottom of the membrane. Our findings indicate that knockdown of FliI 
greatly inhibited cell invasion in Matrigel-coated invasion membranes as compared to WT cells. 
In contrast, the addition of exogenous FliI significantly increased the invasiveness of the cells, 
allowing them to protrude through the membrane. On wounding of cell monolayers in 2D, it 
has been shown that FliI is involved in lamellopodia formation in keratinocytes and remodelling 
of the ECM at the wound site (Cowin et al., 2007). Our findings suggest that FliI may have 
different effects on different cell types and also have a different effect on 3D invasion 
compared to 2D cell motility, which does not involve penetration of the ECM. Invasive tumour 
cells have been demonstrated to present dysregulated cell motility in response to extracellular 
signals from growth factors and cytokines (Wells, 1999) and our results suggest that FliI 
expression in cancer cells may contribute to increased invasiveness. 
Our results also indicate that FliI might play a role in reorganisation of the cytoskeleton to 
create a protrusive actin meshwork, suggesting invadopodia formation in cancer cells; however, 
this needs to be further investigated. FliI has recently been reported to be a novel P-Rex1-
enriched binding partner where FliI is required for P-Rex1-driven cell contraction that may in 
turn lead to cell migration (Marei et al., 2016). P-Rex1 induces Rac-1 downstream effects where 
Rac-1 has the ability to stimulate cell-to-cell adhesion, reduce cell migration and aid in ECM 
degradation by regulation of MMP release (G. Jin et al., 2000). Understanding the mode of 
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migration and invasion is important in designing strategies to target evolving cancer cells and 
block their movement through tissues and organs (Kramer et al., 2013). Migratory and invasive 
properties of cancer cells both involve dramatic reorganisation of the actin cytoskeleton and 
the concomitant formation of membrane protrusions which are required for invasive growth 
(Yilmaz & Christofori, 2009). However, the molecular processes underlying such cellular 
changes are still only poorly understood and the involvement of various migratory organelles, 
including lamellipodia, filopodia, invadopodia and podosomes, still requires better molecular 
and functional characterisation.  
In summary, our results suggest that it may be beneficial to target and block FliI with the 
ultimate aim of limiting cell penetration of a barrier matrix (such as the basement membrane) 
and thus play a role in inhibiting metastasis. 
4.3.2 Knockdown of FliI downregulates cortactin expression 
Cancer cell invasion and metastasis are considered major negative prognostic factors, being 
associated with increased malignancy and decreased patient survival. Therefore, better 
understanding of the intracellular mechanisms controlling metastasis is crucially important to 
designing future therapies. 
In comparisons between WT and knockdown of FliI in CT26 cells, our results showed that 
knockdown of FliI significantly downregulated expression of cortactin. Cortactin is involved in 
cell protrusions via lamellopodia and invadopodia, and it is present at dynamic sites of actin 
assembly (Yamaguchi & Condeelis, 2007). Therefore, cortactin is thought to act as an important 
regulator and a specific marker for invadopodia based on its capability to promote protease 
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secretion at the active adhesion site (Clark & Weaver, 2008). Furthermore, cortactin has the 
ability to bind to several cytoskeletal proteins through its C-terminal SH3 domain, which links it 
to numerous processes, including endocytosis, lamellipodial protrusion and directed cell 
migration (Ammer & Weed, 2008).  
Overexpression of cortactin has been shown to increase ECM degradation via increased 
secretion of MMP-2 and MMP-9 (Clark & Weaver, 2008; Clark et al., 2007), and has also been 
shown to promote cell cycle progression through a RhoA-dependent pathway in cancer cells 
(Croucher, Rickwood, Tactacan, Musgrove, & Daly, 2010). Increased secretion of MMPs in 
tumour cells is closely related to invasive capability, increased metastasis and poor prognosis in 
several types of cancers (Buday & Downward, 2007; Stetler-Stevenson, Hewitt, & Corcoran, 
1996). A previous study by (Bowden et al., 2006) suggested that cortactin and p-
phosphotyrosine signalling is crucial for activation of invadopodia proteases leading to 
degradation of the ECM, thus mediating cell invasion. Cortactin expression has been shown to 
regulate membrane trafficking and adhesion dynamics that could alter the secretion of ECM 
from late endosomal/lysosomal compartments, while cortactin knockdown (KD) cells 
demonstrated defects in both cell motility and lamellipodia functions (B. H. Sung, Zhu, Kaverina, 
& Weaver, 2011). 
In addition to invadopodia, cell adhesion via FAs is an important factor in governing cell motility 
and invasion. In our study, reduced expression of cortactin was observed with knockdown of 
FliI, suggesting that reduced Flil expression may inhibit cell invasion via reduced formation of 
invadopodia, although further experiments are required to confirm this. Elevated levels of 
cortactin expression have been shown to correlate with increased aggressiveness of head and 
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neck squamous cell carcinoma (HNSCC) cells and the cortactin levels were found to directly 
correlate with size of tumour, degree of vascularisation and cell proliferation in an orthotopic 
HNSCC in vivo model (Clark et al., 2009). 
4.3.3 FliI regulation of cell adhesion 
Previously, FliI has been shown to regulate cell adhesion, actin remodelling and intracellular 
signalling by co-localisation with actin and microtubule-based structures (H. D. Campbell et al., 
2002; Davy et al., 2001; Z. Kopecki & Cowin, 2008). Previous studies on fibroblasts and 
keratinocytes by Professor Cowin’s laboratory have suggested that in wound healing, FliI may 
increase cell adhesion by affecting FA proteins. The present study shows that knockdown of FliI 
in cancer cells increased cell adhesion; however, exogenous recombinant FliI had no significant 
effect on adhesiveness of the cells. Invasive cells have often been found to be less adhesive, 
and this is associated with higher motility and higher metabolic activity (Turner & Sherratt, 
2002). In accordance with the effect of FliI on cell adhesion, we also observed a significant 
reduction of invasive cells in knockdown cells.  
Recently, it has been shown that overexpression of FliI impaired the formation of tight junctions 
in mouse skin, which delayed the formation of the epidermal barrier that is required for repair 
(Zlatko Kopecki et al., 2014). During wound healing, FliI was reported to regulate adhesion via 
hemidesmosome formation and integrin-mediated cellular adhesion molecules (Zlatko Kopecki 
et al., 2009; Thiery, 2003). In fact, knockdown of FliI was also shown to increase adhesion in 
migratory cells via actin monomer assembly. However, a more recent study by Kopecki et al. 
(2015) suggested that FliI expression did correlate with increased 3D invasiveness in a 
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squamous cell cancer line. These findings suggest that the role of FliI in adhesion and invasion 
may be dependent on cell type and may be altered in transformed cells.  
In addition, the adhesion process of epithelial cells to the ECM involves linkages to the actin 
cytoskeleton. This adhesion complex involves the adaptor proteins talin, paxillin and vinculin, 
and the ternary complex of pinch, parvin and integrin-linked kinase (ILK) (Yilmaz & Christofori, 
2009). Therefore, expression of these adaptor proteins, specifically paxillin and vinculin, was 
also determined and is discussed in the next section of this study. Cell adhesion to neighbouring 
cells and/or to the surrounding ECM or stroma, the tumour microenvironment, also plays a 
critical role in tumour progression by regulating cell proliferation and survival, which enable 
tumour cell dissemination and metastasis. The local tumour microenvironment, including its 
molecular composition and organisation, density and rigidity of the stromal ECM, has in turn 
been shown to influence tumour malignancy (Deakin et al., 2012). 
4.3.4 Knockdown of FliI increased focal adhesion protein expression: paxillin and vinculin 
Previously, FliI was found to be localised in FAs, which, as mentioned, have been shown to play 
important regulatory roles in cell migration (Mohammad et al., 2012). FliI may affect adhesion 
via hemidesmosome formation, and the integrin-mediated adhesion of migratory keratinocytes 
which overexpress FliI has been shown to impair hemidesmosome formation, resulting in 
decreased wound re-epithelisation (Zlatko Kopecki et al., 2009). FliI has been reported to co-
localise with integrin-binding proteins such as actin and talin (Davy et al., 2001), vinculin (Zlatko 
Kopecki et al., 2009; Mohammad et al., 2012) and paxillin (Zlatko Kopecki et al., 2009), which 
are all known to be actively involved in adhesion-dependent signalling pathways. These actin-
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binding proteins are suggested to form a cytoskeletal complex directly linking the integrin 
receptors to the actin cytoskeleton.  
In this study, we found that expression of paxillin and vinculin was increased by siRNA 
knockdown of FliI in cancer cells, suggesting upregulation of FA proteins in association with FliI. 
Previous studies on non-cancer cells showed that reduced expression of p-paxillin in FliITg/Tg 
fibroblasts (which overexpress FliI) resulted in impaired FA turnover (Z. Kopecki et al., 2011). 
Analysis of adhesion dynamics during 3D migration identified a role for paxillin in regulating the 
adhesion process, including assembly, stabilisation and disassembly. Paxillin-depleted cells have 
been found to show a decreased rate of adhesion disassembly, possibly due to decreased FAK 
activity (Deakin & Turner, 2011). In addition, paxillin may influence Rac1 and RhoA activity of 
the Rho-GTPase signalling pathway during 3D cell migration (Deakin & Turner, 2008), suggesting 
a mechanism for increased cell migration in knockdown cells. In addition, FliI has been shown to 
regulate FA turnover through inhibition of the phosphorylation of paxillin in an Rac1-dependent 
manner (Z. Kopecki et al., 2011). However, in contrast vinculin expression has been shown to 
inhibit cell migration by stabilising FAs via binding of inositol phospholipids, which play an 
important role in FA turnover (Saunders et al., 2006). This situation could be explained by the 
dynamics of FA complexes, and the proportions of phosphorylated and non-phosphorylated 
paxillin may affect the adhesion complex and function (Zaidel-Bar et al., 2007).  
There are thus contradictions regarding a direct correlation between paxillin 
expression/phosphorylation and cancer aggressiveness depending on tissue type and the 
specific roles of paxillin (Brown & Turner, 2004). A study by (Zaidel-Bar et al., 2007) showed that 
cells which overexpress a phosphomimetic paxillin mutant had enhanced lamellipodial 
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protrusions and stabilised the formation of FA complexes, whereas non-phosphorylated paxillin 
enhanced fibronectin fibrillogenesis. Increased expression of paxillin has also been found to be 
directly correlated with the expression of HER2/3 receptor in aggressive breast cancer lines and 
grade III human breast tumors (Vadlamudi, Adam, Tseng, Costa, & Kumar, 1999). However, 
decreased paxillin levels have been shown in canine and feline mammary tumours (Scibelli et 
al., 2003) and lung cancer (Salgia et al., 1999), both of which are highly metastatic cancers. 
As mentioned in the previous chapter, several studies have previously suggested that paxillin 
expression was reduced in colorectal cancer, correlating with poor prognosis and cancer 
progression (Deakin et al., 2012). Our results suggest that reducing FliI expression may reduce 
tumour metastasis and result in a better prognosis. This may be via increasing adhesion through 
FA protein pathways. However, the effect of FliI expression may vary with cell and tissue type.  
Paxillin phosphorylation may play a role in cancer progression regulated by integrin and growth 
factor receptors, both of which play roles in tumourigenesis and invasion (Brown & Turner, 
2004). Invasiveness of cancer cells may be dependent on paxillin phosphorylation, which is 
associated with the formation of a novel signalling-invadopodia complex that includes paxillin, 
cortactin and PKC, but not FAK (Bowden et al., 1999).  
Importantly, other cytoskeletal proteins such as alpha-actinin and zyxin, integrin linkers such as 
vinculin and talin, and signalling molecules such as FAK, paxillin and ERK have also been shown 
to be involved in invadopodia/pedosome formation (Linder & Aepfelbacher, 2003; Weaver, 
2006). These proteins are commonly located in ring-adherent structures of the actin core, 
which consists of several adhesion components and is responsible for mediating invadopodial 
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protrusion, and correlates with invadopodium ECM degradation (Branch, Hoshino, & Weaver, 
2012). Interestingly, recent findings also revealed that paxillin could promote cell survival via 
direct interactions with vinculin, FAK and p210BCR/ABL (Deakin et al., 2012), and regulation of 
cell-survival signalling through the apoptosis inhibitory protein bcl-2 (Sheibani, Tang, & 
Sorenson, 2008). In addition, vinculin has also been shown to be implicated in modulating the 
apoptosis-signalling pathway and has been claimed to exert tumour-suppressing functions in a 
rat adenocarcinoma model (Subauste et al., 2004; Ziegler et al., 2006). 
4.4 Conclusion 
The cellular effects of Flil as an important tumour-regulating factor, specifically cell invasion and 
adhesion, and important biomarkers involved in both processes, specifically cortactin, paxillin 
and vinculin, have been discussed in this chapter. FliI appears to negatively regulate expression 
of the FA proteins paxillin and vinculin, suggesting an effect on cell adhesion that may promote 
tumour spread. FliI knockdown appears to enhance adhesiveness and inhibit invasiveness, 
suggesting a possible tumour-suppressing role. Similarly, decreased cortactin expression in FliI 
knockdown cells could also explain their apparent reduced invasiveness in 3D cultures.  
The next chapter will discuss the role of FliI in regulating tumour growth and dissemination of 
tumour cells in vivo via the establishment of primary and lung nodule murine colon tumour 
models. 
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Chapter 5 Flightless I Modulates 
Cancer Growth and Metastasis in 
Colon Cancer Models 
5.1 Introduction 
Tumourigenesis is a multi-step process of cellular changes, including modification of cell 
proliferation and cell adhesion, and regulation of apoptosis. These changes may initiate 
cancer cell dissemination, and also influence tumour cell motility and migration. In order for 
tumour cells to metastasise, several mechanisms are involved, including angiogenesis, 
enhanced degradation of the ECM and infiltration of tumour cells through the basement 
membrane and surrounding connective tissues, followed by intravasation and extravasation 
through the blood vessels at secondary sites, escape from immune system surveillance and, 
finally, establishment of distant metastatic sites (Wells, 2006).  
The importance of the tumour microenvironment or tumour stroma in driving tumour 
progression and invasion leading to metastasis is now accepted (Quail & Joyce, 2013). The 
contribution of stromal cells to cancer development is not limited to their effects on primary 
tumour growth, but has also been shown to be involved in the establishment of both pre-
metastatic and metastatic microenvironments at distant sites (Hanahan & Weinberg, 2011). 
In fact, the stroma is also important in the context of drug delivery and drug efficacy, and 
may be useful as a biomarker to predict the tumour response to chemotherapy (Hale et al., 
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2013). In addition, many published papers have provided data that has demonstrated the 
interaction between tumour cells and the stroma, which may either promote or in some 
cases limit cancer progression (Erler & Weaver, 2009; Hawinkels et al., 2014; Pietras & 
Östman, 2010).  
Invasive cancer cells are capable of adapting and exploiting their tissue microenvironment, 
leading to cellular and molecular changes of the surrounding cells, including epithelial cells 
and also cells in the stroma such as inflammatory cells, fibroblasts and capillaries. These 
changes include promotion of angiogenesis, attracting immune-cell infiltration (mainly 
macrophages), stimulating the differentiation of CAFs, which are derived from local 
fibroblasts, and the release of cytokines, growth factors and proteases that are involved in 
remodelling of the ECM (Sounni & Noel, 2013). Specifically, the complex tumour 
microenvironment at the primary tumour site mainly consists of endothelial cells of both 
the blood and lymphatic circulation, bone marrow derived–cells (BMDCs) such as 
macrophages, neutrophils, mast cells and mesenchymal stem cells, while in the metastatic 
niche activated stromal cells and TAMs are commonly present, and are associated with 
greater release of proteases, chemokines and growth factors that mediate cell intravasation 
(Joyce & Pollard, 2009). 
Recently, FliI has been shown to promote the progression of a chemically induced 
cutaneous squamous cell carcinoma (SCC) in an animal model, possibly by increased tumour 
cell invasion (Z Kopecki et al., 2015). Reduction of tumour cell apoptosis was also observed 
in the same study. In the present study, primary tumours and disseminating murine colon 
tumour models were established to determine the effects of FliI expression in tumour 
growth and establishment at secondary sites, respectively. 
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This chapter also discusses the role of Flil I in regulating tumour growth and the 
establishment of lung nodules using mice with different levels of expression of FliI; that is, 
using WT and FliI heterozygous knockout (FliI +/−) mice. In addition, tumour growth was 
studied in mice where WT tumour cells were pre-treated with siRNA FliI colon carcinoma 
(CT26) cells prior to inoculation into the mice. This allowed us to examine the effect of 
tumour cell FliI expression independent of the level of FliI expression in the host animal, and 
thus FliI expression in the tumour microenvironment. Knockdown of FliI in this way may tell 
us something about the early effect of FliI deficiency on tumour establishment, even though 
the effect of knockdown is likely to be short-lived. The effects of each model in modulating 
the tumour growth and tumour microenvironment were determined by examining the 
expression of tumour markers of proliferation: PCNA; myofibroblast activation; α-SMA 
expression and invasion of invadopodia marker; and cortactin localisation. The effects of FliI 
expression in the host animal and in the tumour cells were thus studied to determine the 
effects of FliI on cancer progression and establishment of tumour nodules in the lung. 
5.2 Results 
5.2.1 Effect of expression of Flightless I in mice injected intravenously with tumour cells 
 Bodyweight monitoring 5.2.1.1
In this model, FliI heterozygous +/− (FliI +/−) mice with reduced FliI expression and WT 
BALB/c mice were used to determine the effects of lower FliI expression on the 
development and establishment of lung nodules, by determining the number of tumour 
nodules in the lung 14 days post tumour inoculation with colon cancer cells (CT26 WT cells). 
Inoculation was made by intravenous injection via the mouse tail vein. Bodyweight 
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measurement of the mice showed a consistent increment throughout the 14 days post-
inoculation of cancer cells (CT26 WT cells) and mice were also monitored to ensure that 
there was no sign of distress or respiratory discomfort.  
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Figure 5.1: Monitoring of body weight in BALB/c mice expressing different levels of Flil I 
after intravenous inoculation of colon cancer cells. BALB/c mice expressing different levels 
of FliI (WT BALB/c and heterozygous FliI +/−) were injected intravenously with CT26 WT cells 
to induce lung tumours. Bodyweights are shown of WT BALB/c and FliI heterozygous +/− (FliI 
+/−) mice was monitored for 14 days after tumour inoculation with CT26 WT colon cancer 
cells. Results are shown as mean weight ± SEM (n=6 each group). 
 Inhibition of FliI expression reduced development of nodules in the lung 5.2.1.2
FliI+/− heterozygous mice with reduced FliI expression were used in this metastatic model in 
comparison to WT BALB/c mice. Cancer cells (CT26 WT) were inoculated via tail-vein 
injection and allowed to invade and develop nodules in the lung during 14 days post-
injection. There was a reduction in the number of microscopic metastatic nodules observed 
in the lungs of heterozygous mice (BALB/c FliI +/−) compared to WT BALB/c mice (p<0.05) 
after 14 days of tumour inoculation with colon cancer cells (CT26 WT). Histological sections 
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stained with H&E staining were used to count the number of nodules present in the lungs of 
both groups of mice.  
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Figure 5.2: Microscopic tumour nodules in BALB/c mice expressing different levels of FliI 
after inoculation with colon cancer cells. BALB/c mice expressing different levels of FliI (WT 
BALB/c and heterozygous FliI+/−) were injected intravenously with CT26 WT and the numbers 
of microscopictumour nodules counted after H&E staining. Number is shown of microscopic 
nodules present in the lung in WT BALB/c and FliI heterozygous mice (n=6 each group). 
Results are shown as mean ± SEM. *p<0.05 is significantly different from control group 
(Student’s unpaired t-test). 
 Histological sections and FliI expression in lung nodules 5.2.1.3
Histological analysis of nodules established in the lungs showed an increased number of 
tumour nodules in the lungs of WT BALB/c mice; however, very few to no tumour nodules 
were found in the lungs of FliI+/− heterozygous mice (Figure 5.3), 14 days post tumour 
inoculation with colon cancer cells (CT26 WT). Histological sections stained with H&E were 
used to count the number of tumour nodules present in the lungs in the two experimental 
groups.  
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Representative staining of FliI in lung nodules showed higher expression in the tumours of 
WT BALB/c mice and lower expression in the tumours of FliI+/− heterozygous mice (Figure 
5.4). The expression of FliI in positive control tissue, skeletal muscle, is also shown in Figure 
5.4.  
Representative staining for cortactin (Figure 5.5) and α-SMA (Figure 5.6) in the lung nodules 
also showed greater expression of both cortactin and α-SMA in the tumours of WT BALB/c 
mice compared to the tumours in FliI+/− heterozygous mice.  
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Figure 5.3: Microscopic tumour nodules in BALB/c mice expressing different levels of FliI 
after induction of lung nodules with colon cancer cells. Representative H&E staining of lung 
sections of (A, B) WT BALB/c and (C, D) FliI heterozygous (+/−) mice (4X magnification). 
Arrows indicate tumour nodules, which stain darkly in the lung tissue. In FliI heterozygous 
mice, nodules were rarely seen and the large pink/red structures observed here are blood 
vessels. 
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Figure 5.4: FliI expression in tumour nodules in BALB/c mice expressing different levels of FliI after induction with colon cancer cells, shown 
by immunohisctochemical staining. Representative images of immunohistochemical staining of FliI in the lungs in tumour nodules of (A) WT 
BALB/c mice, (B, C) FliI+/- heterozygous mice (20X and 40X magnification) and (D) a negative control are shown. (E) Positive control staining of 
FliI using mouse skeletal muscle (40X magnification). 
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Figure 5.5: Cortactin expression in tumour nodules in BALB/c mice expressing different levels of FliI after induction using colon cancer cells. 
Representative images of immunohistochemical staining of cortactin in the lungs in tumour nodules of (A) WT BALB/c mice and (B) 
heterozygous mice (20X magnification). The densely packed cells at the periphery of the lung in B show a small aggregation of cancer cells 
close to the surface of the lung (arrow). 
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Figure 5.6: Alpha smooth muscle actin (α-SMA) expression in tumour nodules in BALB/c mice expressing different levels of FliI. 
Representative images of immunohistochemical staining of α-SMA in the lungs in tumour nodules of (A, B) WT BALB/c mice and (C) 
heterozygous mice (20X magnification). Arrows indicate expression of α-SMA around tumour cells. The pattern of expression of α-SMA shows 
expression in fibroblasts present in the stroma (rather than in tumour cells).  
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5.2.2 Effect of knockdown of Flil I in cancer cells on primary tumour growth in animal 
model 
 Inhibition of FliI expression in cancer cells reduced the size of primary tumours 5.2.2.1
Primary tumours were induced by injecting CT26 WT and siRNA FliI-treated CT26 cells into 
the right flank of the WT BALB/c mice. Primary tumours were measured daily for a 
maximum of 21 days or until tumours reached 1000 mm3 in size. It was observed that 
smaller tumours were grown in mice inoculated with siRNA FliI-treated CT26 cells compared 
to mice inoculated with CT26 WT cells, with a significant difference observed at days 10 
(p<0.01) and 12 (p<0.05) (Figure 5.7) post-inoculation with colon cancer cells. In contrast, 
larger primary tumours were observed in WT BALB/c mice inoculated with CT26 WT colon 
cancer cells. At 14 days post-inoculation of colon cancer cells, there was no significant 
difference in tumour size observed between the two groups.  
Representative images of primary tumour formation on the right flank of WT BALB/c mice 
inoculated with CT26 WT or siRNA FliI CT26 cells at days 12, 14 and 20 are shown in Figure 
5.8. Larger tumours were grown on the right flank of the WT BALB/c mice inoculated with 
CT26 WT cells, while smaller primary tumours were observed in mice inoculated with siRNA 
FliI-treated CT26 cells (Figure 5.8). 
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Figure 5.7: Measurement of primary tumours in BALB/c mice inoculated with colon CT26 
cells expressing different levels of FliI expression in vivo. The size of primary tumours on 
the right flank of the mice at days 8, 10, 12 and 14 days in BALB/c mice inoculated with CT26 
WT and siRNA FliI CT26 colon cancer cells. Results are shown as mean ± SEM (n=10 each 
group). **p<0.01 and *p<0.05 are significantly different from control group (Dunnet’s 
multiple comparison test).  
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Figure 5.8: Primary tumours in BALB/c mice inoculated with WT or siRNA FliI-treated CT26 
cells. Representative images of primary tumours in BALB/c mice after inoculation with CT26 
WT and siRNA FliI CT26 cells at days (A) 12, (B) 14 and (C) 20 days post-inoculation. 
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5.2.3 Effect of Flil I expression on tumour growth in BALB/c mice 
 Bodyweight monitoring  5.2.3.1
In this model, WT BALB/c mice were inoculated either with CT26 WT cells or siRNA FliI-
treated CT26 cells intravenously via the tail vein. Mouse bodyweight was constantly 
recorded throughout 14 days post-inoculation of cancer cells (CT26 WT and siRNA FliI CT26 
cells) and indicated that mice remained healthy during this experimental period (Figure 5.9). 
There was no sign of distress or respiratory discomfort in the mice.  
 
 
 
 
 
 
 
Figure 5.9: Monitoring of bodyweight in BALB/c mice inoculated with cells expressing 
different levels of FliI. BALB/c mice were injected intravenously with CT26 cells expressing 
different levels of FliI to induce lung tumour nodules. Bodyweight is shown in BALB/c mice 
after inoculation with CT26 WT and siRNA FliI CT26 cells for 14 days post-inoculation. 
Results are shown as mean ± SEM (n=10 each group).  
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 Inhibition of FliI expression in cancer cells reduced tumour nodules in the lung 5.2.3.2
Seeding of tumour nodules in the lung was induced by injecting CT26 WT cells and siRNA 
FliI-treated CT26 cells via the tail vein in BALB/c mice. Mice were then monitored for 14 days 
post-inoculation. At day 14, the mice were killed and the lungs were removed for further 
histological analysis. The number of microscopic nodules present in the lung was counted in 
lung sections after H&E staining. A significantly lower number of lung nodules was observed 
in mice inoculated with siRNA FliI-treated CT26 cells compared to mice inoculated with CT26 
WT cells, which showed greater tumour numbers (p<0.001) (Figure 5.10). 
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Figure 5.10: Quantification of microscopic tumour nodules in BALB/c mice inoculated with 
colon CT26 cancer cells expressing different levels of FliI. BALB/c mice were injected 
intravenously with CT26 cells expressing different levels of FliI and the number of 
microscopic lung nodules counted after H&E staining. Results are shown as mean ± SEM 
(n=10 each group). ***p<0.001 shows significant difference from control group (Student’s 
unpaired t-test). 
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 Histology of lung nodules 5.2.3.3
Histological analysis of the lungs from injected mice showed that an increased number of 
and larger tumour nodules were present in mice inoculated with CT26 WT cells compared to 
mice inoculated with siRNA FliI-treated CT26 cells (Figure 5.11), 14 days post tumour 
inoculation. Histological sections stained with H&E were used to count the number of 
tumour nodules present in the lungs of both experimental groups.  
Representative histological images of H&E staining of nodules in the lung show more and 
larger-sized tumours in WT BALB/c mice inoculated with CT26 WT cells, while fewer and 
smaller tumours are observed in WT BALB/c mice inoculated with siRNA FliI CT26 cells 
(Figure 5.11).  
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Figure 5.11: Histological analysis of tumour nodules in BALB/c mice inoculated with WT or siRNA treated CT26 cells. BALB/c mice were 
inoculated intravenously with CT26 WT cells expressing different levels of FliI and the numbers of microscopic nodules were counted in H&E-
stained sections. Representative histological images of microscopic nodules in the lungs of mice inoculated with (A-C) CT26 WT and (D-F) siRNA 
FliI CT26 cells. Arrows indicate tumour nodules in the lung tissue (4X magnification).  
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5.2.4 Expression of Flil I in primary and lung tumours 
Expression of FliI was determined in the lung sections by immunohostochemistry. As a 
positive control, FliI was detected in skeletal muscle sections, as shown above in Figure 5.4, 
and staining was then optimised and FliI expression detected in tumours (both primary and 
lung). Analysis of immunohistochemistry staining for FliI showed a lower expression of FliI in 
the primary tumours of mice inoculated with siRNA FliI-treated CT26 cells compared to 
tumours derived from CT26 WT cells (Figure 5.12).  
Representative images of the immunohistochemical staining of FliI expression in primary 
and lung tumour nodules after inoculation with CT26 cells expressing different levels of FliI 
are shown in Figure 5.12.  
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Figure 5.12: FliI expression in primary and lung tumours in BALB/c mice inoculated with 
CT26 colon cancer cells. Primary tumour immunostaining with FliI in (A) BALB/c mice 
injected with CT26 WT and (B) BALB/c mice injected with siRNA FliI-treated CT26 cells (40X 
magnification). Tumours in the lung immunostained with FliI showing FliI expression in (C, D) 
BALB/c mice injected with CT26 WT cells and (E, F) BALB/c mice injected with siRNA FliI CT26 
cells which (C) and (E) show low magnification (10X) and (D) and (F) show high magnification 
(20X). 
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 Histological analysis of FliI expression in primary tumours 5.2.4.1
Analysis of FliI expression in primary tumours was performed by scoring the sections 
immunostained with FliI from the tumours of BALB/c mice inoculated with CT26 WT or 
siRNA FliI CT26 cells. Immunoreactive scores for FliI expression were significantly lower for 
the expression of FliI in primary tumours in BALB/c mice inoculated with siRNA FliI CT26 
cells, compared to the expression of FliI in primary tumours in BALB/c mice inoculated with 
CT26 WT cells (p<0.05) (Figure 5.13) post tumour inoculation on the right flank. This result 
suggests that tumour cells had different levels of FliI expression depending on the type of 
cells inoculated, with siRNA FliI CT26 cells successfully lowering FliI expression. 
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Figure 5.13: Quantification of FliI expression in primary tumours in BALB/c mice 
inoculated with colon CT26 cancer cells expressing different levels of FliI. BALB/c mice 
were inoculated with CT26 cells expressing different levels of FliI and primary tumours were 
collected and analysed by immunohistochemistry staining. Primary tumours were 
immunostained with FliI and the immunoreactive score of FliI expression determined in 
primary tumours in BALB/c mice inoculated with CT26 WT and siRNA FliI CT26 (n=5). Results 
are shown as mean score ± SEM. *p<0.05 shows significant difference from control group 
(Student’s unpaired t-test). 
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 Histological analysis of FliI expression in lung tumours 5.2.4.2
Analysis of FliI expression in lung tumours was performed by scoring the lung sections from 
BALB/c mice inoculated with either CT26 WT or siRNA FliI CT26 cells. The immunoreactive 
score for FliI expression was also significantly lower in tumours in the lungs of mice 
inoculated with siRNA FliI CT26 cells, compared to those of mice inoculated with CT26 WT 
cells (p<0.001) (Figure 5.14). This result also suggests that CT26 cells that formed tumours in 
the lung had a lower level of FliI expression after siRNA FliI treatment. 
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Figure 5.14: Quantification of FliI expression in lung tumours in BALB/c mice inoculated 
with colon CT26 cancer cells expressing different levels of FliI. BALB/c mice were 
inoculated intravenously with CT26 cells expressing different levels of FliI and the lungs 
were collected and analysed by immunohistochemical staining. Tumour nodules were 
immunostained with FliI and the immunoreactive score for FliI expression determined in 
tumours from BALB/c mice inoculated with CT26 WT and siRNA FliI CT26 (n=5). Results are 
shown as mean score ± SEM. *p<0.05 shows significant difference from control group 
(Student’s unpaired t-test). 
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5.2.5 Expression of PCNA in primary and lung tumours 
Primary and lung tumours were immunostained for the proliferation marker PCNA to 
determine the effect of FliI expression on cell proliferation. A lower proliferation rate was 
observed in the primary tumours of mice inoculated with siRNA FliI CT26 cells compared to 
those of mice inoculated with CT26 WT (p<0.01) (Figure 5.16). Increased PCNA positivity was 
also observed in tumour nodules in the lungs of BALB/c mice inoculated with CT26 WT cells 
compared to those inoculated with siRNA FliI CT26 cells (p<0.05) (Figure 5.17). It should be 
noted that the very low number of tumour nodules observed in the lungs of siRNA FliI CT26 
injected cells made it more difficult to validly compare the proliferation rates in the lung 
tumour model.  
Representative images of immunohistochemical staining with PCNA of primary tumours and 
lung nodules are shown in Figure 5.15. There was a greater number of proliferating cells 
which stained positively with PCNA (cellular staining) in BALB/c mice injected with CT26 WT 
cells compared to those of BALB/c mice injected with siRNA FliI CT26 cells in both primary 
and lung tumours.  
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Figure 5.15: PCNA expression detected by immunohistochemical staining in primary and 
lung tumours in BALB/c mice. Primary tumour immunostaining with PCNA in (A) BALB/c 
mice inoculated with CT26 WT cells and (B) BALB/c mice inoculated with siRNA FliI CT26 
cells (40X magnification). Tumour nodules in the lungs immunostained with PCNA showing 
PCNA expression in (C,D) mice injected with CT26 WT cells, (E,F) mice injected with siRNA 
FliI CT26 cells (10X and 20X magnification) and (E) positive control of normal low-
proliferating skin tissue (20X magnification). 
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 Proliferative index of PCNA in primary tumours 5.2.5.1
Analysis of PCNA expression in primary tumours was performed by scoring the 
immunostained sections from tumours in BALB/c mice inoculated with CT26 WT or siRNA 
FliI CT26 cells. A significantly lower proliferative index score was found in primary tumours 
of mice inoculated with siRNA FliI CT26 cells compared to those of mice inoculated with 
CT26 WT cells (p<0.01) (Figure 5.16). Lower cell proliferation staining in the primary 
tumours of BALB/c mice inoculated with siRNA FliI CT26 cells thus correlated with the 
reduced size of primary tumours in this experimental group.  
 
 
 
 
 
 
 
Figure 5.16: Quantification of PCNA expression in primary tumours in BALB/c mice 
inoculated with colon CT26 cancer cells expressing different levels of FliI expression. 
Primary tumours were immunostained with PCNA and the immunoreactive score for PCNA 
expression determined in primary tumours in BALB/c mice inoculated with CT26 WT or 
siRNA FliI CT26 cells (n=5). Results are shown as mean score ± SEM. *p<0.05 shows 
significant difference from control group (Student’s unpaired t-test). 
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 Proliferative index of PCNA in lung tumours 5.2.5.2
Analysis of PCNA expression in lung tumours was performed by scoring lung sections 
immunostained with PCNA. Fewer proliferating PCNA-positive cells were detected in 
nodules in the lungs of mice injected with siRNA FliI CT26 cells compared to those of mice 
injected with CT26 WT cells (p<0.05) (Figure 5.17). However, the high level of staining in 
both groups made it difficult to see negatively stained nuclei in the lung nodules. 
 
 
 
 
 
 
 
Figure 5.17: Quantification of PCNA expression in lung tumours in BALB/c mice inoculated 
with colon CT26 cancer cells expressing different levels of FliI. Tumour nodules were 
immunostained with PCNA and the immunoreactive score for PCNA expression determined 
in lung tumours in mice inoculated with CT26 WT and siRNA FliI CT26 (n=5). Results are 
shown as mean score ± SEM. *p<0.05, significant difference from control group (Student’s 
unpaired t-test). 
 
C T 2 6  W T s iR N A F liI  C T 2 6
0
2 0
4 0
6 0
8 0
1 0 0
P
r
o
li
fe
r
a
ti
v
e
 I
n
d
e
x
*
176 
 
5.2.6 Expression of cortactin in primary and lung tumours 
The expression of cortactin was studied as an invadopodia marker, and was evaluated in 
primary and lung tumours. Primary and lung tumours were immunostained with an anti-
cortactin antibody to determine the effect of FliI expression on the expression of cotactin 
and thus potentially on the capacity for tumour cells to invade. Lower expression of 
cortactin was observed in mice inoculated with siRNA FliI CT26 cells compared to mice 
inoculated with CT26 WT cells (Figure 5.18).  
Representative images of immunohistochemical staining for cortactin in primary and lung 
nodules are shown in Figure 5.18. There was a higher level of cortactin cytoplasmic 
expression observed in mice injected with CT26 WT cells compared to mice injected with 
siRNA FliI CT26 cells in both primary and lung tumours.  
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Figure 5.18: Cortactin expression detected by immunohistochemical staining in primary 
and lung tumours in BALB/c mice. Primary tumour immunostaining for cortactin in BALB/c 
mice injected with (A) CT26 WT cells and BALB/c mice injected with (B) siRNA FliI CT26 cells. 
Lung tumour immunostaining for cortactin showing expression of cortactin in (C, D) mice 
injected with CT26 WT cells and (E, F) mice injected with siRNA FliI CT26 cells which (C) and 
(E) show low magnification (10X and 20X respectively) and (D) and (F) show high 
magnification (20X and 40X respectively). 
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 Quantitative analysis of cortactin staining in primary tumours 5.2.6.1
Analysis of cortactin expression in primary tumours was performed by scoring the tumour 
sections immunostained for cortactin from mice inoculated with CT26 WT or siRNA FliI CT26 
cells. Immunoreactive scores for the invadopodia marker cortactin showed lower levels of 
expression in primary tumours in mice injected with siRNA FliI CT26 cells compared to mice 
injected with CT26 WT cells (p<0.05) (Figure 5.19). 
 
 
 
 
 
 
 
Figure 5.19: Quantification of cortactin expression in primary tumours in BALB/c mice. 
BALB/c mice were inoculated with CT26 cells expressing different levels of FliI and primary 
tumours were collected and analysed by immunohistochemistry staining. Primary tumours 
were immunostained with cortactin and the immunoreactive score of cortactin expression 
determined in primary tumours in BALB/c mice inoculated with CT26 WT and siRNA FliI CT26 
(n=5). Results are shown as mean score ± SEM. *p<0.05 is significantly different from control 
group (Student’s unpaired t-test). 
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 Histological analysis of cortactin expression in lung tumours 5.2.6.2
Analysis of cortactin expression in lung tumours was performed by scoring the sections 
immunostained for cortactin in tumours in BALB/c mice inoculated with CT26 WT or siRNA 
FliI CT26 cells. There was also a significantly lower level of staining for cortactin found in 
lung tumours in mice inoculated with siRNA FliI CT26 cells compared to mice inoculated with 
CT26 WT cells (p<0.05) (Figure 5.20). Lower cortactin expression suggests less invadopodia 
formation was observed in the lung tumours of BALB/c mice inoculated with siRNA FliI CT26 
cells. 
 
 
Figure 5.20: Quantification of cortactin expression in lung tumours in BALB/c mice 
inoculated with colon CT26 cancer cells expressing different levels of FliI. BALB/c mice 
were inoculated intravenously with CT26 cells expressing different levels of FliI and tumours 
present in the lungs were collected and analysed by immunohistochemistry. Tumour 
nodules were immunostained with cortactin and the immunoreactive score of cortactin 
expression determined in tumours from BALB/c mice inoculated with either CT26 WT or 
siRNA FliI CT26 (n=5). Results are shown as mean score ± SEM. *p<0.05 is significantly 
different from control group (Student’s unpaired t-test). 
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5.2.7 Expression of α-smooth muscle actin (α-SMA) in primary and lung tumours 
The expression of α-SMA was used as a myofibroblast marker, and was studied and 
evaluated in primary and lung tumours. Primary and lung tumours were immunostained 
with α-SMA to determine the effect of FliI expression on the possible activation of stromal 
fibroblasts as cancer-associated (myo) fibroblasts. The expression of α-SMA was observed in 
fibroblasts present in the primary tumours of mice inoculated with CT26 WT or siRNA FliI 
CT26 cells. No significant difference was observed in the staining between the two groups of 
mice. However, higher expression of α-SMA was observed in lung tumours in mice 
inoculated with CT26 WT compared to mice inoculated with siRNA FliI CT26 cells (Figure 
5.21). 
Representative images of immunohistochemical staining of α-SMA in primary and lung 
nodules are shown in Figure 5.21. There was greater expression of α-SMA in BALB/c mice 
injected with CT26 WT cells compared to BALB/c mice injected with siRNA FliI CT26 cells in 
lung tumours, while no significant difference was found in primary tumours.  
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Figure 5.21: α-SMA expression in primary and lung tumours in BALB/c mice. Primary 
tumour immunostaining with α-SMA in (A) mice injected with CT26 WT cells and (B) mice 
injected with siRNA FliI CT26 cells (20X magnification). Lung tumours immunostained with α-
SMA in (C, D) mice injected with CT26 WT cells and (E, F) mice injected with siRNA FliI CT26 
cells; (C) and (E) show low magnification (20X) and (D) and (F) show high magnification 
(40X). Stromal staining of myofibroblasts (indicated by arrows) in tumours is characterised 
by long spindle-shaped cells commonly aligned in groups (indicated by arrows). 
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  Histological analysis of α-SMA expression in primary tumours 5.2.7.1
Analysis of α-SMA expression in primary tumours was performed by scoring the sections 
immunostained for -SMA in tumours in BALB/c mice inoculated with CT26 WT or siRNA FliI 
CT26 cells. No statistically significant difference was found in the expression of the 
myofibroblast marker α-SMA in the primary tumours of mice inoculated with siRNA FliI CT26 
cells compared to the primary tumours from CT26 WT inoculation (Figure 5.22). 
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Figure 5.22: Quantification of α-SMA expression in primary tumours in BALB/c mice 
inoculated with colon CT26 cells expressing different levels of FliI. BALB/c mice were 
inoculated with CT26 cells expressing different levels of FliI and primary tumours were 
collected and analysed by immunohistochemistry. Primary tumours were immunostained 
for α-SMA and the immunoreactive score determined in BALB/c mice inoculated with CT26 
WT and siRNA FliI CT26 (n=5). Results are shown as mean score ± SEM (Student’s unpaired t-
test). 
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 Histological analysis of α-SMA expression in lung tumours 5.2.7.2
Analysis of α-SMA expression in lung tumours was performed by scoring sections 
immunostained for -SMA from BALB/c mice inoculated with CT26 WT or siRNA FliI CT26 
cells. The expression of α-SMA in lung tumours was higher in mice inoculated with CT26 WT 
cells as compared to mice inoculated with siRNA FliI CT26 cells (p<0.05) (Figure 5.23).  
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Figure 5.23: Quantification of α-SMA expression in lung tumours in BALB/c mice 
inoculated with colon cancer CT26 cells expressing different levels of FliI. BALB/c mice 
were inoculated intravenously with CT26 cells expressing different levels of FliI and tumours 
present in the lungs were collected and analysed by immunohistochemistry. Tumour 
nodules were immunostained with α-SMA and the immunoreactive score determined in 
lung tumours from mice inoculated with CT26 WT or siRNA FliI CT26 (n=5). Results are 
shown as mean score ± SEM. *p<0.05 shows significant difference from control group 
(Student’s unpaired t-test). 
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5.3 Discussion 
Dynamic interaction between cancer cells and their microenvironment is now thought to be 
extremely important in regulating cancer development (Tlsty & Coussens, 2006) and the 
tumour stroma has been found to be critically altered during neoplastic changes (Ronnov-
Jessen, Petersen, & Bissell, 1996). During cancer development, stromal fibroblast cells 
acquire expression of α-sma, vimentin and in some cases smooth muscle myosin, tenascin 
and desmin, and the expression of altered ECM molecules in the stroma has also been found 
to be capable of directly or indirectly regulating cell proliferation, inflammation, 
angiogenesis and dissemination of cells to distant sites (Van den Hooff, 1988). FliI is believed 
to have a major role in rearrangement of the actin cytoskeleton, which is crucial in cell 
motility, adhesion and invasion, and may also serve as a linkage protein between actin 
filaments and various intracellular signalling proteins (Davy et al 2000).  
Major components and functions in the local microenvironment that functionally regulate 
cancer development include inflammatory cells, the activation of fibroblasts as 
myofibroblasts, tumour angiogenesis, and the secretion and reorganisation of the ECM. In 
many cancers, activation of fibroblasts as a CAF phenotype has been found to be crucial, as 
these cells are primarily involved in reorganisation and deposition of the ECM, as well as 
altering its composition, and also importantly in regulating cell proliferation and survival by 
releasing paracrine growth factors (Tlsty & Coussens, 2006). The activation of fibroblasts as 
the myofibroblast phenotype in the tumour stroma has also been linked to poor prognosis 
(Tsujino et al., 2007).  
Although the role of FliI may be mainly intracellular, it has also been reported that FliI was 
secreted from cells and was found to be present in the serum, especially on tissue injury or 
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wounding (Cowin et al., 2007). Since FliI may play both intracellular and secreted roles, 
understanding the regulation and role of FliI in cancer cells, in addition to its potential role 
in stromal cells, is important if FliI is to be a target for therapeutic use. Using mice with 
different genetic backgrounds, in particular FliI heterozygous knockout (FliI+/−) mice, has 
enabled us to examine the effect of reducing FliI expression in the host (stromal) cells and 
the possible importance of their interaction with WT cancer cells in influencing tumour 
growth. By using siRNA FliI knockdown in tumour cells, we aimed to be able to see the effect 
of reducing FliI expression in the tumour cells themselves, and their interaction with a WT 
stroma. However, the limitation of this technique is that the siRNA knockdown of FliI is likely 
to be transient. Therefore, these experiments at best may tell us something about the 
effects of FliI expression during early events in tumour growth. Future experiments should 
look at the possibility of knocking down FliI in vivo, potentially by direct injection of FliI 
siRNA or antisense directly into primary tumours.  
In this study, the inhibition of FliI promisingly showed a reduction in tumour formation in 
both primary and lung cancer models. Reduction of the expression level of FliI in FliI 
heterozygous mice (FliI+/−) significantly reduced tumour nodules in the lung. Previously, 
preliminary studies in our laboratory showed that colon cancer cell inoculation resulted in 
increased tumour size and increased seeding of lung nodules in mice that had higher 
expression levels of FliI (FliI Tg+ mice), while mice with reduced FliI expression showed 
smaller primary tumours and fewer tumour nodules in the lung (Darby et al., unpublished 
data), which we have now confirmed in this study. This suggests that host FliI expression 
levels can regulate tumour growth in this model, possibly through an effect on the 
behaviour of tumour stromal cells leading to increased tumour development.  
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Interestingly, we also found that knockdown of FliI in tumour cells using siRNA FliI CT26 
resulted in smaller primary tumours and fewer nodules in the lung, suggesting FliI 
expression in cancer cells may also influence tumour growth in this model. Smaller tumour 
size and reduced tumour formation were observed at days 10 and 14 after inoculation; 
however, tumours started to increase in size after day 14 and there was no longer a 
significant difference compared to WT cells, most likely because the knockdown of FliI using 
siRNA is a transient process and, based on our finding (not shown), the effectiveness of the 
siRNA FliI CT26 cells decreased in vitro after two weeks and was likely more transient in vivo. 
In addition, similar findings were demonstrated in an in vitro study where decreased cell 
invasion was observed with siRNA FliI CT26 cells, as described in the previous chapter.  
FliI, from its pro-scarring activity discovered in skin wounds, may have the capability to 
cause remodelling of the ECM in a manner that favours tumour growth. Flil has also been 
found to regulate cytoskeletal remodelling where FliI co-localises with actin-associated 
molecules and other molecules to regulate the actin cytoskeleton and other molecules 
involved in the regulation of cell motility and movement, such as GTP binding proteins, Ras 
and RhoA. In addition, an association between FliI and membrane ruffles and actin arcs 
shows the potential importance of FliI in regulating cell migration, proliferation and 
remodelling of cytoskeletal proteins (Cowin et al., 2007; Davy et al., 2001). Previous studies 
have shown that the expression levels of actin-remodelling proteins may play a role in 
regulating tumour progression, and inhibition of those proteins may reduce tumour growth 
and metastasis (Kwang Won Jeong, 2014; Anske Van den Abbeele et al., 2007). 
These findings suggest that FliI expression can promote tumour formation and 
establishment of lung nodules in a colon cancer model, possibly via a role in mediating cell 
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adhesion and increasing cellular invasion, based on our in vitro findings. Furthermore, FliI 
also may have effects on the tumour microenvironment that favour tumour growth, which 
is supported by the observation of alterations in tumour effector function markers, such as 
expression of the myofibroblast marker α-SMA and the invadopodia marker cortactin. 
Correlation with increased cancer cell proliferation using PCNA was also observed. A recent 
study by collaborators also showed similar findings where FliI was shown to exhibit tumour-
promoting activity in an SCC model in mouse skin, and it was concluded that this was 
potentially due to its effects on cell adhesion and migration associated with modification of 
the tumour microenvironment (Z Kopecki et al., 2015). In the same study, FliI was confirmed 
to associate with cortaction in the MET-1 squamous carcinoma cell line at the invading edge 
of cancer cells when they were cultured on a Matrigel basement membrane. In this present 
study, elevated level of cortactin with the expression of FliI suggest that FliI is one of the 
proteins that could possibly mediate invadopodia by association with cortactin to form a 
complex and based on its ability to affect reorganisation of the actin cytoskeleton (Z Kopecki 
et al., 2015; Mohammad et al., 2012). 
5.3.1 Effect of FliI expression on proliferation and tumour effector markers 
It has been shown that the activation of cellular and/or extracellular elements of the local 
host microenvironment can modify the invasive and proliferative behaviour of tumour cells 
(Liotta & Kohn, 2001). In this study, we have shown data that suggest that the inhibition of 
FliI expression in either the host or the tumour cells may affect the expression of markers of 
proliferation and invasion.  
FliI knockdown resulted in a decrease in the expression of the invadopodia marker cortactin 
and a reduced proliferative index at both primary and lung sites. The inhibition of FliI within 
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either host or cancer cells could potentially reduce interactions between cell-to-cell 
junctions and also with the surrounding ECM; these interactions have been found to be 
crucial for initiation of remodelling of the ECM and are also an essential step for local 
invasion and promotion of tumourigenesis (Hanahan & Weinberg, 2011). In addition, it has 
been described previously that host–tumour interdependence effects show an invasion 
process that is mainly regulated by host cells (Coussens & Werb, 2002). However, in this 
study we show that modifying the expression of FliI in invading cancer cells may also affect 
tumour growth, progression and spread.  
Further experiments are needed to understand the relative importance of stromal versus 
tumour cell expression of FliI. These could involve either direct inhibition of FliI expression in 
tumour cells, possibly by injection of antisense or siRNA at the tumour site in vivo, or the 
production of colon tumours in mice overexpressing FliI or FliI-deficient. This would require 
chemical induction of cancer in mice of the FliI transgenic and heterozygous (FliI+/−) 
background, for example using azoxymethane and SDS. Lastly, it would be important to 
know the effects of FliI expression on a truly metastatic model of cancer.  
Changes in stromal cell behaviour have been shown to promote EMT, which can alter both 
cell–cell and cell–matrix signalling. In tumours, there is a significant contribution of 
epithelial cells to the pool of cancer-associated stromal myofibroblasts via EMT (I. A. Darby 
et al., 2016). This may act to allow tumour cells to migrate across tissue boundaries (Liotta & 
Kohn, 2001) by altering matrix-degrading enzyme expression and activation. Furthermore, 
changes in the stiffness of the ECM can also influence tumour growth, as increased ECM 
stiffness has been shown to correlate with highly invasive tumours (I. A. Darby et al., 2016; 
Wei et al., 2015). Increased FliI expression has been previously reported to result in 
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excessive scar formation, including increased collagen I deposition (Z. Kopecki & Cowin, 
2008), suggesting the ability of FliI to cause remodelling and increased deposition of the 
ECM and thus influence the stiffness of the ECM.  
Additionally, MMPs produced by stromal fibroblasts and endothelial cells can lead to 
subsequent matrix degradation, thus mediating tumour-cell invasion via invadopodia 
(Zigrino et al., 2009). FliI was recently found to co-localise with the invadopodia marker 
cortactin, showing a possible mechanism for FliI to interact with or influence invadopodia 
formation. In addition, the polymerisation of actin filaments and their associated actin-
binding proteins in actin remodelling was found to be one of the important elements in the 
formation of invadopodia, which has been shown to mediate invasion and metastasis in 
cancer cells (Yamaguchi & Condeelis, 2007). 
5.4 Conclusion 
In conclusion, we have demonstrated that FliI expression, particularly in the host animal 
stroma, may regulate tumour growth and the establishment of lung tumours in a murine 
colon cancer model. Reducing the expression of FliI by using heterozygous knockout mice 
resulted in a reduced number of nodules in the lung. Promisingly, transient inhibition of FliI 
expression in cancer cells themselves also seemed to reduce primary tumour formation and 
lung seeding, possibly by altering the invasive capacity of tumour cells. Further experiments 
are needed to show whether this can be confirmed, using direct local inhibition of FliI 
expression. FliI inhibition may thus be associated with an improved tumour 
microenvironment that is unfavourable to cancer cell progression and metastasis when FliI 
is decreased in the host tissue or tumour microenvironment. We have also shown that FliI 
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expression levels in tumour cells may regulate cell invasion and metastasis by increasing 
invadopodia activity and thus remodelling of the ECM.  
It remains unclear exactly how Flil influences tumour growth and spread and, furthermore, 
the relative importance of the Flil protein intracellularly and in its secreted form. The 
importance of Flil in the tumour stroma has been suggested by tumour models in animals 
expressing higher or lower levels of Flil. However, the manipulation of Flil in the tumour 
cells themselves would be an important step in examining the importance of its expression 
in the tumour cells themselves. Further experiments are required to address these issues in 
the future. 
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Chapter 6 Therapeutic Effects of 
Flightless I Monoclonal Antibody in 
Colon Cancer Models 
6.1 Introduction 
Recombinant proteins and humanised monoclonal antibodies have become important new 
tools in therapies including treatment of cancers; for example, the application of 
recombinant interferons (IFNs) for multiple sclerosis, hepatitis and cancer treatment, and 
established monoclonal antibody therapies that target growth factors or growth factor 
receptors, including VEGF (known as bevacizumab), which is currently used as a first-line 
therapy for metastatic colorectal cancer (Ferrara, Hillan, Gerber, & Novotny, 2004; 
Schellekens, 2002).  
It is important to acknowledge the crucial interplay between cancer cells and their local 
microenvironment, which has been shown to be actively involved in cancer progression. The 
changes occurring within the surrounding tissue have an important influence on the fate of 
cancer cells, either favouring or inhibiting tumour growth, and the tumour 
microenvironment is now considered to be one of the important cancer hallmarks 
correlating with prognosis and the effectiveness of cancer therapy (Hanahan & Coussens, 
2012). Thus therapies for targeting the tumour microenvironment are now definitely a 
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major target for discovering new treatments, but are potentially limited by the complexity 
and variety of the stromal cells (Sounni & Noel, 2013). 
FliI has been reported to be a negative regulator of wound repair, and treatment with Flil-
neutralising monoclonal antibody (FnAb) by local injection into the wound site was found to 
be effective in porcine and diabetic mouse wound-healing models. These studies showed FliI 
inhibition to have the potential to enhance wound repair and reduce scar formation 
(Jackson et al., 2012; Ruzehaji et al., 2014). In addition, topical application of FnAb in a 
cream onto established blisters showed similar results, with a reduction in the severity of 
skin blistering observed (Zlatko Kopecki et al., 2013). Intradermal injection of FnAb during 
SCC initiation and progression in a chemically induced model of SCC significantly reduced 
tumour size, and treatment using FnAb in vitro was shown to alter cell proliferation and 
migration and to block cellular invasion into basement membrane proteins (Z Kopecki et al., 
2015). Thus FliI seems to play a potential role as a promoter of both scarring and tumour 
growth, at least in an SCC model. 
This chapter discusses the effect of administration of a monoclonal antibody (FnAb) that 
blocks FliI function on primary and lung tumour growth, and the outcome on tumour 
progression in primary and secondary lung models of colon cancer. 
6.2 Results 
6.2.1 Therapeutic effects of Flil-neutralising monoclonal antibody on lung tumour 
growth 
To ascertain the effect of FnAb on lung tumour growth, BALB/c mice were injected 
intravenously with CT26 WT cells. These mice showed no difference in bodyweight with or 
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without treatment with FnAb (Figure 6.1). Experimental mice in each group maintained their 
bodyweight within 10% of their original starting weight. The number of cancer nodules 
observed in the lungs was similar in mice treated with antibodies (either non-specific IgG or 
FnAb) throughout the 14 days of the experimental period. A slightly reduced number of 
macroscopic and microscopic metastatic nodules in the lungs were observed in mice treated 
with 50 µg FnAb compared to the control group treated with non-specific IgG, as shown in 
Figure 6.2, although this was not statistically significant.  
Although the number of lung nodules was not different in mice injected with either FnAb or 
non-specific IgG antibody, when the metastatic nodules were measured for size the area of 
nodules in the lung showed a significant decrease in size in FnAb-treated mice compared to 
mice receiving the non-specific IgG control (p<0.0001) (Figure 6.3). 
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Figure 6.1: Monitoring of bodyweight in BALB/c mice after treatment with FnAb post-
induction with colon cancer cells. BALB/c mice were injected intravenously with 2x105 CT26 
WT cells and at days 4 and 8 post tumour induction, mice were treated with control IgG 
(blue line with circle) and FnAb (pink line with square) (n=10). Bodyweight of mice was 
monitored on a daily basis for the duration of the experiment. Bodyweight is shown as 
mean weight (g) ± SEM. 
 
 
 
 
 
 
Figure 6.2: Number of macroscopic and microscopic lung nodules in BALB/c mice after 
treatment with FnAb post tumour induction. BALB/c mice were injected intravenously with 
CT26 WT cells and at days 4 and 8 post tumour induction, mice were treated with control 
IgG and FnAb, showing the number of (A) macroscopic and (B) microscopic tumour nodules 
present in the lungs of mice treated with FnAb as compared to control group (treated with 
non-specific IgG) (n=10). Results are shown as mean ± SEM. p<0.05 is significantly different 
from control group (Student’s unpaired t-test). 
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Figure 6.3: Quantification of tumour area of microscopic tumour nodules in BALB/c mice 
after treatment with FnAb. BALB/c mice were injected intravenously with CT26 WT cells 
and at days 4 and 8 post tumour induction, mice were treated with control IgG or FnAb 
(n=5). The size of tumour nodules in the lung was quantified using Image J analysis. Results 
are shown as mean ± SEM. ****p<0.0001 is significantly different from control group 
(Student’s unpaired t-test). 
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Representative images of H&E-stained microscopic tumour nodules in mice treated with 
FnAb and the control group are shown in Figure 6.4. FnAb histological images show the 
reduced size of lung nodules in mice injected with FnAb compared to the control group. 
 
 
 
 
 
 
 
 
 
 
Figure 6.4: Histological analysis of lung tumours in BALB/c mice after treatment with FnAb 
post-induction with intravenous injection of CT26 cells. Representative histological images 
of lung sections stained with H&E showing microscopic lung nodules of (A, B) control groups 
(BALB/c mice treated with non-specific IgG) and (C, D) BALB/c mice treated with FnAb (4X 
magnification). 
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6.2.2 Effects of Flil-neutralising monoclonal antibody on expression of PCNA in lung 
tumour model 
Immunohistochemical staining of the proliferation marker PCNA showed greater areas of 
expression of PCNA in the tumours in the lungs of the control mice (treated with non-
specific IgG) compared to smaller areas showing expression in the tumours of mice treated 
with FnAb, as shown in representative images (Figure 6.5). Representative images of the 
immunohistochemical staining of nodules for PCNA are shown in Figure 6.5. Nodules in both 
control mice and FnAb-treated mice showed high levels of PCNA expression (positive nuclei) 
in the tumour cells.  
 
 
  
 
 
 
 
Figure 6.5: PCNA expression in lung tumours of BALB/c mice after treatment with FnAb 
post tumour induction. BALB/c mice were injected intravenously with CT26 WT cells and at 
days 4 and 8 post tumour induction, mice were treated with control IgG and FnAb and 
tumours present in the lungs were collected and analysed after 14 days. Tumour nodules 
immunostained for PCNA in (A) BALB/c mice treated with non-specific IgG (control) and (B) 
BALB/c mice treated with FnAb (20X magnification). 
A B 
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6.2.3 Proliferation index for lung tumours 
Analysis of PCNA expression in the lung tumours was performed by scoring the lung sections 
immunostained for PCNA in the control BALB/c mice treated with non-specific IgG and the 
mice treated with FnAb (Figure 6.6). No difference was found in staining for the cell 
proliferation marker PCNA in tumours when comparing the control group treated with non-
specific IgG and the mice treated with FnAb. Staining showed high levels of PCNA 
proliferation in both groups. 
 
 
 
  
 
 
Figure 6.6: Analysis of PCNA expression in lung tumours in BALB/c mice after treatment 
with FnAb post tumour induction. BALB/c mice were injected intravenously with CT26 WT 
cells and at days 4 and 8 post tumour induction, mice were treated with control IgG and 
FnAb and metastatic tumours present in the lungs were collected and analysed after 14 
days’ duration of the experiment. Sections were immunostained for PCNA and the number 
of PCNA positive cells counted and represented as the proliferative index in mice treated 
with FnAb and the control group (mice treated with non-specific IgG) (n=6). Results are 
shown as mean proliferative index ± SEM. p<0.05 is significantly different from control 
group (Student’s unpaired t-test). 
C o n tr o l ( Ig G ) T r e a te d  w ith  F n AB
0
5
1 0
1 5
T re a tm e n t g ro u p s
P
r
o
li
fe
r
a
ti
v
e
 I
n
d
e
x
199 
 
6.2.4 Effects of Flil-neutralising monoclonal antibody on the expression of α-SMA in lung 
tumours 
The expresssion of the myofibroblast marker α-SMA was determined using 
immunohistochemistry in lung tumour sections from the experimental mice. BALB/c mice 
injected with non-specific IgG showed higher expression of α-SMA in tumour nodules 
compared to BALB/c mice treated with FnAb (Figure 6.7).  
Representative images of the immunohistochemical staining of lung sections showing α-
SMA expression are shown in Figure 6.7. 
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Figure 6.7: α-SMA expression in lung tumours of BALB/c mice after treatment with FnAb 
post tumour induction. BALB/c mice were injected intravenously with CT26 WT cells and at 
days 4 and 8 post tumour induction, mice were treated with control IgG and FnAb and 
tumours present in the lungs were collected and analysed after 14 days’ duration of the 
experiment. Tumour nodules immunostained with α-SMA in (A, B) mice treated with non-
specific IgG (control) and (C, D) mice treated with FnAb. (A) and (C) show histological images 
at low magnification (20X) and (B, D) show histological images at high magnification (40X).  
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6.2.5 Histological analysis of α-SMA expression in lung tumours 
Analysis of α-SMA expression in lung tumours was performed by scoring the sections 
immunostained for α-SMA in control BALB/c mice treated with non-specific IgG and mice 
treated with FnAb (Figure 6.8). Tumour nodules were immunostained and scored using 
immunoreactive scores for quantitative analysis. The expression of the myofibroblast 
marker α-SMA was significantly lower (p<0.05) in lung tumours in BALB/c mice treated with 
FnAb at days 4 and 8 post-inoculation as compared to the control group administered non-
specific IgG.  
 
 
  
 
 
 
Figure 6.8: Quantitative analysis of α-SMA expression in lung tumours in BALB/c mice 
after treatment with FnAb post tumour induction. BALB/c mice were injected 
intravenously with CT26 WT cells and at days 4 and 8 post tumour induction, mice were 
treated with control IgG and FnAb and tumours present in the lungs were collected and 
analysed after 14 days. The immunoreactive score for α-SMA expression was determined in 
tumours in mice treated with FnAb and the control group (mice treated with non-specific 
IgG) (n=6). Results are shown as mean immunoreactive score ± SEM. p<0.05 is significantly 
different from control group (Student’s unpaired t-test). 
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6.2.6 Effects of Flil-neutralising monoclonal antibody on expression of cortactin in lung 
tumours 
The expression of the invadopodia marker cortactin was evaluated in the lung tumours in 
mice, comparing a control group (BALB/c mice treated with non-specific IgG) and a 
treatment group (BALB/c mice treated with FnAb) (Figure 6.9).  
Representative images of the immunohistochemical staining of lung nodules showing 
cortactin expression are shown in Figure 6.8. Immunostaining showed slightly lower 
cortactin staining in the nodules of mice treated with FnAb compared to the control mice; 
however, the immnohistochemical scoring showed no statistically significant difference 
(Figure 6.10). 
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Figure 6.9: Cortactin expression in lung tumours of BALB/c mice after treatment with 
FnAb. Lung tumour nodules immunostained with anti-cortactin antibody in (A) mice treated 
with non-specific IgG (control) and (B) mice treated with FnAb. (A) and (C) show histological 
images at low magnification (10X) and (B) and (D) show histological images at higher 
magnification (20X).  
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6.2.7 Histological analysis of cortactin expression in lung tumours 
Analysis of cortactin expression in metastatic tumours was performed by scoring the 
immunohistological lung sections immunostained with anti-cortactin in control BALB/c mice 
administered non-specific IgG and mice treated with FnAb. Tumour nodules were 
immunostained with anti-cortactin and scored using immunoreactive scores for quantitative 
analysis. There was slightly lower (p>0.05) staining intensity of cortactin in the lungs of mice 
treated with FnAb; however, no significant difference was found in the expression levels of 
cortactin between the treatment groups (Figure 6.10). 
 
 
 
 
  
 
Figure 6.10: Quantitative analysis of cortactin expression in lung tumours in BALB/c mice 
after treatment with FnAb post tumour induction. BALB/c mice were injected 
intravenously with CT26 WT cells and at days 4 and 8 post tumour induction, mice were 
treated with control IgG and FnAb and the lungs were collected and analysed after 14 days. 
Tumour nodules were immunostained with cortactin and the immunoreactive score of 
cortactin expression determined in tumours in mice treated with FnAb and the control 
group (mice treated with non-specific IgG) (n=6). Results are shown as mean 
immunoreactive score ± SEM. p<0.05 is significantly different from control group (Student’s 
unpaired t-test).  
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6.2.8 Inhibition of FliI reduced tumour sphere formation in tumour spheroid invasion 
assay 
Tumour spheroid invasion assays were performed and established using low-adherent cell 
culture plates to generate spheroid formations in CT26 cells. Cells expressing different levels 
of FliI with and without treatment with FnAb were used to generate tumour spheroids. The 
spheroids were photographed and their diameter was measured at days 2, 5 and 10. The 
size of the spheroids produced by siRNA FliI-treated CT26 cells was significantly smaller 
compared to the spheroids of CT26 WT cells and CT26 WT cells treated with FnAb at days 2 
and 5 (Figure 6.11). At day 2, there were smaller diameters of spheroids in both CT26 WT 
and siRNA FliI CT26 cells treated with FnAb, respectively; however, this was not statistically 
significant. Promisingly, treatment of FnAb on CT26 WT cells significantly reduced the 
spheroid size at day 5; however, adding FnAb to siRNA FliI-treated CT26 cells did not result 
in an additional reduction in diameter. At day 10, all tumour spheroids were observed to 
have similar diameters and were starting to dissociate, with prominent necrotic cells at the 
centre.  
Representative images of tumour spheroids for CT26 WT and siRNA FliI CT26 cells treated 
with either non-specific IgG or FnAb at days 2, 5 and 10 are shown in Figure 6.12. Smaller 
spheroids were formed using siRNA FliI-treated CT26 cells compared to CT26 WT cells, and 
both cells also showed a reduction in spheroid diameter after treatment with FnAb at days 2 
and 5. 
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Figure 6.11: Analysis of diameter of spheroids in CT26 cells expressing different levels of 
FliI, with and without treatment with FnAb. Tumour spheroids of CT26 WT and siRNA FliI 
CT26 cells were grown in growth media containing 50 µg/ml of non-specific IgG or 50 µg/ml 
of FnAb for 10 days and the diameter of the spheroids were measured at days 2, 5 and 10. 
Tumour spheroid growth assays show the diameters of the spheroids at (A) day 2, (B) day 5 
and (C) day 10 of CT26 WT cells and siRNA FliI CT26 cells treated with either non-specific IgG 
(control) or FnAb. Results are shown as mean ± SEM (n=3).****p<0.0001, ***p<0.001 and 
**p< 0.01 are significantly different to control cells CT26 WT (Tukey’s multiple comparison 
test). 
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Figure 6.12: Tumour spheroid formation assays in CT26 cells expressing different levels of 
FliI and after treatment with FnAb. Inhibition of FliI using siRNA reduced the size of tumour 
spheroids in CT26 cells. Addition of FnAb had no additional effect on spheroid size. Tumour 
spheroids of CT26 WT and siRNA FliI CT26 were grown in growth medium containing 50 
µg/ml of non-specific IgG or 50 µg/ml of FnAb for 10 days in cells and were photographed at 
days 2, 5 and 10. Representative sphere formation images show spheroids at days 2, 5 and 
10 of CT26 WT and siRNA FliI CT26 cells. Both cell types were treated with either non-
specific IgG as the control or FnAb. 
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 Spheroid live/dead staining 6.2.8.1
Live/dead staining of the tumour spheroids was performed using calcein AM (live cells) and 
propidium iodide (dead cells). Stacked 3D images of the spheroids were visualised using 
confocal microscopy at day 5 (Figure 6.13) and day 10 (Figure 6.15). Representative 
fluorescence images of the spheroids at day 5 (Figure 6.14) and day 10 (Figure 6.16) are also 
shown. As stated above, the inhibition of FliI using siRNA FliI CT26 cells reduced the size of 
tumour spheroids at day 5, and blocking FliI using FnAb also reduced the size of tumour 
spheroids in CT26 WT cells at day 5. Tumour depth of spheroids in CT26 WT control cells 
treated with non-specific IgG was approximately 200 µm (Figure 6.13(A)) as compared to 
the CT26 WT cells treated with FnAb and siRNA FliI CT26, which was approximately 60 µm. 
At day 10, there was no difference in the size of spheroids, possibly as most cells had died 
and the spheroids had developed necrotic centres, as shown in 3D and 2D images at day 10 
(Figures 6.15 and 6.16).  
The number of live and dead cells in the spheroids was quantified using NIS Element 
software (Nikon) at days 5 and 10 (Figure 6.17). At day 5, there was a small decrease in the 
number of live and dead cells in siRNA FliI CT26 cells treated with either non-specific IgG or 
FnAb as compared to CT26 WT cells (both control and treated with FnAb); however, these 
changes were not statistically significant. The number of live cells also decreased at day 10 
compared to day 5, likely indicating more cell death. At day 10, a significant reduction of live 
cells in siRNA FliI CT26 cells treated with FnAb as compared to the number of live cells in 
CT26 WT cells treated with FnAb (Figure 6.17 (B)) was observed.  
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Figure 6.13: 3D stacked confocal images of tumour spheroids in CT26 cells expressing 
different levels of FliI and after treatment with FnAb. Representative live/dead staining of 
spheroids shown as stacked 3D images from confocal microscopy at day 5 of (A) CT26 WT 
and (B) siRNA FliI CT26 cells treated with non-specific IgG as a control, and (C) CT26 WT 
treated with FnAb and (D) siRNA FliI CT26 cell treated with FnAb. Live cells were stained 
with calcein AM (green) and dead cells were stained with propidium iodide (red). Tumour 
spheroids were viewed by an A1 confocal microscope and analysed using NIS Elements 
software (Nikon) at 10X magnification. 
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Figure 6.14: 2D confocal images of tumour spheroids in CT26 cells expressing different 
levels of FliI and after treatment with FnAb. Representative fluorescent 2D images of the 
spheroids at day 5. Live/dead staining of spheroids from confocal microscopy of (A) CT26 
WT and (B) siRNA FliI CT26 cells treated with non-specific IgG as a control, and (C) CT26 WT 
cells treated with FnAb and (D) siRNA FliI CT26 cells treated with FnAb. Calcein AM (green) 
stained live cells and dead cells were stained with propidium iodide (red). Spheroids were 
viewed by an A1 confocal microscope and analysed using NIS Elements software (Nikon) at 
10X magnification. 
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Figure 6.15: 3D stacked confocal images of tumour spheroids in CT26 cells expressing 
different levels of FliI and after treatment with FnAb. Representative live/dead staining of 
spheroids shown by stacking 3D images from confocal microscopy at day 10 of (A) CT26 WT 
and (B) siRNA FliI CT26 cells treated with non-specific IgG as a control, and (C) CT26 WT cells 
treated with FnAb and (D) siRNA FliI CT26 cells treated with FnAb. Calcein AM (green) 
stained live cells and dead cells were stained with propidium iodide (red). Spheroids were 
viewed by an A1 confocal microscope and analysed using NIS Elements software (Nikon) at 
10X magnification.  
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Figure 6.16: 2D confocal images of tumour spheroids in CT26 cells expressing different 
levels of FliI and after treatment with FnAb. Representative fluorescent 2D images of the 
spheroids at day 10. Live/dead staining of spheroids from confocal microscopy of (A) CT26 
WT and (B) siRNA FliI CT26 cells treated with non-specific IgG as a control, and (C) CT26 WT 
cells treated with FnAb and (D) siRNA FliI CT26 cells treated with FnAb. Calcein AM (green) 
shows live cells and dead cells were stained with propidium iodide (red). Spheroids were 
viewed by an A1 confocal microscope and analysed using NIS Elements software (Nikon) at 
10X magnification. 
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Figure 6.17: Quantification of live and dead cells stained with calcein AM (live cells) and 
propidium iodide (dead cells) in CT26 cells expressing different levels of FliI and after 
treatment with FnAb. Number of live and dead cells in tumour spheroids at (A) day 5 and 
(B) day 10 of CT26 WT cells and siRNA FliI CT26 cells treated with either non-specific IgG 
(control) or FnAb. Number of fluorescent cells was analysed using NIS Elements software 
(Nikon). Results are shown as mean ± SEM (n=3). *p<0.05 significantly different to control 
cells CT26 WT (Tukey’s multiple comparison test).  
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6.3 Discussion 
Though there have been improvements in cancer therapies in recent years, there is still a 
great need to discover new and more effective therapies to treat many cancers. A novel 
approach is to target both cancer cells and the tumour microenvironment or stroma, since 
the tumour stroma is now known to provide important properties and functions that are 
crucial for tumour growth and metastatic dissemination (Sounni & Noel, 2013). It is known 
that a variety of stromal cells, including infiltrating immune cells, CAFs, angiogenic vascular 
cells and lymphatic cells, as well as the non-cellular component of the metastatic niche, that 
is, the ECM, contribute to cancer progression, not only at the primary sites, but also at the 
premetastatic and metastatic niche in distant organs (Hanahan & Weinberg, 2011; Lu, 
Weaver, & Werb, 2012).  
Promising approaches to targeting the cellular microenvironment in cancer have been 
established in different types of human cancer, such as the use of anti-angiogenic and anti-
inflammatory therapies (Ebos & Kerbel, 2011). Previously, there were few therapeutic 
approaches that have been designed and successfully undergone clinical trials to target 
different types of stromal cells within the tumour microenvironment (Joyce, 2005). 
Currently, various therapeutic monoclonal antibodies have become established ways of 
targeting angiogenesis. These include bevacizumab (anti-VEGF), volociximab (anti-integrin 
α-5β1), antibodies targeting growth and differentiation signalling such as cetuximab (anti-
EFGR) and mapatumumab (anti-TRAILR1), and antibodies targeting stromal and extracellular 
matrix such as sibrotuzumab (anti-FAP) and 816C (anti-Tenascin).  
FliI has been shown to regulate cell migration and proliferation, and to have effects on the 
remodelling of the ECM (Cowin et al., 2007). It has also been shown to mediate cell 
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adhesion (Zlatko Kopecki et al., 2009) and recently has been shown to increase tumour cell 
invasion in an SCC model in mice (Z Kopecki et al., 2015). Since cell migration, proliferation 
and invasion and also remodelling of the ECM have been shown to be very crucial in cancer 
progression, this suggests FliI could be a possible target for cancer therapy, since it has been 
shown to play a role in all of the processes mentioned. However, to date very little is known 
about its possible role in cancer progression or metastasis. 
FnAb has been previously found to neutralise the secreted form of FliI, and FliI was observed 
to be secreted in response to wounding, suggesting a potential extracellular role for this 
actin-remodelling protein (Cowin et al., 2007). FnAb cream applied on blistered skin was 
shown to be absorbed into the epidermis and papillary dermis, could be detected on the 
skin for up to three days and was found to effectively reduce endogenous Flil protein levels 
(Jackson et al., 2012). However, FnAb was not detected in serum or other organs post 
topical application of FnAb, suggesting that the application of FnAb cream to the skin 
remains localised to the skin (Zlatko Kopecki et al., 2013). Intradermal injection of FnAb in 
porcine models of wound healing has been shown to accelerate wound re-epithelialisation 
and reduce scar formation (Jackson et al., 2012). The systemic effects of FnAb were also 
evaluated in relation to changes in immunological reaction, specifically on the cellular 
infiltration of neutrophils and macrophages; however, no difference was found (Zlatko 
Kopecki et al., 2013). 
In the abovementioned studies, mouse monoclonal antibodies were generated against the 
leucine-rich repeat (LRR) domain of FliI protein, which has been found to mediate protein–
protein interactions, and then the antibody was used in vivo at a concentration of 50 µg/ml 
in mouse models (Jackson et al., 2012). This optimisation study demonstrated that at the 
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concentration of 50 µg/ml, FnAb was optimum to improved porcine incisional wound repair 
(Jackson et al., 2012). Administration of antibodies against these LRR domains was also 
found to improve wound repair in a murine wound-healing model (Cowin et al., 2007). In 
addition, another study showed that intradermal injection of FnAb significantly improved 
healing of burn wounds in WT mice in a burn-injury repair study (D. H. Adams et al., 2009). 
Since there are similarities at the cellular level between wound healing and tumour 
progression, particularly in the activation of the stroma, we have investigated the 
therapeutic effects of the FliI-neutralising antibody (FnAb) in a murine colon tumour model.  
In the present study, a slight reduction in the number of tumour nodules in the lung was 
observed in mice treated with FnAb; however, this did not reach significance as compared 
to the control group treated with non-specific IgG. Interestingly, we did observe a smaller 
size in the tumours present in the lungs of mice treated with FnAb compared to the control 
group treated with non-specific IgG, based on the tumour area. Measurement of this nodule 
size using image analysis confirmed that FnAb appears to reduce the size of tumour nodules 
in the lung, compared to treatment with non-specific IgG.  
In our experiments, FnAb was administered at days 4 and 8 post-inoculation and this could 
be a potential reason why treatment did not show a significant reduction in the number of 
nodules in the lungs; however, promisingly it may have inhibited tumour growth and 
progression of the nodules, resulting in a reduction of the tumour size. Further experiments 
are needed to see whether increased dosage, pre-treatment prior to inoculation or a 
different mode of delivery might result in a greater effect. In the present model, we also 
demonstrated that activated CAFs decreased with a reduction in the expression of the 
myofibroblast or CAF marker α-SMA in mice treated with FnAb. In addition, there appeared 
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to be slight reductions in the expression of PCNA and cortactin, although neither of these 
reached significance. This suggests that treatment with FnAb may inhibit tumour growth, 
possibly by inhibition of the activation of stromal cells, which can lead to subsequent cell 
invasion and angiogenesis. 
Our data suggesting a decrease in fibroblast activation is in alignment with previous studies 
on fibroblasts in wound healing. It has been shown previously that the expression of α-SMA 
decreased in FliI +/− heterozygous knockout mice after injury, suggesting a decrease in 
contractile myofibroblasts, which then resulted in less scar formation in a murine model of 
burn-injury repair (D. H. Adams et al., 2009). Increased α-SMA correlates with activated 
myofibrolasts or CAFs in the stroma, which has commonly been linked to poor prognosis in 
cancer metastasis (Castelino & Varga, 2014; Pickup et al., 2014). Future experiments that 
would aid in elucidating the role of FliI could include daily treatment or more frequent 
administration of FnAb. Also, it would be worthwhile to repeat this experiment using a 
higher dose of FnAb than was used in our study.  
A tumour spheroid assay was used as a 3D model to mimic tumour growth and determine 
the effects of FliI expression on tumour cell aggregation and growth. Interestingly, in vitro 
tumour spheroid assays showed that reduced FliI expression using FnAb resulted in a 
decrease in size of the tumour spheroids at day 5 in CT26 WT cells. In addition, the inhibition 
of FliI expression intracellularly using siRNA FliI CT26 cells (knockdown of FliI in CT26 cells) 
greatly decreased the size of tumour spheroids at days 2 and 5 as compared to control CT26 
WT cells. A combination of FnAb and siRNA treatment had no additional effect on either 
day. However, there was no difference observed in any treatment by day 10, possibly due to 
necrosis and the development of necrotic centres in the spheroids. This finding suggests 
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that the administration of FnAb and the inhibition of intracellular FliI could inhibit tumour 
cell invasion, possibly by neutralisation of intracellular FliI and its secreted form. However, 
the exact mechanism of this inhibition needs to be confirmed. It is not known whether it is 
taken into the cell and the functions that it might affect inside the cell. 
Similar findings were shown previously using MET-1-SCC cell lines treated with FnAb, which 
also reduced tumour spheroid area compared to control antibody-treated cells (Z Kopecki et 
al., 2015). Uptake of FnAb by cells has been shown in a previous study (Zlatko Kopecki et al., 
2013), which showed that the FnAb exhibited neutralisation activity in both cultured cells 
and animal models, with effects on cell migration and on inflammation and repair processes 
(Cowin et al., 2007; Jackson et al., 2012). Uptake of the antibody suggests that 
administration of the neutralising antibody could affect both extracellular (secreted) FliI and 
intracellular FliI.  
Reduced FliI expression was also shown to reduce tumour cell invasion in vitro and 
potentially decreased the establishment or seeding of tumour cells in the lung. FliI’s role in 
the cell may allow it to mediate tumour cell invasion, possibly by facilitating invadopodia 
formation, based on its roles in actin skeleton reorganisation (Mohammad et al., 2012) and 
its coprecipitation with cortactin, an invadopodia marker (Z Kopecki et al., 2015). 
Furthermore, recent findings showed that FliI acts as a P-Rex-1 binding partner, which has 
been shown to increase cell migration in 3D migration assays. This contradicts previous 
findings that FliI negatively regulates cell migration, which was shown in 2D culture systems 
(Marei et al., 2016), suggesting the role of FliI in cells in the tumour microenvironment may 
be to mediate cell migration as an initial step to promotion of cell invasion. 
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6.4 Conclusion 
This present study has demonstrated that the inhibition of FliI expression both 
intracellularly (via siRNA) and potentially in its secreted form using a FliI-neutralising 
antibody reduced tumour cell invasion in vitro, but did not have a significant effect on the 
number of tumour nodules established in the lungs in our mouse model. When the sizes of 
tumour nodules were compared, there was a significant effect on nodule size, with a 
reduction seen in mice that were administered the neutralising antibody. Therefore, this 
finding suggests that it may be beneficial to target and block FliI within the tumour 
microenvironment to potentially inhibit cells from penetrating tissue barriers such as the 
basement membrane or the ECM. FliI inhibition may thus inhibit the metastatic spread of 
tumour cells to other organs, although this requires further experiment using better animal 
models of metastasis. Further experiments looking at varying doses and times of delivery of 
the neutralising antibody are also needed to provide stronger evidence that Flil can reduce 
the number and/or the size of tumour nodules in the lungs. 
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Chapter 7 General Discussion 
7.1 FliI Expression: Role in in vitro Cellular Functions 
In the last decade, most cancer studies have focused on detecting cancer cell mutations, 
such as those that are critically involved in cell cycle control. Tumour suppressor genes, or 
oncogenes, and cell-signalling pathways regulate cell cycle control and thus determine cell 
proliferation and/or cell death. To date, less attention has been paid to the impact of 
surrounding cells/tissue and the stromal microenvironment. However, the fact that the 
tumour stroma is a dynamic microenvironment which consists of heterogeneous cellular 
components and shows reciprocal communication with cancer cells suggests that tumour 
stroma modification in cancer is worthy of research. It is hoped that treatments will be 
discovered which may revert tumour-promoting stroma to normal stroma and therefore 
provide a less favourable tumour-promoting microenvironment, reducing cancer 
progression and metastasis to secondary sites. 
Crosstalk between cancer cells and their local environment is crucial for tumour survival, 
and the ability to modify their surroundings is important for cancer cells to promote both 
tumour progression and dissemination (Sounni & Noel, 2013). Therefore, targeting the 
tumour microenvironment may be beneficial in providing new therapeutic targets to limit 
the growth of cancer cells. The composition of the ECM is now recognised as an important 
regulator of cell behaviour, and changes in the ECM could also alter cancer cell proliferation, 
survival and migration. Reorganisation of the ECM can also stress ECM molecules and 
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potentially release or activate molecules such as latent or bound growth factors known to 
regulate cell migration, proliferation and angiogenesis (Noël, 2012). 
As a member of the actin-remodelling family of gelsolin-like proteins, FliI is involved in cell 
motility, adhesion and contraction (Davy et al., 2000). FliI has also been reported to have 
interactions with several other proteins, including association with β-actin. It is likely, 
therefore, that FliI plays a role in the actin remodelling and polymerisation process (H. D. 
Campbell et al., 2002). FliI has also been shown to regulate cell adhesion to the ECM and 
thus can be associated with changes in cell arrangement and motility (Zlatko Kopecki et al., 
2009). Specifically, FliI has been shown to mediate actin filament reorganisation, as FliI is 
expressed in motility-associated structures such as actin arcs and membrane ruffles, and in 
the migratory structures lamellipodia and filopodia (Davy et al., 2001). The unique structure 
of FliI compared to other actin-remodelling proteins may lead to it mediating signalling 
pathways in actin remodelling (Zlatko Kopecki et al., 2013).  
FliI has been identified as a tumour promoter in various cancers such as colorectal, breast 
and hepatocellular carcinomas (Kwang Won Jeong, 2014; Lifang Wu et al., 2013). Recent 
findings have shown that FliI promotes the progression of SCC in mouse models of SCC, with 
FliI regulating enhanced cell invasion (Z Kopecki et al., 2015). In the current study, we have 
demonstrated that FliI expression both within the host stromal cells (using either WT or 
heterozygous +/− mice) and in cancer cells (by siRNA knockdown of FliI in colon carcinoma 
cells) can influence tumour growth and the establishment of lung nodules in mouse colon 
cancer models. Additionally, the inhibition of FliI in vitro has been found to increase cell 
adhesion and decrease cell invasion capacity, suggesting a possible mechanism by which FliI 
inhibition could limit tumour progression and cancer cell invasion.  
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In vitro findings in this study (Chapter 2) show that FliI expression has effects at the cellular 
level on cell migration, apoptosis and proliferation. Knockdown of FliI in mouse (CT26) and 
human (HT29) colon carcinoma cell lines showed an increase in cell migration in two-
dimensional models, as well as increased proliferation and early apoptosis. This data 
concurs with what has been reported in wound-healing models and suggests that FliI plays a 
possible dual role in either tumour promotion or inhibition, possibly depending on cell type. 
The inhibition of FliI expression in cancer cells also reduced the level of cytokine expression, 
specifically TNF-α, VEGF and 1L-6. In addition, the administration of exogenous recombinant 
FliI (rFliI) to CT29 and HT29 cell cultures was shown to induce apoptosis, while showing no 
effect on other cellular functions such as migration and proliferation.  
The effects of recombinant FliI need to be viewed with some caution, as only a truncated 
form of FliI is available presently, and ours and collaborators’ laboratories have had 
difficulty expressing the full-length form of the protein. The availability of a full-length 
recombinant Flightless 1 protein in the future may help to clarify exactly what exogenous FliI 
induces in tumour cells, giving a better indication of the role of secreted or released FliI. 
The deregulation of cell migration and in particular cell invasion contributes to pathological 
conditions such as tumour angiogenesis and metastasis (Ridley et al., 2003). Aberrant 
regulation of cell motility is commonly linked to increased migration and invasion of cancer 
cells, which is a key step in metastasis (Marei et al., 2016). Studies done previously (Cowin 
et al., 2007) showed that FliI deficiency (using siRNA knockdown) in fibroblast monolayers 
derived from mouse skin increased the rate of wound closure in scratch assays compared to 
WT and FliI overexpressing fibroblasts. In addition, the same study showed that FliI-deficient 
(FliI+/−) mice improved in vivo wound healing by increasing epithelial migration and 
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proliferation. However, FliI has also been found to promote cell migration/invasion in 3D cell 
migration assays via a Rac-1-dependent pathway, which contradicts previous findings on the 
migratory properties influenced by FliI in 2D models (Marei et al., 2016) and provides 
support for our finding that FliI increased 3D cell invasion and decreased cell adhesion 
(Chapter 4). 
FliI expression correlated with reduced adhesiveness and increased invasiveness of cancer 
cells (Chapter 4). We have showed that the inhibition of FliI greatly reduced cell invasion in a 
3D invasion model using Matrigel-coated chambers. Interestingly, the addition of exogenous 
recombinant FliI (rFliI) increased the invasiveness of cancer cells. This finding suggests that 
intracellular and secreted forms of FliI may both play a role in driving cell invasion in a 3D 
model. FliI has been shown to mediate cell migration via activation of P-Rex1-Rac1, where 
FliI has been recognised as a novel Rac1 effector protein (Marei et al., 2016). This points to a 
possible pathway for the promotion of cellular invasion by FliI. Invasive cells have generally 
been found to be less adherent, and this has been associated with high motility and higher 
metabolic activity (Turner & Sherratt, 2002). Upregulation of the invadopodia marker 
cortactin with increased FliI expression suggests FliI may act via driving invadopodia 
formation, and thus may lead to increased cancer cell invasion and spread. In addition, FliI 
appears to have effects on stromal cells (such as fibroblasts) and cancer-associated (myo) 
fibroblasts, through upregulating differentiation to the myofibroblast phenotype in the 
tumour microenvironment, and the presence of these cells has been shown to favour 
tumour progression.  
Several studies have shown that the expression levels of actin-remodelling proteins are 
altered during tumour progression, and research aimed at development of therapies 
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targeting those proteins may lead to treatments that will inhibit cell motility and invasion 
(Baig et al., 2013; Dong et al., 2002; K. W. Jeong, 2014; A. Van den Abbeele et al., 2007). As 
FliI has been identified as a tumour promoter (K. W. Jeong, 2014; L. Wu et al., 2013), it could 
be a potential target for reducing invasion and subsequent metastasis. During invasion, 
reorganisation of the cytoskeleton results in actin protrusions and the production of 
lamellipodia and invadopodia, as well as influencing EMT, which has been widely implicated 
in cancer cell dissemination (Grünert et al., 2003). On wounding, it has been shown that FliI 
is involved in lamellipodia formation in keratinocytes and also in remodelling of the ECM at 
the wound site (Cowin et al., 2007). Invasive tumour cells have been demonstrated to 
present dysregulated cell motility in response to extracellular signals from growth factors 
and cytokines (Wells, 1999). Furthermore, invasive cells were found to be less adherent, and 
this was also associated with higher motility and higher metabolic activity (Turner & 
Sherratt, 2002).  
Significantly, this study finds that FliI expression increased cell invasion, suggesting FliI may 
play a role in tumour progression via effects on cell adhesion and invasion, potentially via 
effects on invadopodia formation. These experiments point to the difficulty in interpreting 
2D culture models and the importance of using 3D systems to examine cell invasion. 
Experiments using CT26 WT and siRNA FliI CT26 cells have showed that knockdown of FliI 
significantly downregulated the expression of cortactin. Cortactin is involved in cell 
protrusions such as lamellipodia and invadopodia, as it is present at dynamic sites of actin 
assembly (Yamaguchi & Condeelis, 2007). In fact, several studies have demonstrated that 
cortactin drives the invasion process and allows cells to penetrate through ECM barriers 
such as the basement membrane (Bryce et al., 2005; van Rossum, Moolenaar, & Schuuring, 
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2006). Invadopodia also appear to correlate with invasion via ECM degradation (Weaver, 
2008).  
Specifically, Flil has been shown to be co-localised with the invadopodia marker cortactin at 
the invading site of SCC cells, indicating enhanced cancer cell invasion into the basement 
membrane via this process (Z Kopecki et al., 2015). Therefore, cortactin is both an important 
regulator and a specific marker for invadopodia, based on its capability to promote protease 
secretion at the active adhesion site (Clark & Weaver, 2008). Overexpression of cortactin 
was shown to increase ECM degradation and also correlated with elevated secretion of 
MMP-2 and MMP-9 (Clark & Weaver, 2008; Clark et al., 2007). Increased secretion of MMPs 
in tumour cells is closely related to invasive capability, increased metastasis and poor 
prognosis in several types of cancers (Buday & Downward, 2007; Stetler-Stevenson et al., 
1996). A previous study (Bowden et al., 2006) found that cortactin and phosphotyrosine 
signalling is crucial for the activation of invadopodia proteases, leading to degradation of 
ECM and mediating cellular invasion.  
In the present study, the inhibition of FliI expression increased cell adhesion, with 
upregulation of the FA proteins paxillin and vinculin (Chapter 4). FliI has been shown to 
regulate cell adhesion, actin remodelling and intracellular signalling via co-localisation with 
actin and microtubule-based structures (H. D. Campbell et al., 2002; Davy et al., 2001; Z. 
Kopecki & Cowin, 2008). Knockdown of FliI can regulate cell adhesion via upregulation of the 
FA proteins paxillin and vinculin. Previous studies have found that Flil was co-localised with 
talin, paxillin and vinculin, allowing it to play a role in regulating cell adhesion (Mohammad 
et al., 2012).  
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It has also been shown that cell adhesion was increased in heterozygous FliI+/− while 
significantly impaired in transgenic FliITg/− keratinocytes and fibroblasts (which overexpress 
FliI) on different substrates (Zlatko Kopecki et al., 2009). During wound healing, FliI was 
observed to regulate adhesion via hemidesmosome formation and integrin-mediated 
cellular adhesion molecules (Zlatko Kopecki et al., 2009; Thiery, 2003). Reduced paxillin 
activity was also found in FliI-overexpressing fibroblasts via inhibition of the paxillin–
tyrosine–phosphorylation signalling pathway mediated by the adhesion molecules Src and 
p130cas (Z. Kopecki et al., 2011). During the adhesion process, protein complexes bind to 
the ECM, then trigger the linkage signal between integrin receptors and the actin 
cytoskeleton to form an active FA site (Hehlgans et al., 2007).  
This result indicates that FliI may have the ability to reorganise the cytoskeleton, which 
creates a protrusive actin meshwork, suggesting invadopodia formation in cancer cells; 
however, this needs to be investigated in the future. Understanding the mode of cancer cell 
invasion is crucial in designing strategies to target evolving cancer cells and block their 
movement through tissues and organs (Kramer et al., 2013). Therefore, this finding suggests 
that targeting and blocking FliI is potentially a means of limiting cell penetration of the 
barrier matrix (basement membrane) and thus serving to inhibit metastasis. 
7.2 FliI Expression in Primary Growth and Lung Seeding Murine Colon Tumour 
Model 
Primary and metastatic murine colon tumour models have been used in this study in order 
to determine the effects of FliI on tumour growth and the seeding of tumour nodules via the 
circulation. Tumour effector functions, including proliferation, invasion and myofibroblast 
expression within the tumour microenvironment, have also been evaluated (Chapter 5). FliI 
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expression levels in mice correlated with an increased size of primary tumours and 
increased number of tumour nodules in the lungs in mouse colon cancer models. In 
contrast, the inhibition of FliI reduced tumour nodule numbers, suggesting that host FliI 
expression levels can regulate tumour growth in this model, possibly through an effect on 
the behaviour of tumour stromal cells.  
Changes in stromal behaviour have been shown to promote epithelial transformation that 
could alter cell–cell and cell–matrix signals, allowing tumour cells to migrate across tissue 
boundaries (Liotta & Kohn, 2001) and promote tumour cell invasion and seeding at distant 
sites. The stromal cells that are abundant and active at the invasive edge of the tumour are 
TAMs and CAFs (Condeelis & Pollard, 2006). These cells actively promote the invasion of 
tumour cells (Van Zijl et al., 2009). Interestingly, the inhibition of FliI expression in cancer 
cells using siRNA FliI CT26 cells in the current study resulted in smaller tumours in mice, 
delay in onset of tumour formation and slower cancer progression. This finding needs to be 
confirmed using more stable methods for lowering FliI expression, since it is likely that the 
FliI knockdown is only transient once cells are in the in vivo environment. Local injection of 
FliI siRNA or antisense oligonucleotides would be a useful approach to this in the future.  
This suggests that FliI expression within cancer cells is linked with tumour growth in this 
model. Similar findings were demonstrated in the SCC model, where there was reduced 
tumour volume in FliI heterozygous (FliI +/−) mice, while overexpression of FliI in FliI 
transgenic mice (Tg+) resulted in larger tumours and more severe SCC progression (Z Kopecki 
et al., 2015). The tumour-promoting activity of FliI is possibly due to its effects on cell 
adhesion and invasion, as well as potential modification of the tumour microenvironment. 
Reduced FliI expression was shown to reduce tumour cell invasion in vitro and potentially 
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decreased the tumour seeding in the lung. This demonstrates a potential role of FliI in 
mediating tumour invasion. A possible mechanism associated with Flil that leads to tumour 
invasion is the facilitation of invadopodia formation. As Flil expression is evident in the 
invadopodia complex and has been shown to play a role in actin cytoskeleton 
reorganisation, it is possible that, via these mechanisms, Flil assists tumour invasion (Z 
Kopecki et al., 2015; Mohammad et al., 2012). 
Activation of intracellular and/or extracellular elements of the local host microenvironment 
could modify the invasive and proliferative behaviour of tumour cells (Liotta & Kohn, 2001; 
Vaccariello et al., 1999). FliI may modify the tumour microenvironment so as to favour 
tumour growth, which is evidenced by the observation that the expression of the 
myofibroblast marker cortactin and greater cancer cell proliferation were seen in both 
primary and lung models (Chapter 5). In contrast, we have demonstrated that the inhibition 
of FliI could affect the tumour microenvironment to make it less favourable to cancer cells, 
leading to reduced invasion and seeding of lung tumours in the mouse model. Several 
studies have shown that the re-education of stromal cells within the tumour 
microenvironment can potentially normalise tumour cell behaviour (Quail & Joyce, 2013). In 
fact, many studies show that a deregulated microenvironment commonly exhibited higher 
cancer incidence (Grivennikov et al., 2010).  
In Chapter 6, we have also demonstrated the potential therapeutic effects of a FliI-
neutralising antibody (FnAB) in reducing tumour growth and spread, using in vivo tumour 
models and spheroid growth assays in vitro. Even though only a slight reduction in the 
number of tumour nodules in the lungs was observed in mice treated with FnAB, we have 
also observed significantly reduced tumour size, where smaller nodules were present in the 
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lungs of mice treated with FnAB compared to the controls. Treatment with FnAB had no 
significant effect on the number of tumours in the lung; however, it has been showed to 
inhibit tumour growth. This may be due to the administration of FnAB on days 4 and 8 post-
inoculation after the seeding event occurred within the lung, or to limitations in the delivery 
of sufficient antibody.  
Therefore, there are several modifications that could be tried in the future, particularly with 
dosage, which needs to be optimised in this animal model. In addition, the treatment 
regimen and duration of the cancer model may need to be longer in order to observe an 
effect. Pre-treatment of the microenvironment with the neutralising antibody may also 
show a greater effect than treatment being applied after tumour cells have had a chance to 
become established. Promisingly, FnAB treatment reduced the size of tumour spheroids in 
3D spheroid invasion assays, indicating a possible action in the microenvironment that 
reduces cell invasion and tumour growth. Similar findings showed that administration of 
FnAB in SCC cell line (MET-1-SCC) spheroids reduced sphere formation and invasion (Z 
Kopecki et al., 2015). Intradermal injection of FnAB was also found to reduce tumour size in 
an SCC mouse model in the same study.  
Targeting of the tumour microenvironment is now a very fruitful new target; however, the 
approach is complicated due to the complexity and variety of the stromal cells found in the 
microenvironment (Sounni & Noel, 2013). As with other monoclonal antibodies that have 
become important new tools in cancer therapy, the FliI-neutralising antibody could be a 
new approach to targeting cancer cells and, more importantly, the tumour 
microenvironment in order to reduce tumour growth and metastasis. 
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7.3 Future Recommendations 
Further experiments are needed to provide a better understanding of the effects of the 
expression of FliI in in vitro and animal models of tumour growth and metastasis. Ideally, we 
would use Flil-overexpressing cancer cells and transgenic mice (that overexpress FliI). In our 
study, we encountered difficulties in expressing the FliI plasmid because it did not produce 
the expected level of FliI expression in CT26 cells. Other groups have reported similar 
difficulties with overexpression studies in vitro (A/Prof. Allison Cowin, UniSA, personal 
communication).  
The mechanism of FliI regulation of invadopodia formation also needs further investigation. 
The exact nature of the association between FliI and the invadopodia complex is also worthy 
of more detailed study. In terms of the influence of intracellular FliI on cellular invasion, the 
role of FliI, if any, in protease secretion and expression of MMPs is another possible subject 
for investigation. In addition, to further strengthen the understanding of how regulation of 
FliI affects cellular adhesion, paxillin localisation would be very beneficial to show how the 
regulation of Flil affects paxillin-rich focal adhesions. 
To deepen our understanding of the potential use of the FliI-neutralising antibody, more 
experiments need to be carried out in animal models of primary tumours and in better 
models of metastatic tumours. Possible beneficial effects of FnAB could be studied in cancer 
models that have a longer duration of initiation and progression, such as chemically induced 
models of colon cancer (for example azoxymethane), which would give a longer and slower 
induction process, as well as a larger window within which to treat animals with the FnAB. 
All of the mode of administration of the FnAB, the time course of administration and the 
dose should also be considered in experiments in order to optimise FnAB treatment. 
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Chapter 8 Conclusion 
Taken together, both in vitro and in vivo studies in this present thesis have contributed to a 
better understanding of the role of FliI in promoting tumour growth and the establishment 
of nodules in distant organs. FliI has been shown to potentially regulate important cellular 
functions in cancer, including cell migration, apoptosis, proliferation, adhesion and invasion, 
all of which can contribute to tumour cell invasion and dissemination. Importantly, both 
intracellular FliI and the secreted form of FliI may play significant roles in contributing to this 
process. FliI expression by either stromal cells or tumour cells may affect the tumour cells 
and the microenvironment, favouring tumour growth, while reducing or inhibiting FliI may 
modify tumour cell behaviour and the tumour stroma, to reduce the severity and potentially 
the spread of cancer.  
Therefore, FliI is a potential therapeutic target such that either intracellular inhibition or 
inhibition of the secreted form via molecular inhibitors or monoclonal antibodies might 
result in a reduction in tumour growth and spread. The administration of a FliI-neutralising 
antibody targeting FliI activity could thus be a strategy in reducing cancer severity, and could 
also inhibit the invasion and establishment of secondary tumours, as well as helping to 
normalise the tumour microenvironment.  
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